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ABSTRACT
Investigational Chemotherapy and Novel Pharmacokinetics for
the Treatment of Cancers of the CNS
Neal Shah, Pharm.D.
This dissertation (a) detailed the optimal imaging times and quantifiable intervals of the
non-toxic tumor surrogate marker D-luciferin in metastatic and primary brain tumors, (b)
characterized the creation, passive permeability, efflux pump status, and vascularity of a
widely-used EGFR-mutant lung cancer cell line, (c) evaluated the in-vitro cytotoxicity
and in-vivo efficacy of three novel chemotherapeutic agents on brain metastases of lung
and breast cancer as well as primary glioblastoma, and (d) provided a review of the
current clinical and preclinical treatment options for breast cancer and lung cancer brain
metastases, and primary glioblastoma.

ACKNOWLEDGEMENTS
The work presented in this dissertation would have been unachievable without
collective and collaborative effort. I am eternally grateful for all the help I have received
through the years.
First, I would like to profoundly thank my mentor Dr. Paul Lockman. Without
your guidance through these three years I would be completely lost. Your support has
meant the world to me, from my initial uneasiness in the first year to surprising you in
your office and saying I wanted to publish papers and graduate in five months. I have
learned so much from you, not only in the field of science, but life in general. You remain
creative in scientific approach and data publication, which is something I am slowly
starting to incorporate into my life. Your flexibility of balancing research and life has
allowed me to explore life and pursue the field of medicine I wish to practice. I feel a
connectedness as our backgrounds are both in clinical practice and this allows us to
balance the mindset of clinician scientists. I enjoyed all of our time together and I hope to
collaborate with you in the future. Thank you, Dr. Julie Lockman, for working with me
through the hectic race at the end for my Masters. You both have shown me the virtues of
patience, hard work, determination, and how an ideal partnership works.
I would also like to thank all the members in my committee for their assistance
throughout the time spent in my PhD. Dr. Cifarelli, Dr. Hazlehurst, Dr. Petros and Dr.
Bey, you reviewed my grant application, provided letters of support and
recommendation, gave me recommendations for experimental approach and creative
suggestions to make my work more impactful. You have seen my progress throughout
graduate school and I hope I have adequately evolved as a scientist in your eyes.

iii

To my seniors, the postdoctoral scholars: Dr. Chris Adkins, where to begin? We
bonded over Indian Pale Ales and Game of Thrones, hot sauce, exercise, and transitioned
from being labmates to friends. One of the most important things I learned from you is
how to be critical of scientific work, especially your own. Thank you for all of your
patience during the transition of my first year, and congratulations again on your position
as a pharmacy school professor. If I move away from Morgantown, I will be sure to eat
some Peppebronis in your honor. Dr. Raj Jagannathan, you had a simple motto: “make
science easy”. Thank you both so much.
To my fellow Lockman Lab PhD graduates: It has been a journey, hasn’t it? Dr.
Tori Terrell-Hall, though our time was limited, it was fantastic. I enjoyed seeing you
problem solve and balance your children and lab work. If I am ever in Texas, I will
definitely contact you! Besides, I think I owe you quite a bit of money from the swear jar.
Dr. Afroz Mohammad, there are no shortage of fond memories with you. Besides Dr.
Lockman, I have spent the most time in lab with you, and you have changed many life
views I held. You stayed very late, long beyond your own long days to help me out with
perform essential procedures creating figures. Even after you defended your dissertation,
up until the day you left, you helped me out. Your upbeat and constantly positive attitude
has shown me there is utility in being optimistic. We laugh more than I thought was
possible. There are so many, most likely too many amazing conversations and quotes:
your “vegan” diet, going to a bar and ordering shots of water, coats-quotes, me being
“hot” from radiation…. you remain an essential part of the Lockman Lab, and we will
stay in contact!
To the future doctors: Rachel Tallman, I owe much of this dissertation to you.
Without your countless hours of slicing brains and initial imaging, much of this work
would have taken another full year. We have had some great times together, from
iv

working out and running to bar-hopping and that one time, hammocking. I am so proud
of you for getting into medical school and I promise I will continue to yell at you when I
see you in the hospital. Memorable quote: “There’s no ‘a’ in orange! Except in the
middle…” Dr. Katie Jarrell, I genuinely think you have made me better, nicer, and more
human. It is always great to hang out with you, discuss life or movies or Game of
Thrones, your future and pharmacy career plans, and so much more. You created “Neal
on Wheels”! I am looking forward to all of our graduations and seeing where we all go
throughout life. You both have helped me out so much!
To the current Lockman Lab PhD students: Samuel Sprowls, thank you for
making me push myself harder in all aspects of life, especially exercise. I will never
forget the day you helped me move and figure out how apartment addresses work. You
and Chris may be the only people who like Game of Thrones more than I do. Your most
memorable quote for when I hit a new lifting record: “Me: Guess what I got on inner leg?
Sam: Herpes?” Mark Pinti, thank you for staying all those long hours in the IVIS and
helping me out with imaging and weighing. Pushkar Saralkar, thank you for all your
assistance with IC50s and experimental analysis, as well as showing me how to play
tennis. I look forward to seeing how massive the Plastic Throne will be. Schuyler
Vickers, it will be great to see where your projects go, and what types of meat you “have
your way with”. Without the assistance provided by you four, this dissertation would be
incomplete.
To the former undergraduates, who are now pursuing a PhD: Emma Dolan, I am
not surprised you ended up with acceptances at Scripps and Duke! It was great catching
up with you in DC for AACR. Jessie Griffith, your most memorable quote is undoubtedly
“How many doctorates does it take to move a cart?” The world may never know this
answer, though I have confirmed it is not three. I hope you are staying warm in
v

Minnesota. Thank you both for all the memories and for help in the initial years of my
PhD.
To the imaging facility, employees of OLAR, and members of the Pugacheva,
Gibson, and Hazlehurst labs: Thank you for all the patience and assistance with these
massive projects. It was frustrating and time-consuming to juggle the hundreds of
animals we did in such a short time span, but you helped me get data I needed.
To Dr. Szklarz, Dr. Salati, Dr. Siderovski, and Dr. Geldenhuys: Thank you for
always being in my corner and being flexible. Even when my ambition surpassed a
passable possibility, you believed in me and helped me make this fervor into reality. I
hope I have made you proud! To Dr. Kolodney, thank you for showing me how a real
MD/PhD scientist is supposed to be. I focus more on clinical aspects, but you reminded
me that a clinician scientist always keeps basic science in the back of their mind. It is a
lifelong balancing act, and I hope to emulate your career.
To the current MD/PhD students: Dr. Brandon Lucke-Wold, every student needs
a peer mentor not only for guidance and as a role model, but to form a bond with, and to
share life experiences with. You have pushed your own career further than is humanly
possible and urged me to do the same. Thank you for taking time to talk with me, address
my concerns, provide me with focus, and ultimately push me along the path of
apotheosis. To Jessica Clemente, thank you for staying in touch and commiserating with
me all this time. I will be sure to mimic Brandon and pass down helpful information as I
finish the latter half of medical school. To Jesse Sundar, it is always great catching up at
the gym. I look forward to seeing where you three end up. To Dr. Joshua Farris, Dr.
Philip Pifer, Dr. Daniel Vanderbilt, Dr. Sriganesh Sharma, Dr. Mark Farrugia, Dr. Sylwia
Brooks, thank you all for helping me out with lab mentors—you really hit a home run
there! I look forward to seeing where your careers take you.
vi

How can it be possible that three years have passed since I took Step 1 and began
my PhD? I was rigid in thought and attitude, while demanding perfection and embodying
frustration. Admittedly not much has changed in these areas, but I have become much
more flexible, understanding, and open-minded. Though I am not the most intelligent
scientist, I am now confident that I am one of the most motivated, focused, and
ambitious, which will continue to serve me well throughout life.
In graduate school, there are weeks—often months—where experiments don’t
work, data collected is unusable, and there doesn’t seem to be a light at the end of the
tunnel. The highs can be high; the lows can be low. Then, you factor in the rest of life and
the scenario seems insurmountable. But though the hardest of these three doctorates, I
have figured out how life really works: it is how we respond and react to hardships that
defines who we are. Life is never going to be completely smooth. We prove we can
handle the hurdles of life and emerge with some semblance of sanity.
The time spent and experiences I have shared with all of you have changed who I
am as a person for the better. The years spent in my PhD have been the best years of my
life, and I would not have done anything differently.
But somewhere
alongofthis
journey, I stopped being human.
[29] years
pain
I irreversibly
physically
Andmentally
I can feeland
it closing
in annihilated myself.
I adopted hatred as my motivator,
served as a catalyst to stay alive as I became
The will towhich
rise above
hollow.
Tearing my insides out
I turned anger into anxiety as I accepted the way I was built.
At the Gates
There is nothing left.
Cold
Not every story has a happy ending.
Slaughter of the Soul

vii

TABLE OF CONTENTS
ACKNOWLEDGEMENTS ............................................................................................ iii
LIST OF FIGURES ........................................................................................................ xii
LIST OF TABLES ...........................................................................................................xv
LIST OF ABBREVIATIONS ...................................................................................... xvii
CHAPTER 1 .......................................................................................................................1
INTRODUCTION..............................................................................................................1
1.1

Introduction .........................................................................................................1

CHAPTER 2 .......................................................................................................................6
CURRENT TREATMENT STRATEGIES FOR LUNG CANCER AND BREAST
CANCER BRAIN METASTASES AND GLIOBLASTOMA.......................................6
2.1 Breast Cancer Epidemiology ...................................................................................6
2.1.1 Breast Cancer Subtypes ........................................................................................7
2.1.2 Breast Cancer Brain Metastases ..........................................................................9
2.1.3 Conventional Breast Cancer Brain Metastases Chemotherapy .....................10
2.1.4 Targeted Breast Cancer Brain Metastases Chemotherapy .............................13
2.1.5 Immunotherapy for Breast Cancer Brain Metastases .....................................15
2.2 Lung Cancer Epidemiology ...................................................................................18
2.2.1 Lung Cancer Subtypes ........................................................................................19
2.2.2 Lung Cancer Brain Metastasis ..........................................................................23
2.2.3 Conventional Lung Cancer Brain Metastases Chemotherapy .......................25
2.2.4 Targeted Lung Cancer Brain Metastases Chemotherapy ...............................26
2.2.5 Immunotherapy for Lung Cancer Brain Metastases .......................................32
2.3 Glioblastoma Epidemiology ..................................................................................34
viii

2.3.1 Glioblastoma Chemotherapy .............................................................................35
2.3.2 Immunotherapy for Glioblastoma .....................................................................36
2.4 References ...............................................................................................................37
CHAPTER 3 .....................................................................................................................63
PHARMACOKINETICS OF LUCIFERIN IN PRECLINICAL BRAIN
METASTASES AND PRIMARY BRAIN TUMOR MODELS ..................................63
3.1 Introduction ............................................................................................................63
3.2 Methods and Materials ..........................................................................................65
3.3 Results .....................................................................................................................69
3.4 Discussion ................................................................................................................73
3.5 Conclusion ...............................................................................................................79
3.6 References ...............................................................................................................80
CHAPTER 4 .....................................................................................................................95
EFFECTS OF ETIRINOTECAN PEGOL (NKTR-102) IN THREE PRECLINICAL
BREAST CANCER BRAIN METASTASES MODELS .............................................95
4.1 Introduction ............................................................................................................95
4.2 Methods and Materials ..........................................................................................97
4.3 Results ...................................................................................................................100
4.4 Discussion ..............................................................................................................102
4.5 Conclusion .............................................................................................................106
4.6 References .............................................................................................................106
CHAPTER 5 ...................................................................................................................125
CHARACTERIZATION OF PRECLINICAL PC-9 LUNG CANCER BRAIN
METASTASES...............................................................................................................125
ix

5.1 Introduction ..........................................................................................................125
5.2 Methods and Materials ........................................................................................127
5.3 Results ...................................................................................................................132
5.4 Discussion ..............................................................................................................139
5.5 Conclusion .............................................................................................................141
5.6 References .............................................................................................................142
CHAPTER 6 ...................................................................................................................166
EFFECTS OF ETIRINOTECAN PEGOL (NKTR-102) IN THE PC-9
PRECLINICAL LUNG CANCER METASTASES MODEL ...................................166
6.1 Introduction ..........................................................................................................166
6.2 Methods and Materials ........................................................................................167
6.3 Results ...................................................................................................................169
6.4 Discussion ..............................................................................................................172
6.5 Conclusion .............................................................................................................174
6.6 References .............................................................................................................175
CHAPTER 7 ...................................................................................................................192
PRELIMINARY DATA OF ETIRINOTECAN PEGOL (NKTR-102) EFFICACY
IN A PRECLINICAL GLIOBLASTOMA MODEL ..................................................192
7.1 Introduction ..........................................................................................................192
7.2 Methods and Materials ........................................................................................193
7.3 Results ...................................................................................................................194
7.4 Discussion ..............................................................................................................195
7.5 Conclusion .............................................................................................................197
x

7.6 References .............................................................................................................198
CHAPTER 8 ...................................................................................................................203
PRELIMINARY DATA OF ABRAXANE AND DOXIL EFFICACY IN
PRECLINICAL BRAIN METASTASES MODELS .................................................203
8.1 Introduction ..........................................................................................................203
8.2 Methods and Materials ........................................................................................204
8.3 Results ...................................................................................................................206
8.4 Discussion ..............................................................................................................207
8.5 Conclusion .............................................................................................................208
8.6 References .............................................................................................................209
CHAPTER 9 ...................................................................................................................215
CONCLUSION AND FUTURE DIRECTIONS .........................................................215
9.1 Conclusion .............................................................................................................215
9.2 Future Studies .......................................................................................................218

xi

LIST OF FIGURES
Figure 3.1. Representative time-course of bioluminescence capture and
quantification....................................................................................................................86
Figure 3.2. Radiance luciferin pharmacokinetics for brain tumor models. ...............87
Figure 3.3. Normalized luciferin bioluminescence profiles for brain tumor models. 88
Figure 3.4. In vitro luciferin kinetics corresponds with in vivo bioluminescence. .....89
Figure 3.5. Radiance and normalized AUC comparisons. ...........................................90

Figure 4.1. Etirinotecan pegol reduces tumor burden in the MDA-MB-231-Br model
compared to conventional chemotherapy and vehicle. ...............................................113
Figure 4.2. Kaplan-Meier survival curve of MDA-MB-231-Br mice treated with
etirinotecan pegol and conventional chemotherapy. ..................................................114
Figure 4.3. Etirinotecan pegol reduces tumor burden in the JIMT-1-Br model
compared to lapatinib and vehicle. ..............................................................................116
Figure 4.4. Kaplan-Meier survival curve of JIMT-1-Br mice treated with
etirinotecan pegol and conventional chemotherapy. ..................................................117
Figure 4.5. Etirinotecan pegol does not significantly reduce tumor burden in the
4T1-Br model compared to vehicle. .............................................................................119
Figure 4.6. Kaplan-Meier survival curve of 4T1-Br mice treated with etirinotecan
pegol and conventional chemotherapy. ........................................................................120
Figure 4.7. Accumulation of irinotecan in tumors and normal brain from 14Cetirinotecan pegol. ..........................................................................................................121

xii

Figure 5.1: Distribution and survival of the brain-seeking PC-9 cell line. .............. 146
Figure 5.2. Oregon Green is a P-glycoprotein substrate. .......................................... 147
Figure 5.3. Distribution of brain metastases in PC-9-Br. .......................................... 148
Figure 5.4. Ventricular infiltration leads to spinal tumor burden. .......................... 149
Figure 5.5. PC-9-Br is less sensitive to chemotherapy compared to the parenteral
line. ................................................................................................................................. 150
Figure 5.6. Permeability changes of PC-9-Br treated with vehicle. ......................... 151
Figure 5.7. Passive permeability changes of PC-9-Br treated with cisplatinetoposide......................................................................................................................... 152
Figure 5.8. Passive permeability changes of PC-9-Br treated with cisplatinpemetrexed..................................................................................................................... 153
Figure 5.9. Passive permeability changes of PC-9-Br treated with gefitinib. .......... 154
Figure 5.10. Passive permeability changes of PC-9-Br treated with afatinib.......... 155
Figure 5.11. Passive permeability changes of PC-9-Br treated with osimertinib. .. 156
Figure 5.12. Comparison of passive permeability between PC-9-Br treatment
groups. ............................................................................................................................ 157
Figure 5.13. Distribution of PC-9-Br tumors. ............................................................ 158

Figure 6.1. Sensitivity to SN-38 for three brain-seeking lung cancer lines. ..............178
Figure 6.2. Bioluminescence in PC-9-Br treated with BEACON therapy. ...............180
Figure 6.3. Kaplan-Meier survival curve of PC-9-Br mice treated with etirinotecan
pegol and BEACON-based chemotherapy. .................................................................181

xiii

Figure 6.4. Bioluminescence in conventional lung chemotherapy in the PC-9-Br
model. ..............................................................................................................................183
Figure 6.5. Kaplan-Meier survival curve of PC-9-Br mice treated with conventional
lung chemotherapy.........................................................................................................184
Figure 6.6. Bioluminescence profiles of EGFR-inhibitors in the PC-9-Br model. ...186
Figure 6.7. Kaplan-Meier survival curve of PC-9-Br mice treated with targeted lung
chemotherapy. ................................................................................................................187

Figure 7.1. U251 is sensitive to SN-38 in the nanomolar range. ................................200
Figure 7.2. NKTR-102 enhances survival compared to vehicle therapy in the U251
model. ..............................................................................................................................201
Figure 7.3. Etirinotecan pegol reduces tumor burden and improves survival
compared to vehicle in the U251 glioblastoma model.................................................202

Figure 8.1. In-vitro cytotoxicity of Abraxane and Doxil on MDA-MB-231-Br
cells. .................................................................................................................................211
Figure 8.2. MDA-MB-231-Br survival is not improved on Abraxane therapy. .......212
Figure 8.3. Doxil bioluminescence and survival effects on MDA-MB-231-Br
tumors. ............................................................................................................................213
Figure 8.4. Effects of Doxil on the PC-9-Br model......................................................214

xiv

LIST OF TABLES
Table 3.1. Timing of luciferin imaging for in vivo cancer cell models. .......................91
Table 3.2. Radiance pharmacokinetic data for tumor models. ...................................92
Table 3.3. Normalized pharmacokinetic data for tumor models. ................................93
Table 3.4. Signal range during bioluminescence imaging. ...........................................94

Table 4.1. Chemotherapy formulations and dosage schedules for NKTR-102
BCBM..............................................................................................................................122
Table 4.2. In-vitro cytotoxicity assay of chemotherapy in cancer cell lines. .............123
Table 4.3. Survival analysis of chemotherapy and vehicle. ........................................124

Table 5.1. In-vitro chemotherapeutic sensitivity comparisons of the parenteral and
brain-seeking PC-9 line. ................................................................................................161
Table 5.2. Sizes of PC-9-Br tumors based on drug treatment. ..................................162
Table 5.3. 14C-AIB fold permeability is less in groups that improve median
survival. ...........................................................................................................................163
Table 5.4. Oregon Green fluorescence intensity does not correlate with median
survival improvement. ...................................................................................................164
Table 5.5. ICG fluorescence intensity is similar in all treatment groups..................165

Table 6.1. Formulations and dosing schedule for NKTR-102 in the PC-9-Br
model. ..............................................................................................................................190

xv

Table 6.2. Survival data of NKTR-102 against chemotherapy in the PC-9-Br
model. ..............................................................................................................................191

xvi

LIST OF ABBREVIATIONS
AUC

Area under the curve

ALK

Anaplastic lymphoma kinase

BBB

Blood-brain barrier

BCBM

Breast cancer brain metastases

BTB

Blood-tumor barrier

CSF

Cerebrospinal fluid

CTLA-4

Cytotoxic T-lymphocyte associated protein-4

EGFR

Epidermal growth factor receptor

EML-4

Echinoderm microtubule-associated protein-4

EPR

Enhanced permeation and retention

ER

Estrogen receptor

Fluc

Firefly luciferase

HER2

Human epidermal growth factor receptor 2

LCBM

Lung cancer brain metastases

NSCLC

Non-small cell lung cancer

PD

Programmed death receptor

PD-L1, -2

Programmed death receptor ligand-1, -2

P-gp

Permeability glycoprotein

PR

Progesterone receptor

SCLC

Small cell lung cancer

T-DM1

Trastuzumab emtansine

TNBC

Triple negative breast cancer

WBRT

Whole brain radiation therapy

xvii

CHAPTER 1
INTRODUCTION
1.1 Introduction
It is odd to think of cancer as a unifier, but in some ways, it is. Cancer has remained
the second-most common cause of death since the 1980s, disregarding sex, ethnicity,
race, or characteristics otherwise. [1] In 2016, cancer was responsible for nearly 600,000
deaths, and with life expectancy increasing, the incidence of cancer diagnosis and deaths
have also increased. [1] In women breast cancer is most common, while in men prostate
cancer is most common; in both genders this is followed by lung cancer and colorectal
cancer. [2] For cancer deaths, in both men and women lung cancer is first, followed by
prostate cancer or breast cancer, respectively, and then colorectal cancer. [2]
Cancer within its tissue of origin is defined as “primary”, spreading to other organs in
a process known as metastasis. [3] It is metastasis that is responsible for the lethality of
cancer and the magnitude of cancer death. [4] While cancer may metastasize to any
location, the highest incidence of metastases occurs in the lung, liver, bone, brain, and
adrenal glands. [5] Depending on cancer type, approximately 10 to 50% of all cancer
patients will eventually develop a metastasis. [6-8]
Treatments for metastases are dependent on tumor location but generally involve a
regimen of radiation, surgery, and chemotherapy. Brain metastases becomes increasingly
challenging to treat due to the physiochemical blood-brain barrier chemotherapy is
limited in its cytotoxic ability, and in combination with the invasiveness of resection. [9]
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Once diagnosed with brain metastases, the median survival typically ranges from three
months to two years. [10]
Fortunately, novel chemotherapeutic agents, redesigned dosage forms, and new
methods of drug administration have allowed for modest improvement of survival in
brain metastases. These new agents often act as antagonists of a pathway upregulated in
cancer cells (such as osimertinib, which inhibits the EGFR signaling pathway), prolong
and enhance cytotoxic effects by conjugation to linker molecules (such as etirinotecan
pegol, which is a tetramer of irinotecan linked by polyethylene glycol chains), or avoid
efflux pumps to penetrate the brain and tumor (such as Doxil, which is a pegylated
liposomal version of doxorubicin). Trends have shown that more molecules are being
developed with the intent to cross the blood-brain and blood-tumor barriers to treat brain
metastases.
In this dissertation, we investigate the effect of novel chemotherapeutic agents
compared to standard-of-care chemotherapy on median survival of two models of brain
metastases and one model of glioblastoma. We additionally correlate in vitro toxicity
assays to in vivo drug efficacy and characterize the optimal timing for luciferin
bioluminescence quantification and its surrogacy for tumor burden in response to
chemotherapy. As our laboratory has extensively characterized the blood-tumor barrier of
breast cancer brain metastases [6], initial characterization of the blood-tumor barrier of a
EGFR-mutated lung cancer brain metastases model is described. Effects of
chemotherapeutic agents on barrier vascular integrity and efflux pumps are visualized
using fluorescence and autoradiography data.
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Chapter 2 reviews the epidemiology, subtypes, prognostic factors, and survival
characteristics of brain metastases from breast cancer and lung cancer, as well as primary
glioblastoma. Conventional chemotherapeutic regimens, novel chemotherapy, and in-trial
agents are also discussed.
Chapter 3 details optimal pharmacokinetic timing for luciferin imaging for breastbrain, lung-brain, and glioblastoma models used subsequently for the rest of these
dissertation experiments.
Chapter 4 describes the survival effects of pegylated irinotecan (etirinotecan pegol) in
three models of breast cancer brain metastases. Etirinotecan pegol is hypothesized to
have preferential accumulation in tumors due to the vasculature leakiness, and may
additionally bypass efflux transporters. In vitro toxicity effects as well as in vivo survival
effects of etirinotecan pegol are compared to BEACON trial agents for the respective
models. Bioluminescence curves are similarly compared for treatment groups.
Chapter 5 illustrates the creation of the PC-9-Br EGFR brain-seeking lung cancer cell
line. Luciferin kinetics reveal the best range of time for in vivo imaging to assess tumor
burden and response to treatments. Fluorescence of tomato red (tumor), Oregon Green
(efflux pump), and indocyanine green (vascularity) characterize the environment of lung
cancer brain metastases, and effects of chemotherapy on this environment. The effects of
the permeability glycoprotein efflux pump at the blood-tumor barrier is visualized and
inhibited to show its contribution to chemotherapy restriction. Autoradiography data
shows restricted tumor accumulation of chemotherapeutic agents, which correlates with
observed survival.
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Chapter 6 depicts the survival effects of etirinotecan pegol in the EGFR-mutated
PC9-Br model of lung cancer brain metastases. In vitro toxicity assays of BEACON
agents, as well as conventional chemotherapy used to treat lung cancer, show sensitivity
and estimated response of the PC9 line to treatments. Results of survival and
bioluminescence are compared to cellular sensitivity. The differences in permeability, in
vitro toxicity, and in vivo survival are discussed, especially in the context of EGFRtargeted tyrosine kinase inhibitors.
Chapter 7 reports the survival effects of etirinotecan pegol in the setting of primary
gliobastoma. In contrast to brain metastases models, the glioblastoma model uses
intracranial injections and a slower-growing tumor, which may favor chemotherapy
deposition.
Chapter 8 describes the in vitro and in vivo effects of nano-albumin-bound paclitaxel
and pegylated liposomal docetaxel on the triple negative breast cancer and lung cancer
models. Chapter 7 and Chapter 8 feature preliminary data, with in vivo comparisons to
conventional chemotherapy ongoing.
In summary, this dissertation evaluates the current treatment strategies and effects of
three novel chemotherapeutic agents featuring enhanced brain permeability on the
survival of preclinical brain metastases and primary lesions. This dissertation also
characterizes the vascular integrity, passive permeability, efflux pump contribution, and
overall environment of brain metastases of EGFR-mutant lung cancer, which provides
insight into why patients on chemotherapy often have relapsing lesions. When viewed
altogether, the data emphasizes a multifocal approach to improve penetrance of
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chemotherapy by molecular design or innovative formulation, with the goal of
minimizing damage to normal brain parenchyma surrounding tumors.
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CHAPTER 2
CURRENT TREATMENT STRATEGIES FOR LUNG CANCER AND
BREAST CANCER BRAIN METASTASES AND GLIOBLASTOMA

2.1 Breast Cancer Epidemiology
Breast cancer remains the most common malignancy in women. Over an 80-year
lifetime, the National Cancer Institute’s Surveillance, Epidemiology, and End Results
reports from 2003 to 2007 report the absolute risk of a woman developing breast cancer
is 1-in-8 (12%), which is a modest increase from the lifetime risk in the 1970s of
approximately 1-in-10 (10%). [1] The strongest risk factor for developing breast cancer is
age, with incidence increasing as age increases. [1] In their 30s, women have less than
1% risk of developing breast cancer, yet in their 70s the risk increases to nearly 4%. [1]
Other risk factors that increase the incidence of breast cancer include family history of
breast cancer, early menstruation, late menopause, use of hormonal therapy, obesity,
Caucasian race, physical inactivity, excessive alcohol intake, smoking, radiation therapy
of the chest, and inherited genetic mutations. [1]
In 2017, it is estimated that more than 250,000 new cases of breast cancer will be
diagnosed and more than 40,000 women will die from breast cancer. [2] From 1989 to
2015, the overall death rates of breast cancer decreased by 39% and from 2006 to 2015 in
all racial and ethnic groups. [2] The rapid decline in mortality is attributed to improved
screening via early mammography and the widespread use of chemotherapy. [2] The
seminal discovery of human epidermal growth factor receptor 2 (HER2) presence in up to
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30% of breast tumors (as well as high levels in other tumor locations) in the mid-1980s
lead to the production of Herceptin (trastuzumab), the first antibody against HER2. [3]
This discovery significantly contributed to the rapid mortality reduction from breast
cancer, as well as introduced a new risk factor for breast cancer metastasis. A conundrum
formed: while non-specific chemotherapy and targeted therapy such as trastuzumab may
provide primary control of breast cancer, these agents do not readily achieve adequate
cytotoxic concentrations in the brain, and allow seeding into the brain and brain
metastases development. [4] With the discovery of HER2, the molecular subtype of
breast cancer was found to influence formation of brain metastases as well as overall
prognosis.
2.1.1 Breast Cancer Subtypes
Breast tissue is responsive to hormones such as estrogen and progesterone as part
of normal physiologic mechanisms. While estrogen stimulates growth of the ductal tissue
components, lobular development is driven by progesterone. [5] Dysregulations of the
estrogen receptor (ER), progesterone receptor (PR), and their signaling pathways have
been attributed to development of breast cancer and are termed “hormone receptor
positive”. [6] With the incorporation of HER2 as both a risk factor and prognostic factor,
the hormone receptor breast cancer split into two further types: Luminal A and Luminal
B.
Luminal A represent tumors that are ER and PR positive, but do not possess
HER2 upregulation (are HER2 negative), while Luminal B tumors retain ER, PR, and
HER2 positivity. [7] Luminal A remains the most common type of primary breast cancer
with over 50% of total diagnosis, and possesses a good prognosis. Luminal B tumors, due
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to their positivity of HER2, are more proliferative and require more intensive therapy. [7]
When tumors are ER and PR negative but retain HER2 positivity, they are simply
referred to as “HER2” or a breast cancer that has “HER2 over-expression”.
On the opposite side, it is possible for breast cancer to possess neither hormone
receptors nor HER2 positivity (ER, PR, HER2-) and are termed “triple negative”. [7]
These tumors mimic basal epithelial cells and thus the triple negative subtype is often
termed “basal”. [7] Since there is no receptor to target, triple negative breast cancer
tumors are more aggressive in growth and systemic therapy is often significantly
deleterious. These tumors occur in younger patients and are associated with lower
survival rates and increased relapse rates compared to luminal subtypes.[7] It is logical
then that the aggressiveness of HER2 and the de-differentiation of triple negative tumors
allows for enhanced metastases. The discovery of HER2 lead to better treatment
modalities, and the recent discovery of checkpoint inhibition pathways seeks to do
similarly.
The programmed death receptor (PD) and PD ligand-1 or -2 (PD-L1, PD-L2) is
thought to play a crucial role in cancer developing immunological resistance. [8]
Expressed on the surface of tumor cells, PD-L1 bind to PD (also known as B7-H1 or
CD274) expressed on T-cells, B-cells, and natural killer cells. [8, 9] This interaction
suppresses T-cell activities such as migration and cytotoxic substance secretion, thus
allowing tumor cells to both escape immune functions. [8] PD-L1 is expressed in
approximately 20% of TNBC [10] and is attributed with metastatic potential and
enhanced proliferation. [11, 12] As TNBC has no ER, PR or HER2+ to target, PD-L1 has
been of great interest to treat triple negative BCBM.
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Within the scope of brain tumors, patients with triple-negative and HER2+
subtypes are at higher risk for formation of brain metastases. [13]
2.1.2 Breast Cancer Brain Metastases
As survival from primary breast cancer tumors increase, the rate of developing
brain metastases also increases. Breast cancer is the second most common cause of brain
metastases, with breast cancer subtype being an important prognostic factor. The basal or
triple negative subtype causes >25% of all breast cancer brain metastases (BCBM),
closely followed by HER2 at approximately 20%. [14] It is approximated that up to 50%
of all patients diagnosed with HER2 or triple negative breast cancer will eventually
develop brain metastases. [15] Treatment for BCBM is restricted to surgical resection,
whole brain radiation therapy, stereotactic radiosurgery, and depending on subtype, either
targeted chemotherapy or nonspecific chemotherapy. [13, 14] Surgical resection is
performed via a minimal craniotomy and endoscope, often with patients still awake but
mildly sedated to monitor integrity of brain functions. [16] Due to the invasiveness of the
procedure, surgical resection is limited to fewer than 3-4 tumors that are large and
symptomatic. [17]
Whole brain radiation therapy (WBRT) is a key therapy option for brain
metastases in general, with typical doses of 30 Gy in 10 fractions to 37.5 Gy in 15
fractions producing significant tumor shrinkage and local disease control. [18] WBRT
can cause significant toxicities such as neurocognitive decline, cataracts, blindness, and
radiation necrosis. [18] For these reasons, stereotactic radiosurgery (SRS) has been
promoted as the preferred radiation therapy. SRS is more precise, using multiple beams
of smaller radiation doses that focus on an area to deliver a cumulative dose. This allows
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a higher dose per fraction to be administered, leading to better local control rates. [18]
Despite its reduced neurocognitive decline advantage, SRS is typically only used when
there are fewer than 4 brain metastases, and studies have shown that survival was not
superior compared to WBRT, possibly due to lower control of total brain metastatic
burden. [18] While neurosurgery and radiation techniques are slowly advancing, there is
an increasing trend to improve brain penetration of existing chemotherapy and to create
new agents that bypass the blood-brain and blood-tumor barriers.
2.1.3 Conventional Breast Cancer Brain Metastases Chemotherapy
Due to limited chemotherapeutic penetration through the blood-tumor and bloodbrain barrier and poor survival statistics, clinical trials have typically excluded patients
with brain metastases. There are currently no FDA-approved medications specifically
indicated for brain metastases, though temozolomide and bevacizumab are often
backbone agents to treating these lesions, and a PCV (procarbazine, lomustine, and
vincristine) combination is a listed option by the National Cancer Institute. [19] Typical
systemic therapy includes taxanes (docetaxel, paclitaxel), anthracyclines (doxorubicin),
platinum compounds (cisplatin), and alkylating agents (cyclophosphamide), often in
combination with other agents. [20-23] These systemic agents were given for total tumor
burden control are not intended to treat BCBM specifically.
Various combinations of cisplatin, etoposide, doxorubicin, 5-fluorouracil,
methotrexate, vincristine, teniposide, lomustine, irinotecan, gemcitabine, paclitaxel, and
temozolomide have been trialed in BCBM patients. The success of cisplatin has propelled
the agent as part of standard non-targeted backbone therapy in combination with other
agents. Cisplatin and etoposide were tested as combination agents in a Phase II trial of 4
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BCBM patients in 1997. Only 1 patient had a partial response, leading authors to
conclude that though cisplatin can penetrate through the blood-tumor barrier albeit
poorly. [24] Cisplatin and etoposide again were tested as combination agents in 56
BCBM patients. 7 patients achieved a “complete” response, 14 achieved partial response,
12 had no change, 16 continued to progress, and 8 patients were deemed as insufficient
treatment or not assessed. An overall response rate of 38% was noted.[25] Cisplatin,
doxorubicin, 5-fluorouracil, methotrexate regimens were given to 4 patients with BCBM.
However, no overall survival improvement was noted, and patients experienced major
toxicity. [26]
Cyclophosphamide, methotrexate, 5-fluorouracil, doxorubicin were tried in 56
BCBM patients. The authors reported no significant prolonging of intracranial metastases
free interval, but progression free survival was prolonged. [27] 15 patients with BCBM
were treated with cyclophosphamide and cisplatin in a Phase II trial. Of these 15, 6
achieved partial response, defined as at least 50% reduction in tumor, and had no new
lesions or progression. [28] In another Phase II trial, 25 patients with BCBM treated with
cisplatin and vinorelbine alongside 30 Gy of fractionated radiation. This therapy resulted
in complete response in 3 patients and partial response in 16 patients, for a total response
rate of 76%. [29] The currently ongoing A-PLUS trial evaluates the BEEP (bevacizumab
followed by etoposide and cisplatin) regimen alongside WBRT in BCBM patients.
[NCT02185352] The BEEP combination was previously featured in a Taiwanese trial of
BCBM, though no results are posted. [NCT01281696] Similarly, in a Phase II trial, 35
patients with BCBM were pretreated with bevacizumab and then given cisplatin and
etoposide, with a 77% response rate.[30] Cisplatin is also being evaluated alongside
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veliparib in the treatment of BRCA-mutated breast cancer and its associated brain
metastasis. [NCT02595905]
Paclitaxel is known to have low brain and CSF concentrations. In 152 metastatic
breast cancer patients with brain metastases, 78 patients responded to paclitaxel, while 6
developed CNS progression. The brain was thought to be sanctuary site for BCBM. [31]
Of 4 BCBM patients given concomitant paclitaxel and bevacizumab, 3 showed partial
response and 1 showed complete response, with no extra progression. [32] Five BCBM
patients receiving similar bevacizumab and paclitaxel treatment showed partial response
(2 patients), stable disease (2 patients), and progression (1 patient). [33]
Temozolomide as a single agent has been studied in a Phase II trial of BCBM,
though no results have been posted. [NCT00831545] In combination with vinorelbine,
temozolomide was used in 6 BCBM patients to achieve only a minor response, which
then progressed. [34] It was then again used in a Phase II trial of 11 BCBM patients. One
had a minor response, while the others were grouped together in stable or progressing
disease. [35]
Though irinotecan is not typically used to treat brain metastases, it has found
utility in combination therapy. It was studied in combination with temozolomide in
BCBM [NCT00617539], but results of the study are not posted. Irinotecan was combined
with iniparib and showed clinical benefit in 27% of patients. [36] Similarly, eribulin is
used as salvage therapy in the treatment of BCBM; as such only case reports or case
series of eribulin efficacy in this setting exist. In one patient, eribulin was fifth-line
initiated. One month later, brain metastases reduced. [37] In three patients with BCBM
(one of each subtype), eribulin was found to be beneficial in heavily treated n=3 patients.
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[38] With concurrent WBRT, eribulin showed regression of one HER2- and one HER2+
BM. [39] Based on positive outcomes, eribulin is being evaluated in a Phase II trial of
women with BCBM. [NCT02581839]
2.1.4 Targeted Breast Cancer Brain Metastases Chemotherapy
Luminal A, Luminal B, and HER2+ BCBM can be treated with targeted
chemotherapy, while the triple negative subtype by definition cannot. The Luminal
subtypes are often treated with selective ER modulators (SERM) such as tamoxifen,
aromatase inhibitors such as anastrozole, or ER degraders such as fulvestrant, but there is
no specific FDA-approved chemotherapeutic agent or regimen. [40, 41] Temozolomide
has been studied in combination with WBRT, irinotecan, and capecitabine in hormone
positive BCBM. [40] Upcoming therapy for hormone positive BCBM includes cyclindependent kinase 4/6 inhibitors such as abemaciclib, palbociclib [NCT02774681], and
ribociclib; PI3K inhibitors such as buparlisib and pictilisib; and tyrosine kinase inhibitors
such as cabozatinib. Due to the favorable prognosis of Luminal BCBM, focus has shifted
to trials and chemotherapy involving the HER2+ receptor and downstream pathways,
which is associated with aggressive tumors and a large percentage of BCBM.
The discovery of the HER2 receptor led to the creation of the targeted monoclonal
antibody Herceptin (trastuzumab). FDA-approved in 1998, trastuzumab displayed a
modest increase in overall survival. [42] Unfortunately, it was discovered that
approximately 70% of patients experienced disease progression or developed metastasis
within a year of starting trastuzumab. [42] Due to its size, trastuzumab is unable to
penetrate the BBB or BTB in adequate concentrations, leading to the formation and
inadequate control of intracranial metastases. [4, 43] The efficacy of the trastuzumab and
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emtansine conjugate in HER2+ BCBM is discussed in the following immunotherapy
section.
The second HER2 antibody, pertuzumab, is often given in combination with
trastuzumab to treat metastatic breast cancer. Case reports [44] and a subset of patients in
the Phase III CLEOPATRA trial show that the combination of pertuzumab, trastuzumab,
and docetaxel delays the onset of CNS metastases—but not the incidence of formation—
compared to placebo, trastuzumab, and docetaxel therapy. [45] The third HER2 antibody
margetuximab is currently in Phase III trials in combination with chemotherapy for the
treatment of metastatic breast cancer. [46]
Tykerb (lapatinib) is a small-molecule tyrosine kinase inhibitor acting
intracellularly to inhibit the HER2 signaling pathway. Unfortunately, much like
trastuzumab, it does not display much efficacy in treating HER2 BCBM as monotherapy.
A Phase II trial of 242 patients revealed an objective response of just 6%, with 21%
patients displaying a ≥20% volumetric lesion reduction. [47] Lapatinib is being explored
in combination with other medications, most frequently capecitabine, and treatment
modalities. A Phase II study in combined lapatinib and capecitabine therapy, where 29 of
44 patients achieved a partial response, though progression occurred in almost all patients
and required brain radiation. [48] Many other trials have shown efficacy of lapatinib and
capecitabine. [47, 49] Lapatinib was unfortunately shown not to work in combination
with topotecan therapy. [50] Recently, a Phase II trial is examining the effects of
lapatinib and WBRT compared to WBRT alone for women with HER2+ BCBM.
[RTOG1119]
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Neratinib, another tyrosine kinase inhibitor of the HER2 pathway, was shown to
be effective in treating HER2+ BCBM in combination with paclitaxel. [51] Another
clinical trial combined neratinib and capecitabine to treat HER2 BCBM, with a 63% 12month survival rate in 39 patients, though 6 patients had to discontinue due to
toxicity.[52] [NCT01494662] In contrast, the HER2+ tyrosine kinase inhibitor afatinib
was compared against monotherapy, combined therapy with vinorelbine, and physician’s
choice therapy in HER2+ BCBM. No improved efficacy in afatanib-containing regimens
compared to physician’s choice was noted. [53]
2.1.5 Immunotherapy for Breast Cancer Brain Metastases
The first immunotherapy to treat cancer was interleukin-2 (IL-2) in advanced
melanoma and renal cell carcinoma. [54] In consideration of brain metastases, IL-2 had a
18.5% clinical response in previously treated patients and a 5.6% response rate in
treatment-naïve patients, with only 2 of 36 naïve patients demonstrating objective
intracranial disease regression. [54] IL-2 was followed by Yervoy (ipilimumab), a
cytotoxic T-lymphocyte associated protein (CTLA)-4 (CD152) antibody inhibitor. In a
Phase II trial, ipilimumab showed control of brain lesions in 14 of 72 metastatic
melanoma patients. [55] Subsequent trials show marginal or equivocal results with
combination therapy or surgical treatment. [56]
Great interest has been placed on immunotherapy in treating brain metastases.
This is because unlike conventional chemotherapy, immunotherapy does not act directly
on tumor cells: rather, T-cell activation leads to clinical responses seen. [57] As expected,
initial trials of immunotherapy specifically precluded the enrollment of patients with
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brain metastases without specific prerequisites. [58] Immunotherapy is now being
explored in the treatment of brain metastases from various cancer types.
The expression of PD-L1 on BCBM tumor surfaces is highly variable. A series of
252 brain metastases from melanoma, breast, renal, colorectal, and non-small cell, and
small-cell lung cancer were analyzed for expression of PD-L1 with less than 10%
showing expression. [59] In contrast, another study of 84 patients with matching primary
breast tumor and brain metastases found 53% PD-L1 expression on brain metastases. [60]
Interest in immunotherapy to treat breast cancer lies especially in the treatment of TNBC,
as no targets naturally exist against this subtype. [10, 61] Additionally, it has been shown
that TNBC may harbor elevated levels of PD-L1. [10]
Nivolumab, an antibody against PD-1, was shown to have a modest response
(22%) in a small 50-patient trial of TNBC patients. [62] Nivolumab is currently involved
in a Phase II trial of metastatic TNBC brain metastases in asymptomatic and steroid-free
patients. [NCT02499367] It is also involved in combination therapy for metastatic TNBC
[NCT02499367], but is not being trialed specifically for brain metastases.
Pembrolizumab, another PD-1 inhibitor, was given to 111 patients with TNBC in
the KEYNOTE-012 trial. Of note, 58.6% of patients had positive expression of PD-L1.
Of 27 evaluatable patients, the overall response rate was 18.5%. [63] The KEYNOTE086 trial of pembrolizumab monotherapy in treating metastatic TNBC showed its
efficacy, but again excluded any patients with brain metastases. [NCT02447003]
Pembrolizumab is now being explored in the treatment of BCBM with the caveat of
excluding HER2+ brain metastases. [NCT02886585]. In a newly launched trial, the
combination of activated T-cells and pembrolizumab to treat metastatic breast cancer
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allows for previously treated, stable HER2+ BCBM patients be enrolled.
[NCT03272334]
The PD-L1 inhibitor atezolizumab showed variable efficacy in the Phase I
TONIC trial of 112 metastatic TNBC patients. While only 10% of patients responded to
atezolizumab, the median duration response was 21 months, and all patients who
responded were alive after 2 years compared to just 11% survival in non-responders after
2 years. [64] Another PD-L1 inhibitor avelumab showed effectiveness in the JAVELIN
trial featuring TNBC patients, but did not look at patients with brain metastases. [65]
Durvalumab is another PD-L1 inhibitor being explored for metastatic TNBC. [61]
Pembrolizumab and atezolizumab are also being explored for the treatment of hormone
receptor positive breast cancer. [66]
The conjugation of trastuzumab and emtansine (T-DM1) allows for specific
targeting and selective cytotoxicity against HER2+ cancer cells. The discovery of T-DM1
efficacy in HER2+ BCBM was surprising, as it is even larger than the parent antibody. In
early 2015, the phase III EMILIA trial compared T-DM1 against capecitabine and
lapatinib in the treatment of HER2+ BCBM. Overall survival was 26.8 months in the TDM1 group and 12.9 months in the conventional treatment group. [67] Later that year, a
case series of 10 patients with HER2+ breast cancer and brain metastases who received
T-DM1 showed 3 patients with partial remissions and stable disease for 6 months in 2
patients, with a median survival of more than 8.5 months. [68] Multiple case series have
reported reductions in intracranial lesion size with T-DM1 therapy in HER2+ BCBM.
[69, 70] It was postulated that the antibody conjugate was better able to cross the
disrupted BBB seen in tumor environments, though this remains highly controversial.
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One retrospective study suggests that T-DM1 therapy, much like trastuzumab therapy,
may lead to formation of brain metastases despite adequate extracranial disease control.
[71] T-DM1 was tested in the BIRTH trial, and is currently involved in the KIARA trial,
both specifically for HER2+ BCBM. [NCT02135159, NCT03203616] It is being
investigated in combination with tucatinib (ONT-380) for the treatment of HER2+
BCBM. [NCT01983501]
The discovery of PD-1/PD-L1 and efficacy of T-DM1 has renewed interest in
exploring the microenvironment of BCBM.
2.2 Lung Cancer Epidemiology
In the United States, lung cancer is the second most common cause of cancer in
men and women, but is the most common cause of cancer death.[72] It is estimated that
more than 200,000 new cases of lung cancer will be diagnosed and more than 150,000
deaths from lung cancer will occur—more than 25% of all cancer deaths. [72]
Worldwide, it is the most common cause of cancer and of cancer death. The median age
of diagnosis is at 70, with median age of death at 72. [73] The incidence of lung cancer
has sharply declined for men and slowly declined for women reflecting new trends in
tobacco use. Despite incidence decreasing due to initiatives to reduce tobacco use, there
is approximately a 20-year lag in mortality improvement: the 5-year survival for lung
cancer is only 18%. This is because more than half of lung cancer will be metastatic on
diagnosis due to the lack of a ubiquitous non-invasive screening tool. [72] Screening for
lung cancer is limited to current or former smokers with at least a 30-pack year history.
Prior to the 1980s, lung cancer was primarily a disease of men. As women began
to consume tobacco, the “gender gap” of incidence and death rates due to lung cancer
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between men and women have narrowed. [74] Women are potentially more susceptible to
developing lung cancer while men have a higher mortality rate. [75] This may be due to
the estrogen receptor ß, which when activated causes proliferation and contributes
significantly to mortality, or other genetic differences allowing for DNA damage to have
greater impact than in males. [74] Smoking history remains the most important risk factor
for developing lung cancer, linked to more than 80% of lung cancer cases and deaths.
[74] Approximately 21% of Americans (46 million people) consume tobacco products.
[73] Smoking rates and linked lung cancer rates have been declining in the United States,
but rising sharply in Asian countries which huge increases in smoking rates. [73]
With smoking such a strong link to smoking to the point of being a causative
factor, it is paradoxical that up to 25% of lung cancer occur in “never-smokers”, which
are defined as people who have smoked fewer than 100 cigarettes in their lifetime. [73]
This finding is geographical, as a Japanese study showed that the percentage of neversmokers with lung cancer increased from 16% to 33% in a 30-year period, while in the
same period only 20% of lung cancer were associated with never-smokers. [73] Though
smoking is postulated as a broad, causative factor for lung cancer, only specific subtypes
of lung cancer are linked with smoking exposure.
2.2.1 Lung Cancer Subtypes
Lung cancer is split into two broad classifications: small-cell lung cancer (SCLC)
and non-small cell lung cancer (NSCLC). NSCLC is responsible for more than 80% of
lung cancer diagnosis. [76] Within NSCLC, the three most common subtypes are
adenocarcinoma, squamous cell carcinoma, and large-cell carcinoma. These cancers form
approximately 39%, 20% and 3% of all lung cancers, respectively. [73, 77] Smoking is
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strongly linked with SCLC and squamous cell carcinoma. Though adenocarcinoma is
more closely linked with never-smokers, the incidence of adenocarcinoma in patients
who smoke is becoming more common. [73]
SCLC is a highly aggressive tumor, possessing rapid growth, neuroendocrine
activity creating paraneoplastic syndromes, high vascularity, and rapid lethality due to
early metastatic dissemination. [78] Though SCLC is highly responsive to both radiation
and chemotherapeutic treatment, resistance rapidly and inevitably occurs, leading to
untreatable relapses. [78] Nearly ubiquitous mutations in TP53 renders genomic
instability and the MYC oncogene promotes rapid growth. [78] Since SCLC typically
does not possess any mutations explicitly for drug targeting, systemic chemotherapy is
given by default. Due to the metastatic nature of SCLC, resection is generally not
performed, in contrast to NSCLC. Patients with non-Stage IV NSCLC typically have
tumor resection via video-assisted thorascopic surgery (VATS) if surgery is tolerable,
followed by radiation and/or chemotherapy. [77]
Within NSCLC, adenocarcinoma possesses several mutations that influence
prognosis and survival. These derangements are checked for on initial diagnosis of
advanced disease. [79] Mutations in the KRAS oncogene occurs in up to 25% of
adenocarcinoma and is associated with smoking history. Presence of KRAS mutations
increases tumor aggressiveness and disease relapse, along with reduced response or
increased resistance to chemotherapy. [80] Interestingly, KRAS mutations have an
inconsistent effect on prognosis, as trials have reported that both wild type and mutated
KRAS have similar outcomes on chemotherapy or that mutants have shorter progressionfree and overall survival. [81] Mutations in KRAS may be a poor prognosis marker
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specifically in women with stage I NSCLC and Asian patients, and mutations in codon 13
confers resistance to chemotherapy when compared to codon 12 mutations. [81] KRAS
acts downstream from the EGFR pathway, thus mutations in the KRAS oncogene lead to
suboptimal therapeutic response or outright resistance to EGFR inhibitors. [82]
Mutations of EGFR occur in approximately 20% of adenocarcinoma, which
allows the evasion of programmed cell death, enhanced migration, and metastases
facilitation. [83] Found in women, never-smokers and Asian patients, EGFR mutations
however confer a positive prognosis, as the receptor is susceptible to inhibition by
competitive tyrosine kinases. [83, 84] The most common EGFR mutations occur on
exons 18-21, with exon 19 deletion (L8658R) being the most common (60%) and a point
mutation on exon 20 being second-most common. [83, 85] It is purported that the
mutations on exons 19 and 21 allow for targeting of tyrosine kinase inhibitors. [86]
Insertions on exon 20 may lead to tyrosine kinase inhibitor resistance, and the T790M
mutation is found in more than half of treated tumors. [83] While EGFR mutation occur
early in disease, amplification occurs late in disease and is associated with metastases.
[87] Inhibitors to overcome this mutation have been developed, which in turn have
caused a C797 mutation to develop within the EGFR ATP-binding site. Unfortunately,
targeted inhibitors do not improve survival without an EGFR mutation, so systemic
chemotherapy must be given to patients with wild-type EGFR. [85]
The discovery of anaplastic lymphoma kinase (ALK) and echinoderm
microtubule-associated protein-like 4 (EML4) rearrangements which occur in 7% of
adenocarcinoma in 2007 was monumental and drove tyrosine kinase inhibitor
development. [88] The t(2;5) chromosomal translocation allows constitutive ALK
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activity. [85] ALK-EML4 mutations are found in never-smokers and younger patients,
similar to EGFR mutations, though mutually exclusive and distant from both and KRAS
mutations. [89] Of 22 potential translocation variants, three major variants of ALK fusion
are found clinically. Variant 1 features a E13;A20 exon fusion (33% of total ALK
mutations), variant 3 has a E6a/b;A20 fusion (29%), and variant 2 possesses a E20;A20
fusion (9%). [88] One small trial of 54 patients discovered that possession of the 3a/b
ALK variant was a source of inhibitor resistance, but other trials report no correlation of
ALK variance type on survival. [90, 91] Possession of an ALK translocation or mutation is
associated with a poor prognosis and relapse or resistance to drugs within the first year of
treatment. [92]
Approximately 2% of lung cancer have ROS-1 fusion mutations. Much like ALKEML4 translocation mutations, ROS-1 mutations are associated with younger age and
never-smokers. [93] Unlike the ALK-EML4 fusion protein, ROS-1 fusion protein
mechanisms are unknown, but often feeds into common tyrosine kinase-signaling
pathways. [94] Since it is so uncommon, ROS-1 testing is often performed only after
EGFR and ALK results are negative. [94] The oncogene initially became an object of
interest when it was discovered it was concomitantly inhibited by the first ALK inhibitor
crizotinib, which subsequently gained FDA-approval to treat ROS-1 rearrangement
NSCLC. [94] ALK and ROS-1 are so similar that more than 75% of amino acids are
similar within the respective ATP-binding sites, which may explain why crizotinib is so
effective in treating ROS-1 mutated NSCLC. [95] Newer ALK inhibitors such as ceritinib,
lorlatinib, and entrectinib also inhibit ROS-1, presumably due to the homology. [96]
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The expression of PD-L1 in NSCLC has been a subject of debate since variable
expression exists not only between patients, but within tumor samples across time as
treatment occur. A study of 95 patients showed that PD-L1 expression might increase
when treated with EGFR inhibitors, thus enhancing the effects of PD-1/PD-L1 therapy.
[97] Another trial of four patients showed that PD-L1 expression changed after
chemotherapy and inhibitor treatment. [98] Though the presence of high levels of PD-L1
is a poor prognosis indicator, especially in NSCLC, the presence allows for treatment
with PD-1/PD-L1 inhibitors, which have revolutionized treatment for many cancer types.
[99, 100] As the check-and-balance process of the immune system is impaired to allow
hyperactivity, PD-1/PD-L1 inhibitors create significant burdensome and severe toxicity.
[101] Despite these drawbacks, inhibitors are becoming a frontline therapy for the
treatment of NSCLC and many solid tumors.
Within the scope of brain metastases, EGFR mutations and ALK or ROS-1
translocations allow targeting via tyrosine kinase inhibitors. First-generation inhibitors
poorly penetrate the blood-brain or blood-tumor barrier and cause relapse within a year.
[102] Subsequent generations are more effective and are being developed with the intent
to treat brain metastases. [103]
2.2.2 Lung Cancer Brain Metastasis
More than 50% of all brain metastases are caused by lung cancer and the most
common place for lung cancer to metastasize is the brain. [104] SCLC is the most likely
lung cancer subtype to metastasize to the brain; at diagnosis approximately 20% of
patients with SCLC will already have brain metastases, and approximately 80% will
develop brain metastases within 2 years. [105, 106] In contrast, approximately 7% of
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NSCLC patients will have brain metastases on presentation and up to 45% will develop
brain metastases within 2 years. [105, 107, 108] Mutation status may play an important
role in the development of lung cancer brain metastases (LCBM). It was found that
mutant EGFR was more likely to develop multiple brain metastases than wild-type, and
exon 19 deletions had smaller brain metastases. [109, 110] Approximately 30% of ALK
NSCLC patients will develop brain metastases. [111] Conversely, ROS-1 mutations may
cause lowered brain metastases rates. [111] Median survival of patients with LCBM at
presentation is approximately 4 months, and with aggressive treatment lengthens to just
over 12 months. [108, 112, 113] Patients who develop brain metastases later in disease
tend to live longer than those at diagnosis, and receiving chemotherapy increases survival
by approximately 2 months. [112]
Much like BCBM, chemotherapy, surgery, and radiation are components in firstline treatment of LCBM. Karnofsky performance status (KPS), age, number of
intracranial metastases, control of primary cancer, and the presence of extracranial
metastases are factors that predict clinical outcomes. [114] Female gender, age less than
58, adenocarcinoma subtype, single brain lesions, and surgical resection are considered to
be favorable prognostic factors. [115] Surgery is typically restricted to large and
symptomatic metastases. In the Quartz trial, WBRT revealed no survival benefit in the
context of LCBM. [116] Additionally, WBRT causes significant neurotoxicity and
cognitive decline. SRS shows a better adverse effect profile, and when combined with
WBRT, shows significant tumor control with lower rates of new intracranial lesions.
[117] Chemotherapy is often given to control primary tumor, but due to the failure to
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adequately cross the blood-brain and blood-tumor barriers, often results in subtherapeutic activities in treating LCBM.[108]
2.2.3 Conventional Lung Cancer Brain Metastases Chemotherapy
Brain metastases from both SCLC and NSCLC have a history of responsiveness
to chemotherapy. SCLC brain metastases are more initially responsive and often have a
complete response, followed by relapse. [118] Brain metastases from NSCLC that
possess a mutation surprisingly have a favorable outcome and responsiveness to
chemotherapy, perhaps due to the necessity of the oncogene to exert tumor activity. [119]
The backbone of most non-targeted lung cancer therapy consists of cisplatin and another
agent such as etoposide, topotecan, or pemetrexed. [108, 120, 121] Temozolomide is
commonly added to treat brain lesions. Other drugs to treat LCBM include vincristine,
cyclophosphamide, lomustine, and doxorubicin. [113]
In the GFPC 07-01 Phase II trial, 43 NSCLC brain metastases patients were
treated with cisplatin and pemetrexed every 3 weeks, in combination with WBRT.
Survival was extended to 7.4 months, with the development of severe hematological
toxicity in 17 patients. [122] Another similar trial with cisplatin, pemetrexed, and
radiation extended survival to 12.6 months with combination therapy. [123] In a
comparison of cisplatin and pemetrexed against temozolomide and pemetrexed, it was
found that the same efficacy existed but pemetrexed and temozolomide had fewer
adverse reactions, making the combination potentially more beneficial for NSCLC brain
metastases. [124] Since pemetrexed achieves CSF concentrations similar to serum levels,
it has been described as the “preferred” agent in platinum doublet chemotherapy. [125]
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Bevacizumab has gained footing as a standard-of-care therapy option in the
treatment of LCBM. Initial concern over bevacizumab administration in brain metastases
due to the risk of intracranial hemorrhage was mitigated as two trials showed its safety in
this setting. [126] In the French EOLE cohort study, bevacizumab alongside platinumdoublet therapy showed similar survival in patients with or without brain metastases.
[127]. In a case series of 4 NSCLC patients with a total of 60 brain metastases,
bevacizumab was combined cisplatin and pemetrexed along with stereotactic
radiosurgery, and was found to reduce the volume of tumors by an average of 75%. [128]
More clinical trials have supported the use of bevacizumab and platinum-based
chemotherapy in the treatment of NSCLC brain metastases. [128-133] Presence of brain
metastases is advocated to no longer be a contraindication to bevacizumab use. [134]
Temozolomide, FDA-approved for glioblastoma, has been explored for treating
LCBM. Results are varied: temozolomide was not shown to have any efficacy in the
Phase II EORTC 08965 study [135], and surprisingly not even in combination with
radiation therapy shows efficacy. [136] In contrast, another Phase II trial showed stable
disease in 10% of patients treated with temozolomide previously treated with WBRT and
chemotherapy.[137] Two clinical trials involving temozolomide specifically for NSCLC
brain metastases have been conducted, but no results are posted. [NCT00076856,
NCT00034697] Currently, temozolomide does not play an active role in first-line therapy
for LCBM.
2.2.4 Targeted Lung Cancer Brain Metastases Chemotherapy
Due to the presence of numerous genetic aberrations, targeted inhibitors are being
explored for concomitant primary lung tumor tumor and accompanying brain metastases
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treatment. Three major therapeutic targets exist: EGFR, ALK, and PD/PD-L1. The latter
will be explored in the immunotherapy subsection. Beginning with the first-generation
EGFR inhibitors in 2004, gefitinib and erlotinib were the first step in personalized
medication for NSCLC. Due to the high presence of brain metastases in NSCLC patients,
gefitinib and erlotinib were tested for efficacy in this setting shortly after discovery.
Gefitinib is the first of the first-generation EGFR inhibitors approved for NSCLC
patients. It has been shown to penetrate through the BBB, though the extent is
controversial. Plasma-to-CSF ratios is reported as approximately 20% [138], with a
strong dose correlation. [139] Human pharmacokinetics apparently vastly differ from
primate kinetic data, which show virtually no gefitinib uptake into brain parenchyma.
[138] Multiple small trials evaluated gefitinib in EGFR-mutated LCBM, both concluded
gefitinib provides enhanced survival. [140-142] Gefitinib has also shown efficacy when
combined with WBRT. [139] One case report shows gefitinib treating LCBM refractory
to erlotinib therapy, which is discussed next. [143]
Erlotinib has been shown to penetrate the BBB ease, achieving concentrations in
the CSF required to reduce intracranial tumor burden. [144] PET/CT scans show erlotinib
accumulating preferentially in brain lesions compared to normal brain parenchyma. [145]
A 69-patient trial showed erlotinib achieving an 82.4% response rate in patients with
EGFR mutant LCBM. [146] In one instance, erlotinib was able to control a brain
metastases refractory to another EGFR inhibitor afatinib, a second generation EGFR
inhibitor, discussed next. [147]
Differences among the first generation EGFR inhibitors exist. A comparison of
119 gefitinib and 13 erlotinib patients with NSCLC brain metastases showed erlotinib
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having both better intracranial disease control and lower recurrence rate. [148]
Unfortunately, both gefitinib and erlotinib require EGFR mutations in order to be active,
and Phase II trials demonstrated no beneficial effects when these agents were given in
EGFR wildtype LCBM patients. [149, 150] Another trial confirmed these findings in
combination with WBRT. [151] The role of first-generation EGFR inhibitors and
radiation therapy is not clear-cut. In instances, erlotinib has been shown to be synergistic
with WBRT [152], while in other cases there was no significant improvement in
combination. [153]
Afatinib, a member of the second-generation EGFR inhibitors, was shown to be
effective in treating EGFR-mutated LCBM during the LUX-Lung 3 and LUX-Lung 6
trials compared to cisplatin-pemetrexed or cisplatin-gemcitabine therapy, respectively.
[154] Patients in these trials respondent to afatinib had an exon 19 deletion and L858R
point mutation. This finding was peculiar, as preclinical work suggested afatinib is a
substrate for drug efflux pumps such as P-glycoprotein and BCRP, restricting
accumulation into the brain. [155] On the other hand, a LCBM model using PC-9 EGFR
mutant cells showed penetration of the BBB and a reduction in tumor burden. [156] The
discordance of preclinical and clinical finding has led to afatinib being involved in a
pharmacokinetic study to determine distribution and dose-responses in LCBM.
[NCT02423525] Dacomitinib, another member of the second-generation irreversible
EGFR inhibitors, was being explored for brain metastases, though the study is now
terminated. [NCT02047747]
Despite these advances in targeted therapy and increasing BBB/BTB penetration,
CNS progression occurs in approximately 50% of patients within 3 years of therapy
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initiation. [157] Due to the high incidence of lung cancer patients developing brain
metastases, focus shifted on creating targeted inhibitors to treat LCBM.
Osimertinib is currently the only FDA-approved member of the third generation
EGFR-inhibitors. While it also targets exon 19 deletions and L858R mutations, it is
specifically used when first- or second-generation EGFR inhibitors have failed and there
is a concomitant T790M mutation. [158] The prevalence and significance of the mutation
is discussed in the subtype section, though one study has noted the presence of T790M
mutations in brain metastases is lower than that of primary lung disease. [159] In the
AURA (extension) and AURA2 trial, 50 patients with asymptomatic brain metastases
were treated with osimertinib. 27 of 50 showed overall improvement and 6 of 50 showed
complete CNS response. [160] In the Phase III AURA3 trial, osimertinib was superior to
chemotherapy in treating T790M LCBM. [161] The AURA17 trial similarly showed
osimertinib leading to complete response in 10 patients and partial response in 15 patients
with T790M LCBM. [NCT02442349] The upcoming Phase II APPLE trial will compare
the effect of osimertinib and gefinitib on LCBM. [162] The upcoming third-generation
AZD3759 is being trialed against osimertinib in the BLOOM study, which specifically
focuses on LCBM efficacy. [163] [NCT02228369]
ALK inhibitor discovery have outpaced that of EGFR inhibitors, perhaps due to
their concomitant ROS-1 inhibition. Three generations of inhibitors exist, and much like
EGFR inhibitors, increases in generation are correlated with enhanced BBB/BTB
penetration for intracranial efficacy.[164]
The first agent FDA-approved for treating ALK-rearranged NSCLC was
crizotinib. Though good at controlling peripheral disease, a case report showed CSF
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accumulation and subsequent CNS disease progression. [165] Pooled data from the
PROFILE 1005 and PROFILE 1007 trials showed that CNS progression occurred in 70%
of patients treated with crizotinib. [166] Crizotinib does initially control intracranial
disease, but progression is inevitable, with most patients developing resistance within 2
years. [167] It is postulated that the inefficacy in LCBM is due to efflux pump activity, as
crizotinib is a substrate for ABCB1/ABCG2. [168] Similar efflux pumps restrict full
ceritinib penetration into the brain, but apparently not its efficacy in LCBM. [169]
Ceritinib, a member of the second-generation ALK inhibitors, is used in patients
who have progressed or become resistant on crizotinib therapy. Results of the ASCEND1 trial showed ceritinib controlled intracranial disease in 15 of 19 treatment-naïve LCBM
patients and 49 of 75 pretreated LCBM patients. [170] This led to the Phase II ASCEND2 trial which confirmed the ASCEND-1 findings of ceritinib use in both crizotinibpretreated and chemotherapy-naïve patients with ALK-mutated LCBM. [171, 172] The
recently-conducted ASCEND-5 trial compared single-agent ceritinib against
chemotherapy in patients who had progressed on both crizotinib and platinum-based
chemotherapy. Preliminary results show ceritinib improving overall survival. [173]
The other second-generation ALK inhibitor, alectinib, is a poor substrate for efflux
pumps such as ABCB1 and ABCG2. [174] In a Phase II study, 84 crizotinib-refractory
LCBM patients were treated with alectinib. 83% of CNS disease rate was controlled for a
median of 10.3 months, though at 12 months 24.8% had CNS progression. [175] Two
recent trials have shown alectinib’s efficacy in LCBM. The Phase III ALEX trial
compared alectinib and crizotinib with a radiation modifier, showing that alectinib
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achieves response with or without radiation [176], and the ALUR trial showed alectinib
superiority over platinum-doublet therapy in treating brain metastases. [177]
Brigatinib, a combined third-generation ALK and EGFR inhibitor, was approved
in April 2017 for the treatment of metastatic NSCLC, specifically as second-line therapy
for ALK-positive NSCLC. In the first of two Phase II trials, 31 patients (35%) had
complete resolution of brain lesions, while in the second study, a combined 25% had
complete resolution of brain lesions. [178, 179]
Lorlatinib, a combined ALK and ROS-1 inhibitor, is undergoing clinical phase
trials for the treatment of ALK-positive NSCLC. It is said that lorlatinib was designed to
primarily permeate through the BTB and treat LCBM. [180] 11C-lorlatinib was given to
non-human primates and PET imaging revealed enhanced distribution to the brain, liver,
and spleen. [180]Similarly, nude mice bearing NCI-H3122 subcutaneous xenografts were
given the radioactive drug and showed enhanced uptake. [180] In a Phase II trial of
patients with ALK-LCBM, 7 of 23 patients had a complete response on the drug, while 4
had a partial response. [181]
Entrectinib, an ALK, ROS-1, and Trk A-C inhibitor, has shown to be effective in
NTRK-positive LCBM. Similar to lorlatinib, it is designed to cross the BBB/BTB. [182]
Two possibilities for initial response followed by relapse is the presence of the
BBB and BTB, which create a sub-therapeutic environment for resistance to form. This is
the case for all chemotherapy acting directly on receptors or targets in tumor cells, but as
discussed next, not a possibility for immunotherapy.
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2.2.5 Immunotherapy for Lung Cancer Brain Metastases
Much like breast cancer, the discovery of PD-1 and PD-L1 checkpoint inhibitors
has propelled agents to first-line therapy in the treatment of lung cancer. It was found that
NSCLC LCBM has higher expression of PD-L1 compared to the primary lung tumor.
[58, 163] Further, PD-L1 expression in the context of NSCLC is associated with poor
prognosis. [183] PD-1 and PD-L1 inhibitors are typically antibodies, such as nivolumab,
pembrolizumab, and atezolizumab. All three are FDA-approved to treat metastatic
NSCLC after progression on platinum-based therapy. [184] Pembrolizumab can be used
as first-line therapy in NSCLC patients without EGFR or ALK mutations, though if these
mutations are present, all three agents are indicated if patients progress despite targeted
therapy.
Since EGFR inhibitors upregulate the PD-L1 expression on tumor cells, trials
initially recruited patients who were refractory to these agents. One study has shown that
patients with wild-type EGFR show better improvement in overall survival compared to
patients with EGFR mutants when given checkpoint inhibitors. [185] The role of PD1/PD-L1 inhibitors in the presence of EGFR mutation has been a subject of investigation.
[186-190] Preliminary reports combined targeted agents and checkpoint inhibitors,
revealing encouraging results but early termination due to significant side effects. [191,
192] Clinical trials are ongoing combining the two therapies. [NCT02039674,
NCT02364609, NCT02013219, NCT02574078, NCT02393625, NCT02584634,
NCT02898116, NCT02323126, NCT02454933, NCT01998126]
Interestingly, KRAS mutations are not associated with increases of tumor PD-L1
expression, and ALK oncogene expression have variable effects. [184, 193] To date, no
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published data specifically combine ALK-inhibitors and PD-1/PD-L1 therapy in the
context of metastatic NSCLC or LCBM, but trials are underway. [NCT02511184,
NCT01998126]
Pembrolizumab, in the KEYNOTE-024 trial, used information from KEYNOTE001 and KEYNOTE-010 to prove that it was superior to physician’s choice of platinumbased doublet therapy in the treatment of NSCLC. Enrollment included patients who had
no EGFR mutations or ALK translocations. [194] In a small Phase II trial with 18 NSCLC
patients with brain metastases, pembrolizumab achieved a response rate in 6 patients
(33%) that was sustained in all but one patient. [195] It is being explored in the treatment
of brain metastases, but excludes SCLC and NSCLC with either EGFR mutations or ALK
translocations. [NCT02886585]
Nivolumab showed an improvement in 2 of 12 patients with untreated NSCLC
CNS metastases in a portion of the CheckMate 012 trial. [196] In five patients with
LCBM, one patient achieved a complete and partial response each. [197] A retrospective
analysis of 48 LCBM patients revealed no response with nivolumab monotherapy, but
did show a response with radiation therapy prior to nivolumab initiation. [196] These data
lead nivolumab to be combined with stereotactic radiosurgery in an active Phase II trial
of LCBM patients. [NCT02978404]
In the Phase III PACIFIC trial, durvalumab showed efficacy in patients with
NSCLC. In this trial, new incidence of LCBM occurred in 11% in placebo-treated
patients compared to 5.5% treated with durvalumab. [198] Capitalizing on this success,
durvalumab is now being studied in patients with brain metastases from NSCLC.
[NCT0266914]
33

Much like the other two checkpoint inhibitors, atezolizumab too has shown
efficacy in LCBM. In a subset of OAK patients, atezolizumab was compared with
docetaxel on survival from, and time to develop LCBM. Atezolizumab improved survival
by nearly 8 months compared to docetaxel, with a lower risk of developing new lesions.
[199] Avelumab, an upcoming PD-L1 inhibitor, was shown to be effective in the
JAVELIN trial for NSCLC, but did not include patients with brain metastases. [200] The
upcoming JAVELIN-100 trial includes asymptomatic LCBM patients with certain
criteria. [NCT02576574]
Other forms of therapy to stimulate the immune system include adoptive cell
transfer of tumor-infiltrating lymphocytes, BCG vaccine, and antigen-specific cancer
vaccines. These have not been shown to be effective in the treatment of NSCLC or their
brain metastases. [201]
2.3 Glioblastoma Epidemiology
While 80% of all intracranial tumors are from metastases, the primary malignant
brain tumor glioblastoma comprises approximately ~16%. [202] Glioblastomas primarily
occur in the frontal or temporal regions of the cortex, though instances of tumors in the
spinal cord, cerebellum, and brain stem have been noted. [202] Though highly invasive
through brain parenchyma, they are restricted to these areas of the central nervous system
and do not metastasize. [203] Much like other intracranial tumors, glioblastoma are
highly heterogeneous and feature mutations in chromosomes leading to tumor suppressor
gene loss and/or amplification and expression of oncogenes. [203] The median age of
diagnosis is 64, with a median survival of 14-16 months and a 5-year survival of 9.8%.
[204]
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The risk factors for developing glioblastoma are not definitively recognized,
however ionizing radiation has been highly associated with the delayed development of
gliomas. [202] Cellular mutations of p53, EGFR, PTEN, PI3K, RAS, and Rb have been
found in glioblastoma, along with isocitrate dehydrogenase 1 mutations in secondary
glioblastomas. [202, 204] Interestingly, the enzyme O-6-methylguanine-DNA
methyltransferase (MGMT) is a predictive factor for survival: patients with MGMTmethylated tumors survive approximately twice as long as non-MGMT-methylated
tumors (22-26 months vs. 12-15 months, respectively). [204] The MGMT enzyme is
associated with better outcomes from medication therapy. [202, 203]
Current therapy for glioblastoma includes surgical resection followed by adjuvant
radiation therapy, often combined with chemotherapy. Aggressive surgical resection,
especially with greater extent around margins, is associated with better outcomes. The
size (>5 cm) and location of tumors (brainstem and diencephalon) are associated with
poorer outcomes. [202] After healing from the surgery, radiation and chemotherapy are
next. The typical radiation schedule is 60 Gy divided in 30 fractions, which is a lower
per-dose fraction than other schedules but gives a higher total dose overall. [203] The
next section talks about two FDA-approved non-specific chemotherapeutic agents for
glioblastoma; no targeted agents exist.
2.3.1 Glioblastoma Chemotherapy
Two DNA-alkylating agents, temozolomide and carmustine, are FDA-approved
for use in treating glioblastoma. [203] Temozolomide is orally administered
concomitantly with radiation therapy, acting as both a cytotoxic agent and radiosensitizer.
[205] It was shown that the MGMT may mediate this radiosensitivity. [205] This is
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because MGMT encodes a DNA-repair enzyme; methylated MGMT inhibits this enzyme
from being expressed and thus temozolomide activity is unimpaired. [202]
Temozolomide as monotherapy improves survival to 15 months from 12 months with
radiation therapy alone, with the combination of drug and radiation leading to 27%
survival at 2 years and 10% at 5 years vs. 11% and 2% for radiation, respectively. [202]
Carmustine, administered as degradable wafers, are applied to the regions
remaining after tumor excision. Though a Phase III trial showed survival benefit
compared to placebo, carmustine toxicity and the ease of temozolomide administration
precludes the wafers from use as first-line therapy to treat glioblastoma. [203]
2.3.2 Immunotherapy for Glioblastoma
Much like melanoma, IL-2 was one of the first immunotherapeutic agents trialed
in the treatment of glioblastoma. In 9 GBM patients, IL-2 administration showing
increases in survival periods ranging 7- to 17-months. [206] A vaccine against the
EGFRvIII, which is displayed in 20-30% of glioblastoma, did not increase survival in
patients with newly diagnosed glioblastoma in combination with temozolomide or in
comparison with temozolomide monotherapy. [207]
Checkpoint inhibition is said to “revolutionize” treatment of solid tumors such as
melanoma, non-small cell lung cancer, breast cancer, cancers which make up the top 8085% of brain metastases. In glioblastoma, the Phase III CheckMate-143 trial compared
nivolumab to standard-of-care bevacizumab. No improvement in overall survival was
noted. [NCT02017717] Despite this finding, nivolumab is being compared to
temozolomide (each in combination with radiation therapy) [NCT02617589] and also in
combination with temozolomide and radiation therapy against placebo. [NCT02667587]
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Pembrolizumab was tested in combination with bevacizumab for newly-diagnosed
glioblastoma [NCT02337491], and with MRI-guided laser ablation in recurrent
glioblastoma [NCT02311582]. Durvalumab is being tested in combination with radiation
therapy and bevacizumab [NCT02336165].
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CHAPTER 3
PHARMACOKINETICS OF LUCIFERIN IN PRECLINICAL BRAIN
METASTASES AND PRIMARY BRAIN TUMOR MODELS
3.1 Introduction
Brain tumors are associated with significant mortality and morbidity, with
patients succumbing to the tumors within two years [1]. Approximately 10-20% of
intracranial lesions arise from cells of the central nervous system (CNS), such as glial
cells which when mutated can result in the formation of glioblastoma [2, 3]. Of
significance, and often overlooked in the preclinical literature is 80% of brain lesions
start as a cancer in a distant tissue outside the CNS. The three dominant metastatic
originating cancers are lung, breast and melanoma [4]. There have been a significant
number of preclinical primary CNS and metastatic CNS models that have been recently
developed. Accordingly, there is a substantial need to be able to longitudinally quantify
tumor growth and response within the skull [5].
Quantifying preclinical intracranial longitudinal tumor response to therapy can be
difficult. Two common current modalities include magnetic resonance imaging (MRI)
and computed-axial tomography (CT) [6]. While these imaging modalities are noninvasive, they are often time-consuming and expensive. Direct cell-labeling with
quantum dots or use of radionucleotides are similarly expensive and may cause
significant toxicity [7, 8]. These imaging methods are being supplanted by the use of
luciferase. Three types of luciferase exist: Gaussia, Renilla, and Firefly, the latter of
which is used most commonly. Incorporation of the firefly luciferase (Fluc) enzyme into
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cells allows for non-invasive, non-toxic visualization and quantification in both in-vitro
and in-vivo settings [9].
In bioluminescence, Fluc oxidizes its substrate D-luciferin in an ATP-dependent
reaction to give off photons of light. These photons have an emission maximum (λmax)
of approximately 560 nm, which exists close to far-red spectra and are easily
distinguished against background light scatter for quantification accuracy [10]. As
vertebral systems do not endogenously express Fluc and since ATP is required in the
oxidation mechanism to produce photons, only living cells incorporated with Fluc will
produce signal, with the amount of signal proportional to amount of photon-producing
cells [10-12]. Neither Fluc incorporation nor D-luciferin create toxic effects in vertebrates
or cells [13, 14]. This allows Fluc and D-luciferin to be a highly sensitive and reliable
pairing for both real-time and longitudinal cellular proliferation, cellular migration, and
tumor burden [10, 15]. This process is bioluminescence imaging (BLI).
The rate of photon production from D-luciferin metabolism generally exhibit a
gradual increase and decrease surrounding peak intensity [16]. It is suggested that this
BLI peak that most accurately represents the extent of tumor burden [17]. Therefore,
performing a D-luciferin pharmacokinetic profile maximizes measurement of tumor
growth, chemotherapy response, and reproducibility in longitudinal studies. Each cell
line, method of luciferin administration, and mode of tumor inoculation will produce
different pharmacokinetic profiles [15, 18].
Herein, we utilize intraperitoneal injections of D-luciferin and firefly luciferase
pharmacokinetics to characterize BLI peak and minimal-error imaging times in three
preclinical metastatic brain and one intracranial cancer models. These models include the
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human HER2+ JIMT-1 and the triple negative MDA-MB-231 breast cancer lines, the
EGFR-mutant PC-9 lung cancer line, and the intracranial U251 glioblastoma line. We
observed an inverse relationship between peak photon production and length of optimal
imaging time: while peak BLI signal is comparatively delayed in the breast-brain
metastatic models, the optimal imaging duration is significantly longer than lung-brain or
intracranial tumors (p < 0.05). Similarly, an inverse relationship between time to peakBLI and statistically error-free period was observed: the lung-brain metastatic and
intracranial model had double the imaging window than the breast-brain metastatic
models (p < 0.05). Large variability exists within the first 10 minutes of imaging in all
models, and in intracranially injected models, this leaves sparse time for optimal
quantification. Significant differences in area under the curve for total photon emission
exists within groups of the in-vivo and in-vitro models (p < 0.05). In-vitro luciferin assays
using the same cell lines produce consistent signal production at similar values to their invivo peaks and greatly vary in their photon production and plateau region of optimal
signal capture, which suggest that each cell line has different intrinsic luciferase kinetics.
3.2 Methods and Materials
Chemicals and reagents
A lentivirus containing Fluc with the hygromycin selection marker was purchased
from Biosettia (GlowCell-16h). 10 μL of viral vector and 10 μL of polybrene (Santa
Cruz, sc-134220) was added to each well in a 6-well plate of JIMT-1-Br or U251 at 70%
confluence. Plates were spun at 1000 RPM for 60 minutes and placed in a 37C incubator
overnight. The following morning, cells were introduced to hygromycin at a
concentration of 10 μL/mL in media to ensure successful transduction. The PC-9-Br line
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was transduced with firefly luciferase plasmid from addgene (32904) by the methods in
Chapter 5.2 and selected for successful incorporation with G418 at 10 μL/mL. The
MDA-MB-231 cell line was pre-transduced with Fluc and kindly provided by Dr. Patricia
Steeg from the NIH. Cells were visualized in the IVIS Spectrum CT for luciferase
expression prior to injection into mice. Firefly D-luciferase potassium salt was purchased
from Perkin Elmer (Waltham, MA). All chemicals and reagents were of analytical grade
and used as supplied.
Cell Culture
The JIMT-1-Br and MDA-MB-231-Br brain-seeking breast cancer lines were a
kind gift from Dr. Patricia Steeg at the National Cancer Institute. The U251 glioblastoma
line was provided by Dr. Gordon Meares at West Virginia University. The PC-9-Br lung
cancer line was provided by Dr. Lori Hazlehurst at West Virginia University. JIMT-1-Br,
MDA-MB-231-Br, and U251 cells were grown in DMEM with 10% fetal bovine serum
and 5% penicillin-streptomycin, along with hygromycin at 10 μL/mL. PC-9-Br cells were
grown in RPMI with 10% FBS, 5% penicillin-streptomycin, and G4918 at 10 μL/mL. All
cells were used in passages 1-15, utilized at 70-80% confluence, and maintained at 37oC
with 5% CO2.
Brain Tumor Models
Female athymic nu/nu mice were purchased from Charles River Laboratories
(Wilmington, MA). All animals were approximately 6-8 weeks on time of model
initiation. Mice were anesthetized under 2% isoflurane and injected with 150,000175,000 cancer cells via the cardiac left ventricle using a stereotactic device (Stoelting,
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Wood Dale, IL). The same stereotactic device was used to inject 500,000 cells in the
intracranial model. U251 cells were injected slowly through the cranium approximately
1.5 mm below and 1mm to the right of bregma at 1 μL/minute for a 5-minute time period.
Animals were monitored until fully recovered. Experiments were conducted under the
institutional Animal Care and Use Committee protocol (WVU #1604001892). All
procedures performed in studies involving animals were in accordance with the ethical
standards of the institution or practice at which the studies were conducted. This article
does not contain any studies with human participants performed by any of the authors.
In-vivo pharmacokinetics
Bioluminescence was captured and quantified on the IVIS Spectra CT
(PerkinElmer). Animals were anesthetized and laid supine on the imaging field, then
given IP injections with 150 mg/kg of D-luciferin. Immediately after injection, image
acquisition was initiated and photon emission was captured every 1-5 minutes for a 4560-minute sequence. Signal was captured using auto exposure, medium binning, F/Stop
1, on Stage D. A region of interest was drawn around the cranium at each time point and
photon emission was collected. This region of interest is defined as radiance
(photons/sec/cm2/steridian) [19]. After radiance collection each animal’s signal was
additionally normalized from peak bioluminescence signal for between-groups
comparison and plotted over time of capture (Fig. 3.1). Area Under the Curve (AUC) was
calculated using radiance and normalized data for imaging duration via GraphPad Prism
6.
In-vitro pharmacokinetics
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To correlate in-vivo bioluminescence with in-vitro assays, pharmacokinetic
profiling of these cell lines were performed on clear-bottom black 96-well plates (B-D
#353220). Cancer cells were seeded at a concentration of 5,000 cells per well and
incubated overnight. The following day, D-luciferin at 15 µg/100 µL was given to each
well and immediately imaged on the IVIS Spectrum CT every 1 minute for a 30-minute
sequence, using auto exposure, medium binning, F/Step 1, and on Stage D. Signal at each
minute was averaged across 96 wells, then plotted over time as radiance
(photons/sec/cm2/steridian) and then separately normalized for additional comparison.
Exponential decay
The exponential decay equation Xt*e-kt, was modified for bioluminescence: Pt*ekt

; where Pt and k represents the amount of photons/second at time t. In vivo, k represents

absorption (α) or elimination (ß); in-vitro this represents fast (Kfast) or slow (Kslow)
elimination. This equation was applied to radiance and normalized values to obtain an α
absorption slope value for each model.
Statistics
The D’Agostino and Pearson omnibus normality test was conducted to confirm
Gaussian distribution of values prior to calculations. A one-way ANOVA for multiple
comparisons using Tukey’s or Dunnet’s multiple comparisons test was performed to
compare radiance and normalized kinetic curves and peaks. Time within bioluminescence
values statistically insignificant from peak values indicates a duration of minimal error.
Error range was calculated by averaging the range of signal in 10-minute intervals. A
one-way ANOVA was performed to compare each model’s in-vivo and in-vitro AUC

68

values. To calculate α and ß slopes for in-vivo luciferin kinetics, one-phase kinetic
modeling was used. A two-phase kinetic modeling was used for in-vitro kinetics to define
Kfast and Kslow. Significance for all tests was defined as a p < 0.05. GraphPad Prism 6.0
was used to calculate all statistics and produce all graphs.
3.3 Results
Peak bioluminescence occurs faster in the intracranial model compared to
metastatic models
To determine peak BLI timing, we injected Fluc-transduced tumor-bearing mice
with D-luciferin and captured the rate of photons emitted through time (radiance). For
distinguishing purposes, data was normalized and all points are plotted at 4-6 minute
intervals. Minimal-error imaging is defined as signal not statistically significant (p <
0.05) from peak value. Radiance data is shown in Fig 3.2. Significant variation exists
between and within animal groups, so results will focus on normalized data. In the MDAMB-231-Br line (n = 4), peak BLI occurred at 20 ± 2.7 minutes, with significant signal
difference occurring before 15 minutes and after 25 minutes (Fig. 3.3a). In the JIMT-1Br line (n = 3), peak BLI occurred at 16 ± 1.2 minutes, with a minimal-error duration of
10 to 24 minutes (Fig. 3.3b). In the PC-9-Br line (n = 4), peak BLI occurred at 12 ± 3.1
minutes, with minimal-error occurring before 5 minutes and after 24 minutes. (Fig. 3.3c).
For the U251 line (n = 3), peak BLI occurred at 9 minutes, with significant signal
difference occurring before 5 minutes and after 21 minutes (Fig. 3.3d). The results are
summarized in Table 3.1. The amount of signal captured (Pmax) at peak BLI follow peak
BLI timing (Table 3.2). Normalized in-vivo data is represented in Table 3.3.
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Optimal bioluminescence capture timing is longer in the metastatic model
compared to the intracranial model
After creating luciferin pharmacokinetic curves for each model, normalized signal
ranges from peak was calculated in 10-minute blocks. It was found that the 10-20 minute
time block contained the smallest range of signal in most models, displaying an intensity
above approximately 95% of peak BLI (Table 3.4). Similar variability of signal and
optimal timing were described in another study of luciferin BLI [20]. Time correlating to
> 95% of peak BLI signal was 15-25 minutes for the MDA-MB-231 model (Fig. 3.3a),
12-20 minutes for the JIMT-1 model (Fig. 3.3b), 9-14 minutes for the PC-9 model (Fig.
3.3c), and 7-12 minutes for the U251 model (Fig. 3.3d); summarized in Table 3.1.
In-vitro bioluminescence reaches a plateau at similar times to in-vivo peak
values
To correlate in-vivo models with their in-vitro counterparts, 5,000 cancer cells
were added to 96 clear-bottom black-welled plates and incubated overnight. The
following day, luciferin was added, followed by quantification and data normalization.
Qualitative 5-minute time lapses are shown (Fig. 3.4a). A plateau was defined as signal
change less than 1% between normalized values. In the PC-9 model, BLI signal rapidly
dropped off until reaching plateau at 70% of initial peak value at 14 minutes (Fig. 3.4c).
This timing qualitatively corresponds exactly with the in-vivo peak seen in this model. In
the U251 model, BLI signal rapidly dropped off until reaching plateau at 43% of initial
peak value at 7 minutes (Fig. 3.4d). This timing qualitatively agrees with the in-vivo peak
luminescence in this model seen at 9 minutes. This qualitatively parallels the in-vivo peak
seen at 20 minutes in this model. The JIMT-1 line diverges from these findings. While
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the in-vivo peak occurs at 16 minutes, the in-vitro plateau begins at 7 minutes and lasts
until 18 minutes, at which point signal begins to fall. Signal within the plateau was 85%
of initial peak value (Fig. 3.4b).
Normalized in-vivo a slopes and radiance ß slopes are correlated with peak invivo bioluminescence times
With regards to absorption slopes, PC-9 had the fastest slope (0.3689) and JIMT-1
had the slowest slope (0.0919), with U251 (0.1476) and MDA-MB-231 (0.2161) in
between (Table 3.2). A linear regression revealed an r2 of 0.01, indicating no correlation.
Normalized α values resemble radiance α values: the PC-9 line had the steepest α slope of
0.4862, while the JIMT-1 line had the lowest α slope of 0.11. The α of the MDA-MB-231
line of 0.2017 and U251 of 0.2980 fell in between (Table 3.3). A linear regression of
peak luminescence times and normalized α slope values produced an r2 of 0.32,
indicating modest correlation. Radiance data shows that the U251 model has the highest ß
value of 0.022 photons/sec, whereas the MDA-MB-231 model has the lowest ß value of
0.0127 photons/sec (Table 3.2). The radiance ß of the PC-9 (0.0128) and JIMT-1
(0.0220) fell in between (Table 3.2). A linear regression of radiance ß and peak
luminescence times had an r2 of 0.33, indicating modest correlation. In contrast, the
normalized ß luciferin elimination slope was the slowest in the PC-9 line at 0.0036
followed closely by the MDA-MB-231 of 0.0053, then U251 at 0.0137, and was the
fastest in the JIMT-1 at 0.0192 (Table 3.3). A linear regression of normalized ß slope
values and peak bioluminescence times produced an r2 of 0.02, indicating no correlation.
Radiance and normalized AUC0-60 are correlated with peak bioluminescence
times
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Radiance was plotted over time and the AUC (total photons given off during
imaging time) for length of capture was quantified. The AUC0-60 was the highest in the
U251 (1.2 x108) and lowest in the MDA-MB-231 model (4.4 x 103), with JIMT (7.4 x
107) and PC-9 (3.0 x 106) falling in between (Table 3.2). This agrees with peak in-vivo
bioluminescence timing, and a linear regression analyses produced an r2 of 0.37. A oneway ANOVA showed significant differences in radiance AUC between all models (p <
0.05). In contrast, the normalized AUC0-60 was the highest in the MDA-MB-231 (3750)
and PC-9 (3550) cell lines, followed closely by JIMT-1 (3120), and lowest in the U251
line (2760) (Table 3.3). A linear regression of peak bioluminescence times and
normalized AUC0-60 resulted in an r2 of 0.52. A one-way ANOVA showed significant
differences between these curves, with the MDA-MB-231 AUC significantly different
from the JIMT-1 and U251 AUCs, the JIMT-1 AUC showing significant difference to
MDA-MB-231 and PC-9 AUCs, and the U251 AUC showing statistically significant
difference from the MDA-MB-231 and PC-9 AUCs (p < 0.05) (Fig. 3.5).
In-vitro two-phase decay Kfast values correlate with peak in-vivo signal times
After plotting radiance and normalized values against time for each in-vitro
experiment, two-phase decay kinetics were utilized to measure decay until plateau (Kfast)
and decay from plateau (Kslow), to elucidate if decay constants correlated with peak invivo luminescence time. The largest radiance Kfast was seen in the U251 model (0.4717),
the smallest in the PC-9 model (0.1810), with MDA-MB-231 (0.3142) and JIMT-1
(0.3830) falling in between (Table 3.2). A linear regression produced an r2 of -0.53,
indicating larger Kfast values are correlated with faster peak bioluminescence timing. The
largest normalized Kfast was seen in the U251 model (0.4717) and the slowest in the
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MDA-MB-231-Br model (0.1352), which was followed by JIMT-1-Br (0.1652) and PC-9
(0.1790) (Table 3.3). The values of normalized Kfast were plotted against peak in-vivo
bioluminescence times resulting in a linear regression producing an r2 of 0.66.
3.4 Discussion
D-luciferin is a non-toxic marker utilized for both in-vitro and in-vitro
bioluminescence measurements. By capturing photon emission and visualizing emission
trends through time, longitudinal assessment of therapy efficacy can be performed. Two
issues with in-vivo and in-vitro BLI collection are addressed in this study: the optimal
time to initiate signal collection, and the duration in which signal will not vary
significantly from peak photon emission time. Both of these issues are dependent on
which type of luciferase is used for BLI data.
Different types of luciferase exist. The three most commonly used are Rluc,
Gaussia Gluc, Fluc, the latter is also termed luc2 [21, 22]. Rluc and Gluc metabolize
coelenterazine to give off an intense burst of light before rapidly returning to nearbaseline levels, termed “flash kinetics” [23]. This makes Rluc and Gluc difficult to work
with, as small differences in imaging time can cause significant quantification
differences. In contrast, Fluc metabolizes D-luciferin to produce light and slowly
decreases in signal intensity, termed “glow kinetics” [23]. Though Fluc does not produce
as intense an initial signal as Rluc or Gluc, it is the most common vector for luciferin BLI
due to the maintenance of signal intensity.
Photons produced by Fluc are away from the blue absorption values of Rluc
(λmax = 480 nm) and Gluc (λmax = 460 nm) [22, 24, 25]. This wavelength range
overlaps with fluorescence with structural proteins such as collagen and elastin, as well as
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enzymes such as NADH and NADPH, and other proteins such as lipofuschin [26, 27].
Tissue often displays “auto-fluorescence”, which can generate significantly obstructive
background signal [28]. The production of photons during in-vivo fluorescence brain
imaging is often attenuated by the cranium [29]. In order to quantitatively image the
brain, thinning of the cranium and a window placement is often required, though data
gathered may not be specific unless used in near-infrared ranges [30]. This is not optimal
for brain metastatic models especially during longitudinal studies due to the number of
tumors produced and the invasiveness of the procedure. The spectra range of photon
emission further supports the use of Fluc over Rluc or Gluc as longer wavelengths (> 600
nm), especially those in the red and far-red spectrum, are better able to transmit through
tissue compared to blue and green spectra [31]. Efforts are made to create Fluc analogs
that produce spectra even closer to the 700 nm range, reaching edges of infra-red
wavelengths [32, 33].
Of interest, we were able to fit, and apply, our data to a linear exponential decay
curve. The exponential equation Xt*e-kt is utilized in many disciplines, including
radioactivity, pharmacological half-life, and fluorescence [34]. In this equation, Xt is a
quantity at time t, and k is a value indicating growth or decay [34]. Adapted for
bioluminescence, the equation becomes Pt*e-kt, where Pt and k represents the amount of
photons/second at time t. In vivo, k can represent absorption (α) or elimination (ß); invitro this can represent fast (Kfast) or slow (Kslow) elimination. Visualized, k is represented
by the slope connecting data points. Thus, the steeper the slope, the faster the rate
constant.
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The timing of signal capture onset is essential, as seen by the large, rapid increase
of photon production occurring within the first 10 minutes after luciferin injection in all
models. This timing is crucial whether working with the “flash” Gluc and Rluc luciferin
reporters due to their rapid onset-offset characteristics. Signal discrepancy from peak BLI
is the lowest during the 10- to 20-minute time block, following an ebb-and-flow pattern
as signal returns to baseline; this time block thus represents the optimal time for BLI
acquisition as maximum signal will be captured. The time to reach peak BLI is generally
delayed in the metastatic models compared to the intracranial model, but have nearly
double optimal imaging collection periods.
It is possible that BLI kinetics of the intracranial model is due the larger number
of cells injected and/or the type of tumor lesion formed. While the 150,000-175,000 cells
administered in the intracardiac metastatic model produce more numerous, small lesions
[35], the 500,000 cell intracranial model creates one large tumor [36]. The size of tumor
may also account for the narrow optimal imaging time and the large minimal-error
window, as a larger tumor may utilize more luciferin in a given period of time, as
evidenced by the U251 radiance Pmax and AUC. This is the impetus for data
normalization, as each animal between and within models is placed on the same scale for
easier and more accurate comparison [37].
Entry to the brain tissue is restricted due to the presence of the blood-brain barrier
(BBB). The BBB is composed of endothelial cells attached by tight junctions, astrocytic
foot processes, and enzymes to efflux and degrade molecules [38]. As cancer cells grow,
they often create new vasculature in a process called angiogenesis. These immature
vessels are compromised, and the blood-tumor barrier (BTB) allows some permeation of
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restricted molecules into tumor and brain tissue [38]. Permeability of a substance through
the BBB or BTB can be estimated using Lipinski’s Rule of 5s, or visualized and
quantified using radioisotope data.
Lipinski’s Rule of 5 are used to estimate if molecules are able to permeate the
blood-brain barrier (BBB). An optimal molecule should have a molecular weight lower
than 500 daltons, lipophilicity measured by logP > 5, not donate more than 5 hydrogen
bonds, and not accept more than 10 hydrogen bonds. [39] It should be noted that most
BBB-permeant molecules have a logP of approximately 2.5 [40]. D-luciferin has a
molecular weight of 280 Da, donates 2 hydrogen bonds, accepts 5 hydrogen bonds, and
has a logP of 0.5, fulfilling three of these four rules [41]. A variant of logP, logD is
calculated using a buffered solution and represents a molecule’s lipophilicity at pH 7.4.
As this mimics physiological conditions, logD may be more useful than logP in
determining the BBB-penetrating capability of a molecule. A logD of 1-4 indicates likely
BBB permeability [42]. D-luciferin has a logD of approximately -2.34 at physiologic pH,
indicating high water solubility, which corresponds with the report of radioisotope 14C-Dluciferin accumulating at comparatively low amounts into brains of naïve nude mice, the
same type used in these experiments [43].
The association between vasculature and BLI is well documented. Antiangiogenic agents cause both a significant delay in peak timing as well as reduced levels
of photon emission [20]. This is confirmed by visualizing reduced blood flow by
magnetic resonance imaging [20]. Additionally, this study found up to 60% variability
between consecutive imaging points, with a 95% confidence interval near peak showing
≤ 20% variability, which are similar to our findings [20]. A VEGFR-luc transgenic stroke
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model showed that increased new vessel formation was associated with increased photon
emission, confirmed with MRI imaging showing enhanced T2 values [44]. An
intracranial glioblastoma model found that luciferin BLI intensity increased as tumor
angiogenesis occurred [45], and luciferin has been used for ex vivo imaging in avascular
tissue such as intervertebral disks [46].
Heterogeneity of tumor vasculature may be responsible for the differences in
delivery of D-luciferin and the kinetic curves. The U251 tumor vasculature is more
permeable to the small 14C-aminoisobutyric acid molecule compared to metastatic
models). Using luciferin for in-vitro experiments removes dependencies of absorption
and vasculature on in-vivo BLI. Maximum photon emission begins directly after addition
of D-luciferin. This is seen in the PC-9 and U251 models which then stabilized to a
plateau, the timing of which is similar to their in-vivo peak time. Rather than beginning
signal capture immediately after D-luciferin administration, for minimized error and
optimal collection, in-vitro models should be imaged upon reaching a signal plateau,
which generally resembles in-vivo peak time.
Both radiance and normalized AUC0-60 is correlated to peak bioluminescence
timing. The U251 model had the smallest AUC0-60 but the fastest peak time, while the
MDA-MB-231-Br model had the highest AUC0-60 and most delayed peak time. This
suggests that despite same Fluc incorporation, cells metabolize luciferin at different rates,
supported by significant differences in in-vivo peak times (highest in MDA-MB-231,
lowest in U251) and in-vitro Kfast values (lowest in MDA-MB-231, highest in U251).
In conclusion, we characterized luciferin bioluminescence curves in brain tumor
models and their in-vitro counterparts, highlighting intra-model similarities and inter77

model differences. Future studies will focus on determining vascularity differences of
preclinical brain metastases and primary glioblastoma, Fluc copy numbers of each cell
line, and enzyme kinetics based on different routes of D-luciferin administration.
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3.5 Conclusion
We report the luciferin pharmacokinetics for emerging brain metastases models
and an established intracranial brain tumor model, but there are three key differences.
Peak bioluminescence occurs later, optimal imaging time is longer, and time of
minimized error is shorter in the metastatic model. In-vitro imaging times exhibit firstorder kinetics in which signal plateau corresponds with in-vivo peak timing, revealing
consistent models. The time to in-vitro plateau and in-vivo peak signal production is
unique to each cell line and cannot be substituted without incurring significant error.
These parameters are critical to consider as the preclinical models are used in
translational efficacy studies.
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Figure 3.1. Representative time-course of bioluminescence capture and
quantification.
150 mg/kg of d-luciferin was administered via intraperitoneal injection into a mouse
bearing the MDA-MB-231 brain-seeking tumor line. A region of interest was drawn
around the skull to quantify photon emission. Counts are displayed as low (blue) to high
(red). Data was normalized to peak values of each animal and plotted against time. The
peak value can be seen at 20 minutes (Panel 4), with optimal imaging time occurring
between 15 (Panel 3) and 25 minutes (Panel 6).
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Figure 3.2. Radiance luciferin pharmacokinetics for brain tumor models.
Photons emitted per second were plotted over time in the (A) MDA-MB-231-Br, (B)
JIMT-1-Br, (C) PC-9-Br, and (D) U251 models. Large variability exists between animals
in the same group. Peak signal production is distinguished as a star-shape in each graph.
All data points represent mean ± SD (n = 3-4).
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Figure 3.3. Normalized luciferin bioluminescence profiles for brain tumor models.
(A) The metastatic breast lines MDA-MB-231 and (B) JIMT-1 have delayed peak times
but longer optimal imaging windows, while the (C) PC-9-Br and (D) U251 models
feature the fastest onset to peak times and smallest optimal imaging window time. Green
represents optimal signal capturing time (above 95% of peak) while yellow represents
values that are insignificant (p < 0.05) from peak intensity but fall outside of the optimal
range. Peak BLI is distinguished as a star-shape in each graph. Data was analyzed using
one-way ANOVA with Dunnet’s multiple comparison test. All data points represent
mean ± SD (n = 3-4).

88

Figure 3.4. In vitro luciferin kinetics corresponds with in vivo bioluminescence.
Qualitative 5-minute imaging for imaging duration is shown for models (A). The JIMT-1
(B), PC-9 (C), and U251 (D) models display first-order kinetics with a rapid followed by
a slow elimination phase. Plateau was defined as a ± 1% change from previous signal. In
vitro models reach signal plateau at similar times to their in vivo peak times (inset
arrows). All data points represent mean ± SD (n = 96), with error ≤ 1% residing within
the plot.

89

Figure 3.5. Radiance and normalized AUC comparisons.
In vivo radiance (A) and normalized (B) bioluminescence AUCs were calculated, as were
in vitro radiance (C) and normalized (D) bioluminescence AUCs for comparison. In both
models, U251 shows the highest radiance AUC and lowest normalized AUC. A one-way
ANOVA using Dunn’s multiple comparisons showed AUC within a plot are significantly
different from each other (p < 0.05) except for normalized in vivo AUCs. Error ≤ 1%
resides within the plot. All data represents mean ± SD, n = 3-4.
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Cell
Line

Number of
animals

Method of
Injection

4

Intracardiac

20

15 – 25

15 – 25

JIMT-1Br

3

Intracardiac

16

10 – 24

12 – 20

PC-9-Br

4

Intracardiac

12

5 – 24

9 – 14

U251

3

Intracranial

9

5 – 21

7 – 12

MDAMB231Br

Peak
Minimal error Time > 95% of peak
bioluminescence imaging timing
bioluminescence
time (minutes)
(minutes)
(minutes)

Table 3.1. Timing of luciferin imaging for in vivo cancer cell models.
Bioluminescence imaging for each cell line were characterized for time to peak signal value, signal statistically insignificant (p
> 0.05) from peak value defined as minimal error time, and time above 95% of peak value defined as optimal imaging time.
Metastatic models feature delayed peak timing compared to the intracranial model. Lengthier BLI peak times are associated
with shorter minimal error time but longer optimal imaging time. An ANOVA with Dunn’s multiple comparison test was
performed to determine minimal error times, significance defined at p < 0.05
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Cell
Line

Radiance

Pmax ±
SD

Radiance

Elimination AUC ±
Slope (ß)
SEM

Kfast

Kslow

MDAMB231Br

0.2161

1.16 ±
0.32
x102

0.0127

4.35 ± 0.31
x103

0.3142

0.1352

JIMT1-Br

0.0919

2.25 ±
1.34
x106

0.0190

7.35 ± 1.04
x107

0.3830

0.1652

PC-9Br

0.3689

8.52 ±
1.29
x105

0.0128

2.99 ± 1.03
x106

0.1810

0.1790

U251

0.1476

4.61 ±
5.31
x106

0.0220

1.19 ± 0.34
x108

0.4717

0.4717

Absorption
Slope (α)

Radiance

Radiance Radiance

Table 3.2. Radiance pharmacokinetic data for tumor models.
BLI signal was plotted as radiance (photons/sec/cm2/steridian) against time. One-phase
kinetic modeling was used to plot in vivo signal rate to peak (α) and elimination rate (ß),
and two-phase kinetic modeling for as in vitro fast (Kfast) and slow (Kslow) signal
deterioration. Area under the curve (AUC) represents total photon emission during signal
capture. The peak radiance (Pmax), AUC, and in vitro kinetics were highest in the
intracranial U251 model while ß was lowest. A one-way ANOVA using Dunn’s multiple
comparison showed the AUC of each model was statistically different from one another
(p < 0.05). All data is based on n of 3-4 per model.
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Cell Line

MDA-MB-

Normalized

Normalized Normalized

Absorption

Elimination

Slope (α)

Slope (ß)

AUC ± SEM

Normalized curve

Normalized

difference (p < 0.05)

Kfast

Normalized
Kslow

0.2017

0.0053

3749 ± 118

JIMT-1, U251

0.1279

0.1279

JIMT-1-Br

0.1054

0.0192

3120 ± 40

MDA-MB-231, PC-9

0.1971

0.0119

PC-9-Br

0.4862

0.0036

3545 ± 83

JIMT-1, U251

0.1817

1.46 x10-16

U251

0.2980

0.0137

2757 ± 89

MDA-MB-231, PC-9

0.4713

1.17x10-16

231-Br

Table 3.3. Normalized pharmacokinetic data for tumor models.
Signal captured during BLI was normalized to percent based on peak and plotted against time to create a normalized
pharmacokinetic profile for each tumor model. In contrast to radiance data, the intracranial U251 model has the largest α and
AUC, while the MDA-MB-231 model has the largest AUC. A one-way ANOVA using Dunn’s multiple comparison showed
statistically different AUC between certain models (p < 0.05). All data is based on n of 3-4 per model.
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Cell Line

0-10

10-20

20-30

30-40

40-50

50-60

MDA-MB231-Br

53.2%

26.5%

16.5%

19.5%

17.6%

14.6%

JIMT-1-Br

75.2%

4.3%

23.8%

27.7%

17.5%

8.1%

PC-9-Br

73.7%

9%

15.3%

15.5%

14.5%

10.6%

U251

78.9%

17.5%

21.0%

15.9%

9.2%

Table 3.4. Signal range during bioluminescence imaging.
After signal acquisition, data was normalized and plotted. Percent range of 10 minute
blocks was calculated. The highest range occurs in the first 10 minutes in all models,
followed by the 10-20-minute block which has the lowest range in most models. Potential
error is greatest if imaging in the first 10 minutes, but minimal in the 10-20-minute block,
corresponding with minimal-error and optimal imaging times.
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CHAPTER 4
EFFECTS OF ETIRINOTECAN PEGOL (NKTR-102) IN THREE
PRECLINICAL BREAST CANCER BRAIN METASTASES MODELS
4.1 Introduction
Breast cancer is both the second-most diagnosed cancer and second-most cause of
cancer death in women resulting in an estimated 250,000 new cases and 40,000 deaths in
2017. [1] Brain metastases occurs in approximately 10-20% of all breast cancer cases. [2]
Prognosis is typically poor and often dependent on metastatic lesion number, size and cell
phenotype. [3] Triple negative breast cancer (TNBC) and human epidermal growth factor
receptor (HER2)-positive metastases occur more frequently, numerously, and are
associated with the shortest survival. [3-5] Treatment of breast cancer brain metastasis
(BCBM) includes surgical resection, whole brain radiation therapy (WBRT), stereotatic
radiation, and systemic and targeted chemotherapy. [6, 7] TNBC makes up approximately
10-15% of breast cancer cases and 20% of BCBM [8] while HER2+ makes up
approximately 20% of breast cancer cases and up to half of patients develop brain
metastases. [9, 10] Despite advances in treatment, survival after diagnosis of BCBM
ranges between 4 and 26 months. [3-5] The resistance of BCBM to chemotherapy is
mainly due to the physiochemical activities of the blood-brain barrier (BBB) and bloodtumor barrier (BTB). [4, 5]
The physical BBB is composed of endothelial cells joined by tight junctions, a
basement membrane, pericytes, and astrocytic foot processes. [11] Efflux transporters
such as P-glycoprotein (Pgp), breast cancer resistance protein (BCRP), and intracellular
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enzymes (phosphatases, oxidases) comprise the chemical portion of the BBB, further
restricting brain penetration of chemotherapy. [11, 12] In brain metastases, vasculature is
often compromised, resulting in the BTB. Though often described as “leaky”, vascular
disruption in the BTB does not always significantly impact chemotherapeutic penetrance
due to intact efflux activity. [13, 14] Pharmaceutical development of chemotherapy that
offers enhanced brain penetration often consists of active agents conjugated to polymers
like polyethylene glycol (PEG). [15]
Etirinotecan pegol consists of four arms in which each arm is composed of a PEG
polymer, a cleavable ester linker, and a molecule of irinotecan. As a 20 kDa molecule,
penetration of etirinotecan pegol into normal tissue is limited by intact vasculature but
has less difficulty penetrating tumor vasculature. [16, 17] Upon administration, ester
cleavage slowly releases irinotecan which is further metabolized to the active SN-38
molecule, providing sustained topoisomerase I inhibitory activity. [18] Etirinotecan pegol
has shown efficacy as monotherapy in chemotherapy-resistant metastatic ovarian [19]
and breast cancer [20]. The BEACON trial did not show significant survival difference of
etirinotecan pegol against physician’s choice (eribulin, vinorelbine, gemcitabine,
paclitaxel or docetaxel) in the treatment of advanced breast cancer [16] but post-hoc
analysis of data showed that BCBM patients could benefit from therapy. [21]
As previously reported, etirinotecan pegol dosed at 50 mg/kg equivalents of
irinotecan in a preclinical triple negative BCBM model provides SN-38 concentrations
similar to the 145 mg/m2 dose used in the BEACON trial, which lead to improved
survival against placebo and conventional irinotecan 50 mg/kg. [17] Adapting the intent
of the BEACON trial, we hypothesized that this dose of etirinotecan pegol would
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significantly improve survival when compared to eribulin, vinorelbine, gemcitabine, or
docetaxel monotherapy in the human triple negative MD-MBA-231-BrLuc, murine triple
negative 4T1-BrLuc, and human HER2+ JIMT1-BrLuc BCBM models.
Herein, we present evidence that etirinotecan pegol 50 mg/kg preferentially
accumulates into metastatic lesions compared to non-tumor brain parenchyma.
Etirinotecan pegol increases median survival in both MDA-MB-231-BrLuc and JIMT-1BrLuc human breast-brain metastases models (p < 0.05) compared to traditional
physician’s choice chemotherapy (p > 0.05), but does not improve survival in the murine
4T1 model (p > 0.05).
4.2 Methods and Materials
Animals
Female athymic nude mice aged 4-8 weeks weighing 20-25 grams were bought
from Charles River Laboratory (Kingston, NY) and housed for a minimum of 72 hours to
facilitate acclimation prior to intracardiac injection. Mice were housed in microisolator
cages with a 12-hour light/dark cycle and received sterilized food and water ad libitum in
accordance with West Virginia University’s Animal Care and Use Committee (ACUC
protocol 13–1207). Upon reaching survival endpoints animals were euthanized by
ketamine (100 mg/kg) and xylazine (8 mg/kg) mixture. All animal experiments were
performed according to the principles of the Guide for the Care and use of Laboratory
animals.
Cells
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Firefly luciferase transfected into the human metastatic brain-seeking MDA-MB231-BrLuc cell line, and was kindly provided by Dr. Patricia Steeg from the National
Institutes of Health (NIH). Similar transfection was done to JIMT1 cells to create the
JIMT1-BrLuc line, and the 4T1 line to create the 4T1-BrLuc line. Cells were kept at 37o
in 5% CO2, grown in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with
10% fetal bovine serum and 5% penicillin-streptomycin. All cells used for in vivo and in
vitro experiments were between passages 5 to 10.
In-vitro toxicology
5,000 cancer cells per well were seeded into a 96-well plate. Chemotherapy was
dissolved in negligible amounts of DMSO and prepared in media. For consistency, the
same amount of DMSO was added to control media. After addition of chemotherapy,
plates were incubated for 72 hours. On endpoint, 50 μg/50 μL of MTT was added to each
well and allowed to incubate for a further 2 hours. Wells were then aspirated and 100 uL
of DMSO was added to each well for to solubilize the purple formazan crystals. After
gentle shaking for an hour, wells were analyzed for absorbance at 570 nm. Concentration
curves were plotted and IC50 values were calculated using a four-phase non-linear
analysis.
Stereotactic intracardiac injection
Mice were induced and maintained by inhaling 2% isoflurane anesthesia and
placed in a stereotactic apparatus (Stoelting). 1.75x105 MDA-MB-231-BrLuc, JIMT1BrLuc, or 4T1 cells in 100 uL of PBS were measured by an Invitrogen Countess I
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(ThermoFischer) and then injected into the left ventricle by approximation or ultrasound
guidance. [17]
Drugs and dosing
Gemcitabine, docetaxel, and vinorelbine were acquired from SelleckChem.
Eribulin was acquired from Adooq BioSciences. Lapatinib was acquired from ApexBio.
Etirinotecan pegol was provided by Nektar Therapeutics. Saline was chosen as the
vehicle. Gemcitabine, vinorelbine and etirinotecan pegol were dissolved in saline.
Docetaxel was dissolved in 5% ethanol/5% Tween 80/90% saline. Eribulin was dissolved
in 5% ethanol/15% distilled water/80% saline. Vinorelbine 10 mg/kg [22, 23], docetaxel
10 mg/kg [24-26], and etirinotecan pegol 50 mg/kg equivalent of irinotecan were dosed
every 7 days via tail vein; eribulin 1.5 mg/kg [27] and Gemcitabine 60 mg/kg [28] were
injected every 4 days via intraperitoneal injection. Lapatinib was suspended in 0.1%
Tween 80 and 1% hydroxypropylmethylcellulose in water, dosed orally twice daily at
100 mg/kg. [29] Dosing was initiated on Day 21 (Week 3) for the MDA-MB-231-BrLuc
group, on Day 14 (Week 2) for the JIMT1-BrLuc group, and on Day 3 for the 4T1-BrLuc
group (Table 4.1). All doses were made fresh on the day of administration and
administered approximately half an hour after luciferin imaging.
Imaging and Survival
Animals were given a 150 mg/kg injection of D-luciferin potassium salt
(PerkinElmer, Waltham, MA) via intraperitoneal injection and placed into 2% isoflurane
for sedation. After 10-15 minutes to ensure luciferin circulation, animals were then
transferred to the IVIS Lumina II (PerkinElmer) and bioluminescence imaging (BLI) was
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performed. BLI was taken twice weekly to measure tumor burden. Regions of interest
(ROI) were drawn based on cranial circumference and BLI is reported as radiance
(photons/sec/cm2/steradian).
Autoradiography
Animals were anesthetized and given 10 μCi of 14C-etirinotecan pegol via femoral
vein injection. Mice were allowed to recover while the radioactive drug circulated for 24
hours. At the endpoint, mice were again anesthetized and the descending aorta was
clamped. Phosphate buffer saline was infused via left ventricle at 5 mL/min for 2 minutes
to provide a washout. Brains were then extracted and frozen to be sliced in 20 μm slices,
then placed in autoradiography cassettes to develop for 21 days. Cresyl violet stains were
used to trace tumor areas, which were then overlaid on autoradiographic slides for use by
MCID software for analysis.
Statistics
Survival analysis was plotted on a Kaplan-Meier curve and statistically compared using
log-rank statistics. All results and statistical analysis were performed on GraphPad Prism
6.0, and were considered statistically significant at p < 0.05.
4.3 Results
In-vitro sensitivity to SN-38 correlates with in-vivo survival efficacy
To determine sensitivity of cell lines to BEACON chemotherapy, MTT
toxicology was performed as outlined in the methods and materials. The MDA-MB-231BrLuc line was the most sensitive to NKTR-102’s parent drug irinotecan (1 μM ± 0.11
μM) and active metabolite SN-38 (10.5 nM ± 2.9 nM) compared to the 4T1-BrLuc (12.7
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μM ± 0.47 μM and 24.9 nM ± 0.06 nM, respectively) and JIMT-1-BrLuc (39 μM ± 1.78
μM and 222.8 nM ± 0.17 nM, respectively). The results are summarized in Table 4.2.
Etirinotecan pegol prolongs survival of human triple negative and HER2+ breast
cancer brain metastases, but not the murine triple negative model
To evaluate our main aim in comparing the efficacy of our investigational drug to
established chemotherapeutics, we injected MDA-MB-231-BrLuc, 4T1-Br, and JIMT1BrLuc cells as described. Tumor growth was monitored using bioluminescence (BLI)
twice weekly starting on day 21 (Week 3) post-injection in the 231-Br line (Fig. 4.1A),
14 days (Week 2) in the JIMT1-Br line (Fig. 4.3A), and 3 days in the 4T1-Br line (Fig.
4.5A). In 231-Br vehicle animals, tumor burden increased nearly 1000-fold from baseline
(Fig. 4.1B) resulting in a median survival of 40 days (Fig. 4.2). Similarly, animals treated
with gemcitabine in this cell line had bioluminescence increase nearly 1000-fold (Fig.
4.1B), but survived longer (median survival 68 days, Fig. 4.2). Eribulin, docetaxel and
vinorelbine treated animals had tumor burden increase nearly 100-fold with median
survivals as 40.5, 39, and 43 days, respectively (Fig. 4.2). No animals in the 231-Br
vehicle or conventional chemotherapy group survived beyond day 60. Etirinotecan pegol
treated mice in the 231-Br model had bioluminescence plateau 10-fold above baseline
(Fig. 4.1B) and median survival was 86 days (Fig. 4.2) with four mice (40%) surviving
until the end of the trial. In the JIMT1 model, dosing was initiated on day 14. Vehicle
burden peaked a maximum of 10,000-fold from baseline (Fig. 4.2B) with a median
survival of 28 days (Fig. 4.4). Bioluminescence in lapatinib mice peaked at 100-fold
above baseline (Fig. 4.2B) with a median survival of 29 days (Fig. 4.3B). Etirinotecan
pegol closely followed the bioluminescence curve of lapatinib in this model, but like in
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the 231-Br group, prevented further increases in signal (Fig. 4.2B) with a median survival
of 34 days (Fig. 4.4). In the 4T1-Br group, both NKTR-102 and conventional
chemotherapy had similar bioluminescence curves aside from gemcitabine, which was
significantly right-shifted but eventually reached similar maximum values (Fig. 4.5B).
Survival corresponded with the bioluminescence curve for 4T1-Br, as gemcitabine’s
median survival (28.5 days) was nearly double that of vehicle (15 days) and most other
conventional chemotherapy agents (Fig. 4.6). The results are summarized in Table 4.3.
Etirinotecan pegol accumulates preferentially in tumor tissue compared to brain
parenchyma
To evaluate the distribution of etirinotecan pegol, 10 μCi of 14C-labeled drug was
administered and circulated for 24 hours. After brain extraction, 20 μm slices placed in
autoradiography cassettes and developed for 21 days. Cresyl violet staining was
performed to outline tumor areas (Fig. 4.7A). Quantification of 20 tumors revealed that
14

C-etirinotecan pegol accumulated to 2603 ± 917 ng/g in tumor tissue and 220 ± 40 ng/g

in control regions of brain (Fig. 4.7B), more than a 10-fold difference (Fig. 4.7C).
4.4 Discussion
The principal finding of the present experiment was that etirinotecan pegol
significantly improved survival compared to vehicle and conventional chemotherapy
groups in the human MDA-MB-231-BrLuc and JIMT-1-BrLuc groups, but not the
murine 4T1-BrLuc group. In the MDA-MB-231-BrLuc group, etirinotecan pegol
administration prolonged survival beyond double of any conventional chemotherapy
group with nearly half of treated mice surviving until the end of the 90-day trial.
Similarly, etirinotecan administration led to one mouse surviving in the JIMT-1 group
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until the end of the trial. No conventional chemotherapy treatment mice of any cell line
survived until the end of the trial. In both the MDA-MB-231-Br and JIMT-1-Br lines,
etirinotecan pegol shows early control of tumor burden based on bioluminescence, which
was sustained in the 231-Br model. The results of this study correspond with findings in
our previous trial with etirinotecan pegol in the 231-Br model [17].
The timing of chemotherapeutic administration is crucial to its effects on survival.
In order to prevent metastases, chemotherapy has to be given while cancer cells are still
circulating or initially attaching to parenchyma, typically before two weeks in preclinical
models [30]. In our model, metastases have been established and allowed to grow for up
to three weeks prior to chemotherapy administration, mimicking clinical settings. Though
lapatinib has shown efficacy in reducing lesion size and improving survival in HER2
BCBM settings, the JIMT-1 cell line is intrinsically resistant to the drug and represents a
pre-treated model, explaining why the drug did not improve survival compared to the
vehicle in this setting [30, 31].
The 11-fold greater accumulation of 14C-etirinotecan pegol into tumor tissue
compared to non-tumor parenchyma demonstrates that the drug is able to traverse the
disrupted BTB to create its sustained effects. This replicates findings of the previous
study using autoradiographic data in which 14C-etirinotecan pegol significantly and
preferentially accumulated in brain metastases compared to non-tumor regions [17]. As
expected, the sustained depot-like effects of pegylating irinotecan allowed for sustained
SN-38 delivery to tumors, which led to superior tumor burden control as evidenced by a
plateau in BLI in the 231-Br and JIMT-1 models.
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Conventional irinotecan has typically not been used as part of a therapeutic
regimen for BCBM, and has not demonstrated any significant improvements in
increasing median survival in preclinical settings. [17, 32] However, liposomal irinotecan
increased median survival by 13 days at equivalent doses to conventional irinotecan [32].
Additionally, liposomal irinotecan was found to increase and prolong the exposure of the
active SN-38 metabolite compared to conventional irinotecan, which corresponds to the
findings of the previous etirinotecan pegol study [17, 32]. This sustained exposure to SN38 is documented clinically in two Phase 1 [33] and two Phase 2 etirinotecan trials [19,
20], and has led to liposomal irinotecan involvement in a clinical trial (NCT01770353).
The discrepancy of NKTR-102 efficacy may be due to the origin of cell lines
used. MDA-MB-231-BrLuc and JIMT-1 are human epithelial derived lines, whereas
4T1-BrLuc is a murine derived line. Since NKTR-102 is a topoisomerase I inhibitor used
in human cancer, it is possible that the administration of the drug did not have any
significant effect in the murine model.
Another possibility is NKTR-102 did not penetrate as readily into 4T1-Br tumors
as it does in 231-Br tumors. While both cell lines create tumors in the brain, 4T1 tumors
are more numerous and smaller, whereas 231 tumors are larger in size and fewer in
number [34]. The smaller size and reduced vascularity of 4T1 tumors could restrict the
large 20kDa NKTR-102 molecule from penetrating and effectively reducing tumor
burden. This is not problematic for gemcitabine as it is a small molecule and readily
uptaken by tumor cells due to its resemblance as a nucleotide, which may explain
gemcitabine’s efficacy in the 4T1 model [35].
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Alternatively, the efficacy of etirinotecan pegol may be due to tumor
aggressiveness. While the MDA-MB-231 and JIMT-1 lines take 14-21 days postintracardiac injection to establish brain metastases, the 4T1 line is quicker to form and
grow tumors, with most treatment groups’ median survival occurring in this time period.
It is possible that etirinotecan pegol works on slower-growing tumors, allowing for the
release of SN-38 over time to appropriately achieve cytotoxic concentrations and effect.
This phenomenon is known as enhanced permeation and retention (EPR).
Compromised tumor vasculature allows for increased permeability and allow
substances to create a reserve and slowly release for days to weeks [36, 37]. Clinicallyused dosage forms exhibiting EPR include encapsulation in liposomes (Myocet®),
conjugation to polyethylene glycol (Onzeald®) or albumin (Abraxane®), or a
combination of both, as is the case with pegylated liposomal doxorubicin (Doxil®) [36].
Preclinical and clinical evidence has shown that these formulations improve circulation
half-life and extravasate in metastatic lesions, though effects on overall survival are
ambiguous [36]. With autoradiographic evidence that etirinotecan pegol deposits and is
retained in tumor tissue, along with sustained irinotecan and SN-38 levels in the tumor
environment, we believe that the molecule achieves its tumoricidal effects through EPR.
The continuous effects of etirinotecan pegol may also lead to a preventative phenomenon,
as circulating cancer cells sensitive to the agent may be killed before extravasating and
developing into metastases.
Etirinotecan pegol is demonstrated to be efficacious in two preclinical models
representing the most common types of BCBM. We have observed that etirinotecan
pegol provides long systemic concentrations of irinotecan and SN-38. Our radiographic
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data demonstrate etirinotecan pegol permeates through the compromised BTB and
accumulates in BCBM, which we believe is responsible for the increase in survival
compared to conventional chemotherapy and vehicle groups in the 231-Br and JIMT-1
models. The translational findings of this trial are significant.
As targeted and novel chemotherapy agents surge in development, survival from
brain metastases of breast cancer remains poor with a prognosis between 2 to 34 months.
The post-hoc clinical findings from the BEACON trial, in combination with previous
preclinical findings and this preclinical trial, support the use of etirinotecan pegol as a
therapeutic option in the ongoing ATTAIN trial, which evaluates its efficacy against TPC
to treat brain metastases from triple-negative and HER2+ breast cancer.
4.5 Conclusion
Etirinotecan pegol accumulates in metastatic brain lesions and significantly
improves survival compared to conventional chemotherapeutic agents in two human
cellular models of triple-negative and HER2+ brain metastases of breast cancer. These
data support the use of etirinotecan pegol in the Phase III ATTAIN trial.
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Figure 4.1. Etirinotecan pegol reduces tumor burden in the MDA-MB-231-Br model
compared to conventional chemotherapy and vehicle.
(A) Following intracardiac injection of MDA-MB-231-Br cells and establishment of
brain metastases, biweekly imaging on the IVIS Lumina tracked tumor growth and
chemotherapeutic efficacy. Images shown are of the same animal sequentially. (B) Mean
BLI signal versus time in 231-Br mice treated with therapy. Treatment was initiated on
day 21. Each data point represents mean ± SD (n = 2-10 per time point). Tumor burden in
etirinotecan pegol-treated mice was significantly lower than conventional chemotherapy
or vehicle treatment groups (p < 0.05).
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Figure 4.2. Kaplan-Meier survival curve of MDA-MB-231-Br mice treated with
etirinotecan pegol and conventional chemotherapy.
On day 21 after intracardiac injection of MDA-MB-231-Br cells, mice were treated with
vehicle (saline, n = 8), docetaxel (10 mg/kg, n = 8), vinorelbine (10 mg/kg, n = 8),
eribulin (1.5 mg/kg, n = 8), gemcitabine (60 mg/kg, n = 9), or etirinotecan pegol (50
mg/kg, n = 10). Median survival time were 40 days for vehicle, 39 days for docetaxel, 43
days for vinorelbine, 40.5 days for eribulin, 48 days for gemcitabine, and 86 days for
etirinotecan pegol. Etirinotecan pegol significantly increased median survival in 231-Br
tumor mice compared to vehicle or conventional chemotherapy, with 40% of mice
surviving to the end of trial (p < 0.05). Data was analyzed using log-rank statistics.
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Figure 4.3. Etirinotecan pegol reduces tumor burden in the JIMT-1-Br model
compared to lapatinib and vehicle.
(A) Following intracardiac injection of JIMT-1-Br cells and establishment of brain
metastases, biweekly imaging on the IVIS Lumina tracked tumor growth and
chemotherapeutic efficacy. Images shown are of the same animal sequentially. (B) Mean
BLI signal versus time in JIMT-1-Br mice treated with therapy. Treatment was initiated
on day 14. Each data point represents mean ± SD (n = 2-10 per time point). Tumor
burden in etirinotecan pegol-treated mice was significantly lower than lapatinib or
vehicle treatment groups (p < 0.05).
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Figure 4.4. Kaplan-Meier survival curve of JIMT-1-Br mice treated with
etirinotecan pegol and conventional chemotherapy.
On day 14 after intracardiac injection of JIMT-1-Br cells, mice were treated with vehicle
(saline, n = 9), lapatinib (100 mg/kg, n = 9), or etirinotecan pegol (50 mg/kg, n = 10).
Median survival times were 28 days for vehicle, 29 days for docetaxel, and 34 days for
etirinotecan pegol. Etirinotecan pegol significantly increased median survival in JIMT-1Br tumor mice compared to vehicle or conventional chemotherapy, with 10% of mice
surviving to the end of trial (p < 0.05). Data was analyzed using log-rank statistics.
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Figure 4.5. Etirinotecan pegol does not significantly reduce tumor burden in the
4T1-Br model compared to vehicle.
(A) Following intracardiac injection of 4T1-Br cells and establishment of brain
metastases, biweekly imaging on the IVIS Lumina tracked tumor growth and
chemotherapeutic efficacy. Images shown are of the same animal sequentially. (B) Mean
BLI signal versus time in JIMT-1-Br mice treated with therapy. Treatment was initiated
on day 3. Each data point represents mean ± SD (n = 2-10 per time point). Tumor burden
in etirinotecan pegol-treated mice was not significantly lower than vinorelbine, eribulin,
or vehicle treatment groups (p > 0.05).
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Figure 4.6. Kaplan-Meier survival curve of 4T1-Br mice treated with etirinotecan
pegol and conventional chemotherapy.
On day 3 after intracardiac injection of 4T-1-Br cells, mice were treated with vehicle
(saline, n = 9), docetaxel (10 mg/kg, n = 10), vinorelbine (10 mg/kg, n = 8), eribulin (1.5
mg/kg, n = 10), gemcitabine (60 mg/kg, n = 8), or etirinotecan pegol (50 mg/kg, n = 9).
Median survival time were 15 days for vehicle, 19 days for docetaxel, 17 days for
vinorelbine, 16.5 days for eribulin, 28.5 days for gemcitabine, and 16 days for
etirinotecan pegol. Unlike gemcitabine or docetaxel, tirinotecan pegol did not
significantly improve median survival compared to vehicle (p > 0.05). Data was analyzed
using log-rank statistics.
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Figure 4.7. Accumulation of irinotecan in tumors and normal brain from 14C-etirinotecan pegol.
(A) A representative sagittal image of a MDA-MB-231-Br brain metastases and corresponding (B) 14C-etirinotecan pegol
accumulation 24 hours after intravenous administration of radiolabeled etirinotecan pegol. (C) The mean lesion accumulation
of 14C-etirinotecan pegol was significantly higher than non-tumor regions (p < 0.05). Data represent mean ± SD of n = 20
tumors.
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Drug

Source

Dose

Formulation

Administration

Docetaxel

SelleckChem

10 mg/kg

5% ethanol, 5% Tween 80, 90% saline

IV every 7 days

Eribulin

Adooq

1.5 mg/kg

5% ethanol, 15% distilled water, 80%
saline

IP, every 4 days

Etirinotecan

NEKTAR

50 mg/kg

Saline

IV every 7 days

pegol

Therapeutics

Gemcitabine

SelleckChem

60 mg/kg

Saline

IP, every 4 days

Lapatinib

ApexBio

100 mg/kg

Vinorelbine

SelleckChem

10 mg/kg

mesylate

0.1% Tween 80, 1%
hydroxypropylmethylcellulose,
distilled water
Saline

Table 4.1. Chemotherapy formulations and dosage schedules for NKTR-102 BCBM.
IV: intravenous via tail vein, IP: intraperitoneal, PO: per os, oral gavage.
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PO twice daily

IV every 7 days

MDA-MB-231-Br
Compound

IC50 ± SD

Docetaxel

0.41 ± 0.2 µM

Eribulin

3.1 ± 0.2 µM

JIMT-1-Br
IC50 ± SD

IC50 ± SD

4.3 ± µM

Gemcitabine
Irinotecan

4T1-Br

174 ± nM
1 ± 0.11 µM

Lapatinib

39 ± µM

12.6 ± µM

1.4 ± µM

SN-38

11.2 ± 2.9 nM

Vinorelbine

16.4 ± 11.2 nM

222 ± nM

24.9 ± nM
10 ± nM

Table 4.2. In-vitro cytotoxicity assay of chemotherapy in cancer cell lines.
5,000 cancer cells per well were treated with increasing concentrations of compound. All
data represents mean ± SD, n = 96.
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MDA-MB-231-Br
Survival
(Days)
Docetaxel

vs. Vehicle

JIMT-1-Br
Survival
(Days)

vs. Vehicle

4T1-Br
Survival
(Days)

vs. Vehicle

39

0.41

18.5

< 0.01*

40.5

0.54

16.5

0.83

Gemcitabine

48

0.11

26

< 0.01*

Irinotecan

42

0.90

NKTR-102

86

< 0.01*

16

0.80

Eribulin

Lapatinib
Vehicle

40

Vinorelbine

43

34

< 0.01*

29

0.49

28

16

0.93

17

0.52

Table 4.3. Survival analysis of chemotherapy and vehicle.
Intracardiac injections resulted in triple negative (231-Br, 4T1) or HER2+ (JIMT-1) breast cancer brain metastases which were
treated with chemotherapy. NKTR-102 extended median survival by 46 days in the 231-Br model, 6 days in the JIMT-1
model, but did not improve survival in the 4T1 model.
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CHAPTER 5
CHARACTERIZATION OF PRECLINICAL PC-9 LUNG CANCER
BRAIN METASTASES
5.1 Introduction
Lung cancer is the leading cause of cancer death in both men and women
worldwide. [1] Lung cancer is the most common cause of brain metastases, which is
often a fatal prognosis due to a lack of curative treatment modalities. [2] There is no one
universal effective screening tool for lung cancer as there are for other cancer types, such
as breast cancer or melanoma. [3] The lapse between disease onset and diagnosis allows
the majority of lung cancer to be metastatic on presentation. Up to 65% of all lung cancer
patients will eventually develop brain metastases, making lung cancer brain metastases
(LCBM) a disease with heavy burden. Though certain characteristics are known about
brain metastases in general, investigation has revealed surprising information about brain
metastases based on tissue of origin.
In 2010, it was discovered that breast cancer brain metastases (BCBM) featured
increased vascular permeability due to loss of integrity, and that accumulation of
chemotherapy is increased in metastatic lesions compared to brain parenchyma. [4] This
permeability was variable within metastases, between the triple negative and HER2+
subtypes, and due to the blood-tumor barrier (BTB) restriction of chemotherapy, only
approximately 10% of brain metastases were reaching cytotoxic concentrations. [4]
Multiple preclinical studies since have demonstrated that permeability within and
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between BCBM are heterogeneous, with the conclusion that more brain-penetrating
agents must be created, or methods developed to escape the barrier restriction. [5, 6]
Characterization of vascular permeability and chemotherapy uptake are yet to be
performed on LCBM. The two most common types of LCBM are small-cell and nonsmall-cell lung cancer, the latter has three prominent mutations: KRAS, EGFR, and
EML4-ALK. Currently, no FDA-approved targeted therapy exists towards the most
common KRAS mutation. Within the scope of EGFR, the deletion on exon 19 confers
sensitivity to targeted inhibitors. Subsequently, the PC-9 cell line bearing the EGFR del
19 mutation was developed into brain-seeking metastatic lines and studied in the context
of effects of passive vascular permeability and chemotherapeutic efficacy.
Herein, we use the passive permeability marker 14C-aminoisobutyric acid (MW
103.12), a P-glycoprotein substrate Oregon Green (MW 509.38), and albumin-bound
vascularity marker indocyanine green (MW 774.96) to study effects of chemotherapy on
tumor vasculature in the PC-9 model of LCBM. Permeability of these markers was
studied in vehicle brains and brains treated with cisplatin and etoposide, cisplatin and
pemetrexed, and the EGFR tyrosine kinase inhibitors gefitinib, afatinib, and osimertinib.
We observed that the brain-seeking variant of the PC-9 line are more resistant to
chemotherapy than their parenteral counterparts. Passive permeability of 14C-AIB was
generally significantly higher in tumor regions compared to non-tumor regions. In
contrast, there was no significant correlation between tumor size and 14C-AIB
permeability. OG and ICG fold increases varied between each treatment group and were
not predictable. Tumor sizes are smaller in treatment groups that extend median survival.
Lastly, we observed that there was no correlation between survival and tumor size. This
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is the first paper to illustrate the heterogeneity of tumor distribution and vascular
permeability of lung-brain metastases, especially in the context of therapeutic treatment.
5.2 Methods and Materials
Animals
The animal protocol used is the same as in Chapter 3.2.
Cells
The parenteral PC-9 cells were provided by Dr. Lori Hazlehurst’s laboratory, and
came transduced to display Tomato Red and Firefly luciferase (Luc2=tdT), allowing for
fluorescence quantification and bioluminescence tracking. The pcDNA3.1(+)/Luc2=tdT
was a gift from Christopher Contag (addgene plasmid # 32904). Cells were grown in
RPMI supplemented with 10% fetal bovine serum, 5% penicillin-streptomycin, and 10
μL/mL of G4918 to ensure selection of transduced cells. Cells were kept at 37C and 5%
CO2. All cells used for in-vivo and in-vitro experiments were between passages 1-10.
Stereotactic injection
Mice were anesthetized and induced using 2% isoflurane. After placement into a
stereotactic device (Stoelting), approximately 150,000 PC-9 cells in 100 μL were injected
into the left ventricle. Bioluminescence verified presence in the brain. Upon termination,
animals were euthanized and brains were extracted to begin ex-vivo creation of the PC-9
brain seeking line (PC-9-Br).
PC9-Br-6 creation
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The protocol developed by Yoneda et al. was similarly followed to establish the
PC-9-Br line. [7] After cancer cells were injected and animals became moribund with
neurological symptoms, they were given 100 mg/ketamine and 8 mg/kg xylazine and
then euthanized. The brain was removed from the cranium and minced into fine pieces.
The minces were added to 10 mL of 1.5 mg/mL of collagenase I in DMEM and shaken at
300 RPM for 1 hour at 37C. The partially-digested mince was passed through a 19G
syringe to further break up tissue, then strained through a 70 μm cell strainer. The
collagenase-containing mixture was neutralized with equal amount of DMEM and FBS
for 10 minutes, then rinsed with 10 mL of PBS. To separate myelin from the cells, 10 mL
of 25% bovine serum albumin in PBS was added and spun at 2000 to 2200 RPM for 15 to
20 minutes. Cells were then collected and placed immediately in media with G418
selection to allow for growth. After 3 days, cells were washed and re-plated for at least 24
hours prior to re-injection in mice. This process was repeated until the extracted
population predominantly formed tumors in the brain, which was 6 times for the PC-9
line.
Drugs and dosing
Cisplatin (5 mg/kg, weekly) and either etoposide (100 mg/kg, days 2 through 5
after cisplatin administration) or pemetrexed (100 mg/kg, days 3 through 5 after cisplatin
administration) were selected to represent the most common nonspecific platinum
doublet therapy given to lung cancer patients. Cisplatin and pemetrexed were dissolved in
saline, and etoposide was dissolved in 5% DMSO, 5% Tween 80, and 90% saline prior to
intravenous dosing. Gefitinib (6.25 mg/kg), afatinib (30 mg/kg), and osimertinib (25
mg/kg), representing three generations of EGFR inhibitors, were dosed orally once daily,
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and were formulated in 1% DMSO, 29% polyethylene glycol 400, and 70% distilled
water. All chemotherapy was purchased from SelleckChem. Drugs, formulations, and
dosing regimens are summarized in Table 5.1.
Brain extraction
Upon reaching survival endpoints, mice were anesthetized and given tail vein
injections of 150 μg of Oregon Green (OG) dissolved in PBS, along with 10 μCi of 14Caminoisobutyric acid (14C-AIB). Following a 10-minute circulation, the descending aorta
and inferior vena cava were clamped off. A solution of 6 mg of indocyanine green (IR820, ICG) bound to 0.27% bovine serum albumin (270 mg in 10 mL) was perfused
through the left ventricle at 5 mL/min to provide a washout. Brains were then rapidly
removed and submerged in isopentane (-80oC) and stored at -20oC prior to tissue slicing
and visualization.
Tissue processing and quantification
Brains were mounted and 20 μm slices were created with the Leica CM3050S
cryotome (Leica Microsystems, Wetzlar, Germany), which were transferred to charged
microscope slides. Each slide contains 3 slices for a total of approximately 120 slices per
brain. Brain slice fluorescence was acquired using a stereomicroscope (Olympus
MVX10; Olympus, Center Valley, PA) equipped with a 0.5 NA 2X objective and a
monochromatic cooled CCD scientific camera (Retiga 4000R, QIMaging, Surrey, BC,
Canada). Tomato Red fluorescence was imaged using a DsRed sputter filter
(excitation/band λ 545/25nm, emission/band λ 605/70nm and dichromatic mirror at λ
565nm) (Chroma Technologies, Bellows Falls, VT), Oregon Green using an ET-GFP
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sputter filter (excitation/band λ 470/40nm, emission/band λ 525/50nm and dichromatic
mirror at λ 495nm) (Chroma Technologies, Bellows Falls, VT), and ICG using a Cy7
sputter filter (excitation/band λ 710/75nm, emission/band λ 810/90nm and dichromatic
mirror at λ 760nm) (Chroma Technologies, Bellows Falls, VT). Fluorescence was
captured and analyzed using CellSens (Olympus) software. OG and ICG fluorescence
intensity increases were determined by sum intensity per unit of metastatic lesion area
relative to non-tumor brain regions.
Quantitative autoradiography
Fluorescence imaging slides and 14C-AIB slides were placed in quantitative
autoradiography (QAR) cassettes (FujiFilm Life Sciences, Stanford, CT) along with 14C
autoradiographic standards (American Radiochemicals, St. Louis, MO). A phosphor
screen (FujiFilm Life Sciences, 20 × 40 super-resolution) was placed with the slides and
standards and allowed to develop for 21 days. QAR phosphor screens were developed in
a high-resolution phosphor-imager (GE Typhoon FLA 7000, Uppsala, Sweden) and
converted to digital images, which were then calibrated to 14C standards and analyzed
using MCID Analysis software (InterFocus Imaging LTD, Linton, Cambridge, England).
Metastases permeability fold-changes were calculated based on 14C-AIB signal intensity
within confirmed metastases locations (determined using cresyl violet and Tomato Red
fluorescence intensity overlays) relative to non-tumor brain 14C-AIB signal intensity.
Tumor Staining
Tissue sections were processed as described above. After allowing tissues to
become adherent to charged slides overnight, slides were briefly dipped in PBS. Staining
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was performed using 0.1% cresyl violet acetate (Sigma-Aldrich, St. Louis, MO) (2
minutes) followed by briefly rinsing in tap water. Sections were cleared in 70% ethanol
(15 seconds), 95% ethanol (30 seconds), 100% ethanol (30 seconds), respectively.
Images were obtained with a 2x objective on the Olympus MVX microscope.
Cytotoxicity assays
Following the creation of PC-9-Br, in vitro MTT toxicity was performed to
determine potential differences in drug sensitivity between the parenteral line and the
brain-seeking line. 5,000 cells per well were plated in a 96-well plate and allowed to
attach overnight in an incubator. The next day, after aspiration, drugs were added to
wells. For all cytotoxicity assays, drugs were dissolved in DMSO or media to create a 10
mM stock, then further diluted in media to create standard concentrations. If drugs were
dissolved in DMSO, similar amounts of DMSO were added to control wells. Plates were
then incubated for 72 hours. 50 μL of a 1 mg/mL solution of MTT was then added per
well and incubated for another 2 hours. Wells were then aspirated and 100 μL of DMSO
was added per well and gently shaken for 1 hour to solubilize formazan crystals. Plates
were then read at 570 nM on the Synergy Hybrid 1 plate reader. Fluorescence values
were converted to percentages based on the control average and plotted against a logscale of drug concentration.
Statistics
All statistics were performed on GraphPad Prism software. XY plots were
analyzed by linear regression. Median and interquartile ranges are used for permeability
changes and size of metastases. A D’Agostino and Pearson omnibus test was performed
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and determined a non-Gaussian distribution of data. Statistical analysis of permeability
and size was performed using the non-parametric Kruskal-Wallis test followed by Dunn's
multiple comparison test. Animal median survival data was analyzed using the log-rank
test. Significance for all tests was defined as p < 0.05.
5.3 Results
The sixth round of PC-9 injections predominantly seeds the brain and has
shorter survival than the parenteral line
Using the method developed by Yoneda et al, PC-9 cells were injected and
extracted through six rounds in female nude mice. The cells from this sixth round are
“brain-seeking” and the line is now termed PC-9-Br. Fig. 5.1 shows the distribution of
the sixth round of PC9 injections (A), stills from a 3D reconstruction of a mouse with
brain tumor (B-E), and the survival curve of the parenteral and brain-seeking PC-9 line
(F). While the median survival was 61.5 days (n = 2) in the parenteral line, the median
survival for the brain-seeking line is significantly shorter at 45.5 days (n = 4) (p < 0.05).
Oregon Green is a substrate for P-glycoprotein efflux
In order to determine if OG is a P-glycoprotein substrate, a Fluoroblock transwell
experiment featuring increasing concentrations of OG and a Texas Red dextran 3kDa
control were performed. A normalized time-lapse of OG (Fig. 5.2A) revealed increased
concentrations when given the P-gp inhibitor tariquidar 1 µM, while a time-lapse of
Texas Red dextran (Fig. 5.2A) showed no significant changes through time when
exposed to tariquidar. For comparison, (Fig. 5.2B) raw fluorescence units show similar
findings. A comparison of OG and 14C-AIB in the drug models (Fig. 5.2C-H) reveals
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similar results to the effects of rhodamine 123 and 14C-AIB in BCBM models, indicating
that OG is effluxed by tumors due to P-glycoprotein. [8]
PC-9-Br creates numerous, widespread, and various sized brain metastases
To view the tumor and vascular distribution of PC-9-Br, an intracardiac perfusion
of OG was performed on a vehicle-treated PC-9-Br mouse. After extraction, the brain
was placed on a glass petri dish and imaged on the Olympus MVX. Fig. 5.3 presents the
metastatic lesions and cerebral vasculature from the frontal cortex to the cerebellum.
Bioluminescence (Fig. 5.3A) and fluorescence (Fig. 5.3B) outline the location of tumors
within the brain. Four coronal slices were taken 800 – 1600 μm apart, which are depicted
in a brain atlas (Fig. 5.3 C1-F4).
The PC-9-Br line forms spinal metastases due to ventricular infiltration
While the majority of PC-9-Br tumor burden is within the brain, vertebral lesions
often develop. This is an expected distribution of most brain-seeking tumor lines, with
spinal cord affinity as a theorized mechanism. [9] Fig. 5.4 shows a brain slice of a vehicle
mouse with a tumor on the periphery of the right lateral ventricle, with the choroid plexus
separating the tumor into two sections. On bioluminescence imaging, a spinal lesion is
noted in the mouse that this brain was taken from (Fig. 5.4A). Within the ventricle, tumor
cells are seen co-opting the choroid plexus, which contains OG (Fig. 5.4B-D).
PC-9-Br are less sensitive to conventional and targeted lung chemotherapy than
parenteral PC-9 in-vitro
A cytotoxic assay was performed to evaluate the chemotherapeutic sensitivity of
the parenteral and brain-seeking PC9 lines. In the parenteral line, SN-38 sensitivity is 7
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nM, more than two orders of magnitude lower than the 6 µM SN-38 sensitivity of the
brain-seeking line. The etoposide sensitivity of the parenteral line (408 nM) is more than
100-fold lower than in PC-9-Br (6.4 µM). Pemetrexed sensitivity is modestly higher in
the PC-9-Br (512 nM) compared to PC-9-P (391 nM), while cisplatin sensitivity is
slightly lower (593 nM vs. 669 nM, respectively). This trend is seen again in targeted
tyrosine kinase inhibitors. While the parenteral line is sensitive in the femtomolar range
to erlotinib, gefitinib, afatinib, and osimertinib, the PC-9-Br sensitivities are in the
nanomolar range, more than a 10-fold difference. A representative IC50 curve
demonstrating the reduced sensitivity of PC-9-Br to PC-9-P is depicted in Fig. 5.5. The
PC-9-Br are more sensitive to tyrosine kinase inhibitors than conventional lung
chemotherapy agents and SN-38 (Table 5.1).
Vehicle treated tumors are significantly more permeable to 14C-AIB and have
higher OG but not ICG fluorescence intensity than non-tumor regions
As animals became moribund with neurological symptoms, we sought to
determine the extent and differences of passive permeability, P-gp efflux, and vascularity
of control and drug-treated tumors via use of three different molecular weight markers,
starting with vehicle (Fig. 5.6). Passive permeability changes in vehicle metastatic lesions
ranged from 0.4505 to 38.39-fold over normal brain with a median (IQR) fold change of
3.254 (1.928 – 5.971) for 14C-AIB (Fig. 5.6F), which were significantly higher than nontumor regions (p < 0.01). For OG, fluorescence intensity ranged from 0.9974 to 1.271fold with a median (IQR) fold change of 1.007 (1.004 – 1.013), which was significantly
higher than non-tumor regions (p < 0.01). For ICG, fluorescence intensity ranged from
0.9866 to 1.053-fold with a median (IQR) fold change of 1.0 (0.9953 – 1.002), which was
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not significantly higher than non-tumor regions (p > 0.05). No correlation was observed
(r2 < 0.02) for OG, ICG, or 14C-AIB passive permeability and metastasis size (Fig. 5.6G).
Cisplatin-etoposide treated tumors are significantly more permeable to 14CAIB, and have higher OG and ICG fluorescence intensity than non-tumor regions
After seeing a positive trend in vehicle tumors, we turned our sights on
characterizing tumors treated with conventional lung therapy, starting with the cisplatin
doublet therapy with etoposide (Fig. 5.7). Passive permeability changes in cisplatinetoposide metastatic lesions ranged from 0.3021 to 18.55-fold over normal brain with a
median (IQR) fold change of 1.231 (0.8541 – 2.077) for 14C-AIB (Fig. 5.7F), which was
significantly higher than non-tumor regions (p < 0.01). For OG, fluorescence intensity
ranged from 0.9891 to 1.190-fold with a median (IQR) fold change of 1.020 (1.007 –
1.037), which was significantly higher than non-tumor regions (p < 0.01). For ICG,
fluorescence intensity ranged from 0.9597 to 1.078-fold with a median (IQR) fold change
of 0.9885 (0.9810 – 1.001), which was significantly higher than non-tumor regions (p >
0.01). There was a no correlation (r2= 0.07) to changes in 14C-AIB permeability and
lesion size, while a moderate correlation was observed (r2 = 0.42) for OG but not ICG (r2
= 0.03) fluorescence intensity and metastasis size in the cisplatin-etoposide model (Fig.
5.7G).
Cisplatin-pemetrexed treated tumors are significantly more permeable to 14CAIB and have higher OG but not ICG fluorescence intensity than non-tumor regions
After seeing a positive trend in the cisplatin-etoposide doublet therapy, we turned
our sights on characterizing the cisplatin-pemetrexed doublet therapy (Fig. 5.8). Passive
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permeability changes in cisplatin-pemetrexed brain tumors ranged from 0.1601 to 24.83fold over normal brain with a median (IQR) fold change of 4.235 (1.681 – 7.046) for 14CAIB (Fig. 5.8F), which was significantly higher than non-tumor regions (p < 0.01). For
OG, fluorescence intensity ranged from 0.0652 to 1.565-fold with a median (IQR) fold
change of 1.049 (1.010 – 1.144), which was significantly higher than non-tumor regions
(p < 0.01). For ICG, fluorescence intensity ranged from 0.5926 to 4.490-fold with a
median (IQR) fold change of 0.9991 (0.9941 – 1.005), which was not significantly higher
than non-tumor regions (p > 0.05). There was a moderate correlation (r2= 0.44) in 14CAIB permeability and lesion size. No correlation was observed for OG (r2 = 0.12) or ICG
(r2 = 0.03) fluorescence intensity and metastasis size in the cisplatin-pemetrexed model
(Fig. 5.8G).
Gefitinib treated tumors are significantly more permeable to 14C-AIB and have
higher OG but not ICG fluorescence intensity than non-tumor regions
Aside from platinum doublet therapy, EGFR-mutated tumors can be treated with
targeted tyrosine kinase inhibitors. Gefitinib represents a first-generation targeted EGFRinhibitor (Fig. 5.9). Passive permeability changes in gefitinib brain tumors ranged from
0.7222 to 12.94-fold over normal brain with a median (IQR) fold change of 4.537 (2.707
– 8.20) for 14C-AIB (Fig. 5.9F), which was significantly higher than non-tumor regions
(p < 0.01). For OG, fluorescence intensity ranged from 0.9747 to 1.352-fold with a
median (IQR) fold change of 1.028 (1.006 – 1.066), which was significantly higher than
non-tumor regions (p < 0.01). For ICG, fluorescence intensity ranged from 0.9985 to
1.070-fold with a median (IQR) fold change of 1.030 (1.002 – 1.042), which was not
significantly higher than non-tumor regions (p > 0.05). There was a moderate correlation
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(r2= 0.33) to changes in 14C-AIB permeability and lesion size. No correlation was
observed for OG or ICG (r2 < 0.03) fluorescence intensity and metastasis size in the
gefitinib model (Fig. 5.9G).
Afatinib treated tumors are significantly more permeable to 14C-AIB, and have
higher OG and ICG fluorescence intensity than non-tumor regions
Afatinib represents a second-generation EGFR-tyrosine kinase inhibitor (Fig.
5.10). Passive permeability changes in afatinib brain tumors ranged from 0.2958 to
7.936-fold over normal brain with a median (IQR) fold change of 1.315 (0.8746 – 2.197)
for 14C-AIB (Fig. 5.10F), which was significantly higher than non-tumor regions (p <
0.01). For OG, fluorescence intensity ranged from 0.9854 to 1.080-fold with a median
(IQR) fold change of 1.011 (1.003 – 1.021), which was significantly higher than nontumor regions (p < 0.01). For ICG, fluorescence intensity ranged from 0.9975 to 1.055fold with a median (IQR) fold change of 1.001 (0.9957 – 1.007), which was also
significantly higher than non-tumor regions (p < 0.05). There was a no correlation (r2 <
0.01) to changes in 14C-AIB, OG, or ICG passive permeability and metastasis size in the
afatinib model (Fig. 5.10G).
Osimertinib treated tumors are significantly more permeable to 14C-AIB, and
have higher OG and ICG fluorescence intensity non-tumor regions
Osimertinib represents a third-generation EGFR-tyrosine kinase inhibitor (Fig.
5.11). Passive permeability changes in osimertinib brain tumors ranged from 0.1618 to
8.891-fold over normal brain with a median (IQR) fold change of 1.950 (1.328 – 3.033)
for 14C-AIB (Fig. 5.11F), which was significantly higher than non-tumor regions (p <
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0.01). For OG, fluorescence intensity ranged from 0.9703 to 1.375-fold with a median
(IQR) fold change of 1.077 (1.041 – 1.138), which was significantly higher than nontumor regions (p < 0.01). For ICG, fluorescence intensity ranged from 0.9862 to 1.054fold with a median (IQR) fold change of 1.006 (1.002 – 1.020), which was also
significantly higher than non-tumor regions (p < 0.01). There was a no correlation (r2 <
0.05) to changes in 14C-AIB, OG, or ICG passive permeability and metastasis size in the
osimertinib model (Fig. 5.11G).
14C-AIB

permeability is associated with chemotherapeutic efficacy

A comparison of fold increases of OG and ICG fluorescence increases across drug
treated groups reveals that most tumor regions are similar to control areas (Fig. 5.12). In
comparison, 14C-AIB passive permeability in tumors is much higher, ranging from 3- to
12-fold above non-tumor regions. Lower 14C-AIB fold increases over control areas are
found in cisplatin-etoposide, afatinib, and osimertinib-treated groups, which are the only
treatment groups to increase survival.
PC-9-Br tumor size and number are moderately correlated with survival
After survival endpoints were reached, brains were sliced and analyzed for tumor
count. A D'Agostino & Pearson omnibus normality test showed no compounds tested
displayed a Gaussian distribution, so median and interquartile range column statistics
were calculated (Table 5.2). Of 114 vehicle tumors, median tumor size was 0.1844 mm2
(IQR: 0.1129 – 0.3097) with a 42-day median survival. Of 117 cisplatin-etoposide
tumors, median tumor size was 0.1093 mm2 (IQR: 0.0533 – 0.2384) with a 51.5-day
median survival. Of 110 cisplatin-pemetrexed tumors, median tumor size was 0.2492
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mm2 (IQR: 0.1305 – 0.4054, with a 45-day median day survival. Of 34 gefitinib tumors,
median tumor size was 0.5530 mm2 (IQR: 0.2868 – 0.6787), with a 48-day median
survival. Of 85 afatinib tumors, median tumor size was 0.1459 mm2 (IQR: 0.0687 –
0.2809) with a 73-day median survival. Of 56 osimertinib tumors, median tumor size was
0.1293 mm2 (IQR: 0.0629 – 0.2125), with a 73-day median survival. Linear regression of
median metastases size and days of survival on chemotherapy produced an r2 of 0.3461,
while a linear regression of tumor number and survival produced an r2 of 0.22.
Distribution of PC-9-Br tumors follow surface area and blood flow patterns
After slicing and characterizing dye fold increases, we sought to determine the
distribution of tumors within the brain (Fig. 5.13). The majority of tumors occur in the
cortex regardless of treatment (Fig. 5.13J). Blood flow is approximately 1 mL/g/min in
these mouse regions, and so the plot of tumors based on brain blood flow (Fig. 5.13K)
resembles that of total number of tumors (Fig. 5.13J). Gefitinib was observed to have the
lowest number of tumors of the brains analyzed.
5.4 Discussion
As tumors grow, their requirement for enhanced nutrition stimulates the formation of
new vasculature that joins nearby blood vessels in a process known as angiogenesis. [10]
As vessels form, they are initially immature and compromised; the resultant loss of
barrier integrity allows passive permeation of formerly restricted substances into tumor
and brain parenchyma. [11]
Typical chemotherapy sizes range from a molecular weight of 300 (nucleotide
analogues) to more than 100,000 (antibodies). Cisplatin (300 Da), etoposide (589 Da),
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pemetrexed (472 Da), gefitinib (447 Da), afatinib (486 Da), and osimertinib (500 Da) are
clinically used therapeutics in the treatment of lung cancer. The size range of these agents
are encompassed by 14C-AIB (103 Da) and the P-gp substrate OG (509 Da), with
albumin-bound ICG representing antibody size and vascularity. [12, 13]
To create a brain metastatic model, two main methods exist: intracardiac and
intracarotid injections. [14] While intracarotid injections deliver cancer cells directly to
the brain compared to intracardiac injections which allow cancer cells to circulate
throughout the arterial system, intracarotid injections are much more invasive and timeconsuming, and often have similar results to intracardiac injections. [15] Our method of
injection occasionally leads to mandibular metastases (S1) which are often found in
preclinical brain metastases models as well as clinical settings. [16-18] Of note,
ventricular infiltration and development of spinal metastases have been noted in BCBM
models as well. [19, 20]
The PC-9 cell line is commonly utilized in preclinical lung cancer research to
evaluate the effects of chemotherapy in an EGFR-mutant model. [21-23] PC-9 are
sensitive to first generation (gefitinib) and second generation (afatinib) tyrosine kinase
inhibitors, and can be induced to form the T790M mutation which often leads to drug
resistance and relapse in the clinical setting. [24, 25] Osimertinib, a third generation
inhibitor, overcomes the T790M mutation and is used when resistance to first or second
generation inhibitors forms. Non-T790M mutated PC-9 cells are also sensitive to
osimertinib, which is why it was included in our trial. [21, 26]
Similar to preclinical breast cancer brain metastases (BCBM), PC-9-Br tumors are
generally less than 1 mm2, however PC-9-Br are far less permeable to both 14C-AIB and
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similarly-sized fluorescent markers. [27] The median permeability of 14C-AIB in LCBM
ranges between 1.2- to 4.5-fold above control regions, while in BCBM the median
permeability ranges between 2.1 to 12-fold above control regions. [27] Both BCBM and
LCBM contrast with primary glioblastoma, whose lesions are much larger and much
more permeable to 14C-AIB, with rates of transfer that near water diffusion. [28]
The effect of tumor size and survival is not yet fully understood. A preclinical model
of BCBM showed that larger tumor sizes were associated with higher median survival.
[27] In contrast, smaller median tumor sizes (≤ 1.5 mm2) were associated with longer
median survival in our LCBM model. These smaller median tumor sizes were also linked
with therapy that extended median survival, thus portraying a therapy-size-survival
interaction. Our LCBM findings correspond with targeted inhibitors showing reduction of
brain metastases size in the clinical setting. [29, 30]
Much like the BCBM models, the PC-9-Br line expresses the efflux pump Pglycoprotein. [8] In this model, rhodamine 123 (Rh123) was perfused and compared
against 14C-AIB fold changes in tumor regions and control areas. Much like our OG
results, Rh123 values ranged between 0.9 and 1.5-fold above non-tumor regions,
indicating that P-gp exists at the tumor barrier and though some dye does passively
permeate into tumor, OG is also a substrate for P-gp-mediated efflux.
5.5 Conclusion
The EGFR-mutant PC-9-Br creates many scattered brain metastases, most of
which are ≤ 1.0 mm2. These tumors are similarly permeable to breast cancer brain
metastases and have active P-glycoprotein to efflux chemotherapy. Conventional
chemotherapy such as cisplatin, etoposide, and pemetrexed are not as effective in
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increasing median survival as targeted EGFR inhibitors, especially second (afatinib) and
third (osimertinib) generation agents. Tumors treated with these agents have smaller
tumor sizes and lower 14C-AIB permeability.
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Figure 5.1: Distribution and survival of the brain-seeking PC-9 cell line.
(A) Visualization of tumor burden in athymic nude female mice injected with PC-9-Br cells. The majority of tumor burden is
within the brain, with a smaller amount of vertebral metastases. (B-E) Micro-CT reconstruction of a mouse with a PC-9-Br
tumor shows the anatomical location of the tumor. (F) Median survival for the PC-9-P parenteral line is 61.5 days (n = 2),
which is significantly reduced in brain-seeking PC-9-Br line (45.5 days, n = 4) (p < 0.05).
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Figure 5.2. Oregon Green is a P-glycoprotein substrate.
(A) A Fluoroblock transwell experiment of Oregon Green ± tariquidar 1µM and known
non-P-gp substrate Texas Red Dextran 3kDa ± TQ shows OG fluorescence increases over
time when exposed to TQ, with data normalized for ease of comparison. (B) Unadjusted
data is shown for comparative purposes. (C) Vehicle, (D) C+E, (E) C+P, (F) Gefitinib,
(G) Afatinib, and (H) Osimertinib feature similar OG permeability ratios to known P-gp
substrate rhodamine-123, signifying that OG is a P-gp substrate. All data is mean ± SEM.
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Figure 5.3. Distribution of brain metastases in PC-9-Br.
(A) Luciferin bioluminescence shows the large PC-9-Br tumor burden. (B) Fluorescence imaging contrasts the Oregon Greenperfused vasculature and the distribution of Tomato Red-expressing tumors. Four numbered slices (1 = # mm; 2 = # mm; 3 = #
mm; 4 = # mm) correspond to the coronal sections (C-F). (C) Visualization of brain metastases based on cresyl violet staining.
(D) Tomato Red tumors accurately represent tumor burden confirmed by cresyl violet staining. (E) Oregon Green highlights
normal and disrupted vasculature in tumor brain. (F) An overlay of Oregon Green and Tomato Red depicts tumor environment
and vascular integrity. Scale bars = 1 mm.
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Figure 5.4. Ventricular infiltration leads to spinal tumor burden.
(A) Bioluminescence data shows a large tumor burden in the brain with smaller spinal
lesions. The brain was extracted, sliced, and imaged. (B) Fluorescence imaging shows a
Tomato Red tumor invading the lateral ventricle. (C and D) A tumor mass and individual
cells are visible within the ventricle and around the choroid plexus (Oregon Green).
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Figure 5.5. PC-9-Br is less sensitive to chemotherapy compared to the parenteral
line.
A representative IC50 curve depicts the reduced etoposide sensitivity of PC-9-Br (6.4 µM)
compared to the PC-9-P line (0.41 µM).
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Figure 5.6. Permeability changes of PC-9-Br treated with vehicle.
(A) A representative cresyl violet brain slice (approximately corresponding to Fig. 3.3
C4) of vehicle-treated PC-9-Br tumors, with (B) corresponding Tomato Red tumor
fluorescence. (C) The same slice with Oregon Green, (D) ICG, and (E) 14C-AIB autoradiographic data to quantify permeability increases. (F) The median and interquartile
ranges for fold-increases of passive permeability markers in 114 tumors over control
regions. For vehicle brains, tumors were significantly more permeable to OG and 14CAIB (p < 0.05), but not ICG (p > 0.05). (G) The fold increases of OG, ICG, or 14C-AIB
were not correlated with metastases size (r2 < 0.02). For all depicted brain slices, tumor
regions are outlined while control areas are squares. Scale bar = 1 mm.
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Figure 5.7. Passive permeability changes of PC-9-Br treated with cisplatinetoposide.
(A) A representative cresyl violet brain slice (approximately corresponding to Fig. 5.3
C1) of cisplatin-etoposide-treated PC-9-Br tumors, with (B) corresponding Tomato Red
tumor fluorescence. (C) The same slice with Oregon Green, (D) ICG, and (E) 14C-AIB
autoradiographic data to quantify P-gp, vascularity, and permeability increases,
respectively. (F) The median and interquartile ranges for fold-increases of dyes in 117
tumors over control regions. For cisplatin-etoposide-treated brains, tumors were
significantly more permeable 14C-AIB and had more P-gp and vascularity than control
regions (p < 0.05). (G) The fold increases of OG, ICG, or 14C-AIB were not correlated
with metastases size (r2 < 0.02). For all depicted brain slices, tumor regions are outlined
while control areas are squares. Scale bar = 1 mm.
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Figure 5.8. Passive permeability changes of PC-9-Br treated with cisplatinpemetrexed.
(A) A representative cresyl violet brain slice (approximately corresponding to Fig. 5.3
C3) of cisplatin-pemetrexed-treated PC-9-Br tumors, with (B) corresponding Tomato Red
tumor fluorescence. (C) The same slice with Oregon Green, (D) ICG, and (E) 14C-AIB
autoradiographic data to quantify P-gp, vascularity, and permeability increases,
respectively. (F) The median and interquartile ranges for fold-increases of passive
permeability markers in 96 tumors over control regions. For cisplatin-pemetrexed-treated
brains, tumors were significantly more permeable to 14C-AIB and had more P-gp effects
(p < 0.05), but not vascularity (p > 0.05). (G) While the OG intensity had a modest
correlation with mm2 (r2 = 0.42), ICG and 14C-AIB were not correlated with metastases
size (r2 < 0.15). For all depicted brain slices, tumor regions are outlined while control
areas are squares. Scale bar = 1 mm.
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Figure 5.9. Passive permeability changes of PC-9-Br treated with gefitinib.
(A) A representative cresyl violet brain slice (approximately corresponding to Fig. 3.3
C2) of gefitinib-treated PC-9-Br tumors, with (B) corresponding Tomato Red tumor
fluorescence. (C) The same slice with Oregon Green, (D) ICG, and (E) 14C-AIB
autoradiographic data to quantify P-gp, vascularity, and permeability increases,
respectively. (F) The median and interquartile ranges for fold-increases of passive
permeability markers in 34 tumors over control regions. For gefitinib-treated brains,
tumors were significantly more permeable 14C-AIB and had more P-gp activity (p <
0.05), but not vascularity (p > 0.05). (G) While the permeability-fold increases of 14CAIB had a modest correlation with mm2 (r2 = 0.33), OG and ICG were not correlated with
metastases size (r2 < 0.13). For all depicted brain slices, tumor regions are outlined while
control areas are squares. Scale bar = 1 mm.
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Figure 5.10. Passive permeability changes of PC-9-Br treated with afatinib.
(A) A representative cresyl violet brain slice (approximately corresponding to Fig. 5.3
C2) of afatinib-treated PC-9-Br tumors, with (B) corresponding Tomato Red tumor
fluorescence. (C) The same slice with Oregon Green, (D) ICG, and (E) 14C-AIB
autoradiographic data to quantify P-gp, vascularity, and permeability increases,
respectively. (F) The median and interquartile ranges for fold-increases of passive
permeability markers in 85 tumors over control regions. For afatinib-treated brains,
tumors were significantly more permeable 14C-AIB and had more P-gp activity and
vascularity (p < 0.05). (G) The fold increases of OG, ICG, or 14C-AIB were not
correlated with metastases size (r2 < 0.01). For all depicted brain slices, tumor regions are
outlined while control areas are squares. Scale bar = 1 mm.
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Figure 5.11. Passive permeability changes of PC-9-Br treated with osimertinib.

(A) A representative cresyl violet brain slice (approximately corresponding to Fig. 5.3
C4) of osimertinib-treated PC-9-Br tumors, with (B) corresponding Tomato Red tumor
fluorescence. (C) The same slice with Oregon Green, (D) ICG, and (E) 14C-AIB
autoradiographic data to P-gp, vascularity, and permeability increases, respectively. (F)
The median and interquartile ranges for fold-increases of passive permeability markers in
56 tumors over control regions. For osimertinib-treated brains, tumors were significantly
more permeable to 14C-AIB and had more P-gp activity and vascularity (p < 0.05). (G)
The fold increases of OG, ICG, or 14C-AIB were not correlated with metastases size (r2 <
0.05). For all depicted brain slices, tumor regions are outlined while control areas are
squares. Scale bar = 1 mm.
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Figure 5.12. Comparison of passive permeability between PC-9-Br treatment
groups.
PC-9 tumors are more permeable to the small 14C-AIB markers than non-tumor areas.
The reduction of 14C-AIB permeability in cisplatin-etoposide, afatinib, and osimertinib
groups compared to vehicle or cisplatin-pemetrexed groups is linked with an increase in
median survival. All data represents median and interquartile ranges. AFT: afatinib; C-E:
cisplatin-etoposide; C-P: cisplatin-pemetrexed; GEF: gefitinib; OSI: osimertinib; VEH:
vehicle.
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Figure 5.13. Distribution of PC-9-Br tumors.
Representative slices of (A) anterior, (D) middle, and (G) posterior slices from the Allen
mouse brain atlas. Colors represent different regions of the brain. These correspond with
representative (B) anterior, (E) middle, and (H) posterior cresyl violet slices of brains
with PC-9-Br tumors. Color outlines correspond with atlas brain regions. Tomato red
tumors of (C) anterior, (F) middle, and (I) posterior slices are similarly outlined with
color. (J) A plot of the total number of tumors based on area of the brain in all treated
brains. (K) A plot of the number of tumors based on surface area. (L) A plot of the
number of tumors based on blood flow. Median data is plotted with colors representing
different treated groups.
158

Supplemental Figure 5.1. Mandibular metastases in the PC-9-Br line.
Multiple mandibular metastases are present along with intracranial metastases
characteristic of the PC-9-Br line. This distribution is seen in multiple brain-seeking
metastatic cell lines, including breast cancer.
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PC9-P
Compound

PC9-6-Br
IC50 ± SD

IC50 ± SD

BEACON AGENTS
Gemcitabine
Docetaxel

0.2 nM

Eribulin

20.3 nM

Vinorelbine

7.1 nM

SN-38

7.7 ± 39 nM

6 ± 0.1 µM

CONVENTIONAL LUNG CHEMOTHERAPY AGENTS
Cisplatin

669 ± 653 nm

593 ± 550 nm

Etoposide

408 ± 123 nm

6.4 ± 0.4 µM

Pemetrexed

391 ± 346 nm

512 ± 590 nm

EGFR-TYROSINE KINASE INHIBITOR AGENTS
Erlotinib

< 100 fM

514.2 ± 100 nm

Gefitinib

< 100 fM

41.5 ± 9.3 nm

Afatinib

< 100 fM

5.2 ± 2.1 nm

Osimeritinib

< 100 fM

4.5 ± 1.9 nm
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Table 5.1. In-vitro chemotherapeutic sensitivity comparisons of the parenteral and
brain-seeking PC-9 line.
MTT assays show that the parenteral cell lines are generally more chemosensitive than
the brain-seeking line. All data is based on an n = 64.
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Therapy

n

Survival (days)

median size
2

IQR (mm2)

(mm )
Vehicle

114

42

0.1844

Cisplatin-

117

51.5

0.1093

0.1129 – 0.3097

0.0533 – 0.2384
Etoposide
Cisplatin-

96

45

0.2492
0.1305 – 0.4054

Pemetrexed
Gefitinib

34

48

0.5530

0.2868 – 0.6787

Afatinib

85

73

0.1459

0.0687 – 0.2809

Osimertinib

56

73

0.1293

0.0629 – 0.2125

Table 5.2. Sizes of PC-9-Br tumors based on drug treatment.
Treatment groups that extended median survival significantly beyond vehicle (cisplatinetoposide, afatinib, and osimertinib) have median tumor sizes below 0.15 mm2.
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14

C-AIB fold increase

Therapy

Median

IQR

r2 vs. size

Vehicle

3.254

1.928 – 5.971

0.014

Cisplatin-

1.231

0.8541 – 2.077

0.068

4.235

1.681 – 7.046

0.444

Gefitinib

4.537

2.707 – 8.200

0.325

Afatinib

1.315

0.8746 – 2.197

0.004

Osimertinib

1.950

1.328 – 3.033

0.004

Etoposide
CisplatinPemetrexed

Table 5.3. 14C-AIB fold permeability is less in groups that improve median survival.
In therapy that does not improve median survival (vehicle, cisplatin-pemetrexed, and
gefitinib), 14C-AIB increases are higher than those that do improve median survival
(cisplatin-etoposide, afatinib, and osimertinib). No correlation between fold increase and
size exists.
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OG fold increase
Therapy

Median

IQR

r2 vs. size

Vehicle

1.007

1.004 – 1.013

0.001

Cisplatin-

1.020

1.007 – 1.037

0.420

1.049

1.010 – 1.144

0.123

Gefitinib

1.028

1.006 – 1.066

0.030

Afatinib

1.011

1.003 – 1.021

0.003

Osimertinib

1.077

1.041 – 1.138

0.001

Etoposide
CisplatinPemetrexed

Table 5.4. Oregon Green fluorescence intensity does not correlate with median
survival improvement.
Fluorescence intensity increases in Oregon Green are similar for all treatment groups.
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ICG fold increase
Therapy

Median

IQR

r2 vs. size

Vehicle

1.000

0.9953 – 1.002

< 0.001

Cisplatin-Etoposide

0.9885

0.9810 – 1.001

0.031

Cisplatin-Pemetrexed

0.9991

0.9941 – 1.009

0.030

Gefitinib

1.030

1.002 – 1.042

0.021

Afatinib

1.001

0.9957 – 1.007

0.013

Osimertinib

1.006

1.002 – 1.020

0.042

Table 5.5. ICG fluorescence intensity is similar in all treatment groups.
As a measure of vascularity, ICG is similar in all groups, and is there is no correlation to
size.
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CHAPTER 6
EFFECTS OF ETIRINOTECAN PEGOL (NKTR-102) IN THE PC-9
PRECLINICAL LUNG CANCER METASTASES MODEL
6.1 Introduction
Lung cancer is the second-most commonly diagnosed cancer in the United States,
and is the most common cause of cancer death worldwide. [1, 2] It is estimated that more
than 200,000 new cases of lung cancer will be diagnosed and more than 150,000 cancer
deaths in the United States in 2018. [2] The average age of diagnosis is 70, while the
median age of death is 72. The short time from diagnosis to death may be due to the
advanced stage on presentation. [3]
Lung cancer metastasizes to the brain in approximately 10 to 30% of patients and
is responsible for the majority of brain metastases. [4] The propensity to form brain
metastases is also influenced by lung cancer subtype. Approximately 85% of lung cancer
are non-small cell lung carcinoma (NSCLC) with small-cell lung carcinoma (SCLC)
comprising the rest. [5] SCLC presents with brain metastases in 20% of patients, forming
in 80% within 2 years of diagnosis. [6] Adenocarcinoma, the most common subtype of
NSCLC, presents with brain metastases in 10% of patients, forming in 40% throughout
illness progression. [3] Within adenocarcinoma, the most common mutation is KRAS,
followed by EGFR and EML4-ALK translocation. Targetable drugs exist for EGFR and
EML4-ALK, but not for KRAS.
Therapeutic options in the treatment of lung cancer brain metastases (LCBM)
include surgical resection, stereotactic radiosurgery, whole brain radiotherapy, and
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chemotherapy. [7] Even when used in combination, these options rarely improve survival
to over 12 months [8] and are thus often palliative. Incremental improvements have been
made in treating brain metastases, especially in creating targeted agents and repurposing
nonspecific chemotherapy. The presence of the blood-brain barrier (BBB) and bloodtumor barrier (BTB) can significantly hinder penetration of chemotherapeutic agents into
both tumor and brain tissue. [9]
The BBB consists of a physical barrier of vascular endothelial cells linked
together by tight junctions, enzymes such as phosphatases to degrade substances, and
efflux transports actively restricting molecular entry into the brain, all surrounded by
astrocytic foot processes performing similar activities. [10] In the BTB, immature
vasculature structure leads to increased permeability and though drug permeation is
enhanced, the magnitude of enhancement often falls below therapeutic amounts required
for efficacy. [9]
Due to its prevalence in LCBM and in vitro sensitivity to SN-38, the EGFRmutant PC-9 cell line was created into a brain-seeking line and tested for preclinical
survival efficacy of NKTR-102 against BEACON-agents, conventional lung
chemotherapy, and targeted EGFR inhibitors. Herein, we report that NKTR-102 did not
reduce tumor burden or improve survival significantly from vehicle, BEACON-agents,
gefitinib, or the cisplatin-pemetrexed combination lung therapy. Conversely, cisplatinetoposide and the targeted inhibitors afatinib and osimertinib improved survival with
most animals surviving until trial completion for the latter two agents.
6.2 Methods and Materials
Animals
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The animal protocol used is the same as in Chapter 3.2.
Cells
The PC-9 parenteral line was provided by Dr. Lori Hazlehurst pre-transduced
with the pcDNA3.1(+)/Luc2=tdT plasmid. These cells were serially intracardially
injected and extracted through brains six times to create the PC-9-Br line. Cells were
grown in a 37C incubator at 5% CO2, and grown in RPMI with 10% fetal bovine serum,
5% penicillin-streptomycin, and 10-11 μL/mL of G4918 (Geneticin) to ensure plasmid
expression. All cells used in this experiment are between passages 1 to 10. A549 and
CCL-185IG were acquired from American Type Culture Collection (ATCC). A549 has a
KRAS mutation while CCL-185IG is a modified A549 to express the EML4-ALK fusion
peptide. Hence, A549 will be termed A549N, while CCL-185IG will be termed A549F.
Stereotactic injection
The protocol for intracardiac cell injection is the same as in Chapter 4.2.
Drugs and dosing
The dosing regimen and solubility of cisplatin, etoposide, pemetrexed, gefitinib,
afatinib, and osimertinib are the same as in section 4.2. The dosing regimen and solubility
for irinotecan, eribulin, docetaxel, vinorelbine, gemcitabine, and NKTR-102 are the same
as in Chapter 4.2. These are summarized in Table 6.1.
Longitudinal bioluminescence
Animals were given an intraperitoneal 150 mg/kg injection of d-luciferin
potassium salt and anesthetized with 2% isoflurane. Based on the results from Chapter 3,
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after 10 minutes of circulation, animals were transferred to the IVIS Spectra CT
(PerkinElmer) and bioluminescence (BLI) was captured at auto-exposure and one-minute
time spans on Stage D with medium binning, fitting within the optimal imaging time for
the PC-9-Br line (Figure 4.2). BLI was taken twice weekly to measure chemotherapy
response and tumor burden, performed at least an hour prior to drug administration to
avoid interactions. For quantification, a region of interest (ROI) was drawn based on
cranial circumference. BLI based on ROI is reported as radiance
(photons/sec/cm2/steridian).
Toxicology
MTT in vitro toxicity studies were performed using the same protocol as in
Chapter 4.2.
Statistics
On survival endpoints, mice were sacrificed and date of death recorded. KaplanMeier curves were generated and compared using log-rank statistics. All statistics were
performed on GraphPad Prism 6.0 and considered significant at p < 0.05.
6.3 Results
PC-9-Br shows the most SN-38 sensitivity of the developing LCBM lines
In order to determine which cell line to conduct NKTR-102 in vivo, an in vitro
toxicology study was performed on parenteral lung cancer cells using NKTR-102’s active
metabolite SN-38. The EGFR-mutant PC-9 showed the highest sensitivity to SN-38 at 7.3
nM, while the KRAS mutant A549N and ELM4-ALK-expressing A549F were 979 nM and
6.2 μM, respectively (Fig. 6.1). PC-9-Br was chosen as the model for the NKTR-102
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efficacy study, along with targeted agents against the exon 19 deleted EGFR receptor it
possesses. Subsequently, a brain-seeking line was created through 6 passages of
injections and extractions.
Non-targeted chemotherapy does not significantly prolong survival of PC-9
brain metastases compared to vehicle
The main focus of the study was to evaluate the efficacy of NKTR-102 compared
to BEACON-specific agents, conventional lung cancer chemotherapy, and targeted
chemotherapy in the experimental LCBM model. For grouping purposes, outcomes will
be reported as “non-targeted” (e.g. NKTR-102, BEACON agents, and lung
chemotherapy) and “targeted” (e.g. EGFR inhibitors). After the injection of 150,000 PC9-Br cells into the left ventricle, metastatic lesions were allowed to grow for 21 days prior
to drug administration and BLI measurements. Thus, 21 days (Week 3) is the baseline to
normalize further values. BLI was taken twice weekly as a quantitative surrogate for
tumor burden and chemotherapeutic efficacy.
In vehicle PC-9-Br animals (Fig. 6.2A), tumor burden increased by 29,400-fold
from baseline across 8 weeks (Fig. 6.2B). Similarly, gemcitabine increased 28,400-fold,
eribulin increased 14,800-fold, docetaxel increased 8000-fold, and vinorelbine increased
400-fold above baseline, and NKTR-102 signal increased by 1870-fold (Fig. 6.2B). The
BEACON-agents and NKTR-102 featured almost identical increases in tumor burden for
6 weeks after injection, then separated as survivors who bore lower BLI populated the
curve (Fig. 6.2B). The similarities of BLI curves are also represented in survival curves.
Vehicle mice survived for a median of 42 days, with irinotecan-treated mice surviving for
a median of 42 days, gemcitabine mice surviving for a median of 45.5 days, docetaxel
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mice surviving for a median of 42.5 days, eribulin mice surviving for a median of 43.5
days, vinorelbine mice surviving for a median of 41 days, and NKTR-102 mice surviving
for a median of 43 days (Fig. 6.3). No significance in median survival was seen with
BEACON-agents or NKTR-102 compared to vehicle (p < 0.05) (Table 6.2).
For conventional lung chemotherapy (Fig. 6.4A), cisplatin and pemetrexedtreated mice had a 4400-fold increase in BLI (Fig. 6.4B) and survived for 45 days (Fig.
6.5), while cisplatin and etoposide administration increased tumor BLI by 2700-fold (Fig.
6.4B) and significantly extended median survival to 51.5 days after injection compared to
vehicle (p < 0.05) (Fig. 6.5). The cisplatin and etoposide combination is the only nontargeted chemotherapy to significantly extend survival (Table 6.2). Two eribulin mice
and one NKTR-102 mouse responded to therapy, with the latter excluded from Fig. 6.2B
due to significantly lowered bioluminescence values. The responder curve is attached as a
supplementary figure (S1).
Targeted second- and third-generation tyrosine kinase inhibitors significantly
prolongs survival in PC-9-Br mice compared to vehicle
EGFR-targeted inhibitors were administered daily via oral gavage to mice (Fig.
6.6A). In gefitinib-treated mice, BLI rose in a similar fashion to vehicle-treated mice
albeit much lower, with a maximum 1200-fold above baseline (Fig. 6.6B). Gefitinib
median survival was 48 days, which was not significant compared to vehicle (p < 0.05)
(Fig. 6.7). In contrast, daily administration of the EGFR-inhibitors afatinib and
osimertinib led to an early and sustained response compared to non-targeted
chemotherapy and gefitinib. BLI was increased by 100-fold in the afatinib-treated mice
(Fig. 6.6B) and 8 of 9 mice survived until the end of the trial (Fig. 6.7), and in the
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osimertinib-treated group tumor burden increased 300-fold compared to baseline (Fig.
6.6B) with 8 of 9 mice surviving until the end of the trial (Fig. 6.7). Both afatinib and
osimertinib significantly increased survival compared to vehicle (Table 6.2).
6.4 Discussion
Significant variability exists of a chemotherapy entering peripheral tissue vs. the
brain. This may be due to the brain being a “sanctuary site” for metastases, due to the
presence of the blood-brain and blood-tumor barriers.
Platinum-based therapy, including cisplatin-etoposide and cisplatin-pemetrexed,
have shown limited efficacy in multiple Phase II trials involving EGFR-mutated LCBM.
[8] Platinum doublet therapy has largely been replaced by the use of targeted inhibitors.
It was shown that gefitinib was superior to carboplatin-pemetrexed therapy in
prolonging progression-free survival in EGFR-mutated brain metastases. [11] Despite
being substrates for P-glycoprotein efflux, it was demonstrated that erlotinib [12] and
gefitinib [13] enter the brain metastatic parenchyma and numerous case reports depict
prolonged survival and positive outcomes using these first-line EGFR-tyrosine kinase
inhibitors. [14, 15] Similarly, afatinib is a substrate for P-glycoprotein [16] and has
shown some clinical benefit in the LUX-Lung 3 and LUX-Lung 6 trials, where there was
an overall 2.8-month increase in progression-free survival. [17] Osimertinib, the only
third-generation EGFR TKI, has been shown to penetrate and accumulate in brain tissue,
[13] with the FLAURA trial showing osimertinib having a superior progression-free
survival compared to standard of care. [18]
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It is unclear as to why NKTR-102 did not show an improvement in median
survival compared to either other non-targeted agents or targeted inhibitors. NKTR-102 is
shown to penetrate the blood-tumor barrier and accumulate in tumors to provide a
sustained cytotoxic exposure to the topoisomerase I inhibitor SN-38. [19] NKTR-102
improved survival in two models of BCBM (Chapter 4) compared to BEACON therapy
and preliminary evidence shows its efficacy in the glioblastoma model (Chapter 7). The
use of irinotecan in small cell lung cancer brain metastases is documented, though its use
in NSCLC brain metastases is not documented.
It is hypothesized that NKTR-102 works best in large, slow-growing tumors.
Median survival for PC-9-Br in this study (42 days) is similar to the median survival for
the MDA-MB-231-Br (38 days) and longer than the JIMT-1-Br (28 days) BCBM vehicle
groups (Chapter 4). PC-9-Br tumors are smaller and more numerous than either BCBM
tumor types, which may limit the ability of NKTR-102 to sufficiently act in a depot
fashion.
It is also unclear why gefitinib failed to improve median survival in this
preclinical model when reports of its efficacy exists in the clinical setting. It is possible
that the dose used was insufficient to penetrate into tumor parenchyma. A recent paper
utilizing gefitinib, afatinib, and osimertinib in the PC-9 model of brain metastases was
published and the doses inside are used in our model. In this paper, gefitinib was dosed at
6.25 mg/kg and showed no effect on improving median survival compared to control [13]
while another paper utilized gefitinib at 40 mg/kg in their preclinical PC-9 brain tumor
model and showed great improvements in median survival compared to vehicle therapy.
[20] Similarly, afatinib was dosed at 7.5 mg/kg [13] while another paper utilized afatinib
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at 15 to 30 mg/kg in their preclinical PC-9 brain tumor model. [16] We opted to use the
higher afatinib dosing but performed our study prior to the higher gefitinib dosing
publication, which if followed may have had vastly different results.
6.5 Conclusion
While etirinotecan pegol shows efficacy in preclinical models of breast-brain
metastases and glioblastoma, it does not improve median survival compared to vehicle or
conventional chemotherapy in a preclinical EGFR-mutated lung cancer model. The
second- and third-generation tyrosine kinase inhibitors show early tumor burden control
which eventually shows resistance, mimicking the effects of continuous dosing seen in
clinical settings.
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Figure 6.1. Sensitivity to SN-38 for three brain-seeking lung cancer lines.
Increasing concentrations of SN-38 were used to create a cytotoxicity assay curve. The
EGFR-mutant PC-9 shows the greatest sensitivity to SN-38. Data presented is based on
an n = 96 and presented as mean ± SEM.
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Figure 6.2. Bioluminescence in PC-9-Br treated with BEACON therapy.
(A) BEACON-treated mice do not stop tumor growth in PC-9-Br cells. (B)
Bioluminescence values in vehicle-treated mice is similar to that of BEACON therapy.
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Figure 6.3. Kaplan-Meier survival curve of PC-9-Br mice treated with etirinotecan
pegol and BEACON-based chemotherapy.
On day 21 after intracardiac injection of PC-9-Br cells, mice were treated with vehicle
(saline, n = 10), docetaxel (10 mg/kg, n = 10), vinorelbine (10 mg/kg, n = 9), eribulin (1.5
mg/kg, n = 10), gemcitabine (60 mg/kg, n = 10), irinotecan (50 mg/kg, n = 10) or
etirinotecan pegol (50 mg/kg, n = 10). Median survival time were 42 days for vehicle,
42.5 days for docetaxel, 41 days for vinorelbine, 43.5 days for eribulin, 45.5 days for
gemcitabine, 42 days for irinotecan, and 43 days for etirinotecan pegol. Etirinotecan
pegol did not improve median survival compared to vehicle or other BEACON
chemotherapy (p > 0.05). Data was analyzed using log-rank statistics.
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Figure 6.4. Bioluminescence in conventional lung chemotherapy in the PC-9-Br
model.
(A) Longitudinal imaging shows tumor burden increases similarly in vehicle- and
cisplatin-pemetrexed-treated mice, while cisplatin-etoposide has slightly better tumor
burden control.
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Figure 6.5. Kaplan-Meier survival curve of PC-9-Br mice treated with conventional
lung chemotherapy.
On day 21 after intracardiac injection of PC-9-Br cells, mice were treated with vehicle
(saline, n = 10), combined cisplatin-etoposide (n = 10), or combined cisplatin-pemetrexed
(n = 9). Median survival time was 42 days for vehicle, 51.5 days for cisplatin-etoposide,
and 45 days for cisplatin-pemetrexed. Cisplatin-etoposide significantly improved median
survival compared to vehicle (p < 0.05), though cisplatin-pemetrexed did not (p > 0.05).
All data was analyzed using log-rank statistics.
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Figure 6.6. Bioluminescence profiles of EGFR-inhibitors in the PC-9-Br model.
(A) While gefitinib does not control tumor burden compared to vehicle therapy, afatinib
and osimertinib control tumor burden until the end of the trial. (B) All targeted inhibitors
show reduced bioluminescence signaling compared to vehicle therapy, though afatinib
and osimertinib show early and sustained tumor control, with drug resistance occurring at
the end of the trial.
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Figure 6.7. Kaplan-Meier survival curve of PC-9-Br mice treated with targeted lung
chemotherapy.
On day 21 after intracardiac injection of PC-9-Br cells, mice were treated with vehicle
(saline, n = 10), gefitinib (n = 9), afatinib (n = 9), or osimertinib (n = 8). Median survival
time was 42 days for vehicle, 48 days for gefitinib, and undefined for afatinib and
osimertinib. One mouse each died in the afatinib and osimertinib groups not due to tumor
or drug toxicity, and were counted in the statistics. Gefitinib did not improve median
survival compared to vehicle (p > 0.05), but both afatinib and osimertinib significantly
improved median survival (p < 0.05) with all but one mouse surviving until the end of the
trial in both groups.
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Supplemental Figure 6.1. Bioluminescence curves of conventional chemotherapy
responders.
Two eribulin- and one NKTR-102-treated mice responded to therapy and showed a
decrease in tumor burden. This did not impact the overall median survival of the groups.
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Drug
Afatinib

Source
SelleckChem

Dose

Formulation

30

5% DMSO, 10%

mg/kg

polyethylene glycol 400,

Administration
PO, every day

85% distilled water
Cisplatin

Docetaxel

Doxil ®

Eribulin

SelleckChem

5

5% dimethylformamide,

mg/kg

95% saline

10

5% Ethanol, 5% Tween

mg/kg

80, 90% saline

WVU

6

Pegylated liposomes in

Pharmacy

mg/kg

5% dextrose

Adooq

1.5

5% ethanol, 15%

mg/kg

distilled water, 80%

SelleckChem

mesylate

IV, every 7 days

IV, every 7 days

IV, every 7 days

SQ, every 4 days

saline
Etirinotecan

NEKTAR

50

Saline

IV every 7 days

pegol

Therapeutics

mg/kg

Etoposide

SelleckChem

10

5% DMSO, 5% Tween

IV on days 2-5

mg/kg

80, 90% Saline

from cisplatin
administration

Gefitinib

SelleckChem

6.25

5% DMSO, 10%

mg/kg

polyethylene glycol 400,

PO every day

85% distilled water
Gemcitabine

SelleckChem

60

Saline

mg/kg
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SQ, every 4 days

Irinotecan

Osimertinib

NEKTAR

50

5% Dextrose

IV, every 7 days

Therapeutics

mg/kg

SelleckChem

25

5% DMSO, 10%

PO, every day

mg/kg

polyethylene glycol 400,
85% distilled water

Pemetrexed

SelleckChem

100

Saline

mg/kg

IV, on days 3, 4,
5 from cisplatin
administration

Vinorelbine

SelleckChem

10

Saline

IV, every 7 days

mg/kg
Table 6.1. Formulations and dosing schedule for NKTR-102 in the PC-9-Br model.
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Median Survival
Treatment

Surviving

vs. Vehicle (Log-

(%)

Rank)

n
(days)

BEACON AGENTS
Vehicle

42

10

0

Irinotecan

42

9

0

0.6720

NKTR-102

43

10

1 (10%)

0.1609

Gemcitabine

45.5

10

0

0.1055

Docetaxel

42.5

10

0

0.7636

Eribulin

43.5

10

2 (20%)

0.1246

Vinorelbine

41

9

0

0.2364

CONVENTIONAL LUNG CHEMOTHERAPY AGENTS
Cisplatin +
51.5

10

0

0.0331*

45

9

0

0.2626

Etoposide
Cisplatin +
Pemetrexed
EGFR-TYROSINE KINASE INHIBITOR AGENTS
Gefitinib

48

10

0

0.1336

Afatinib

(73)

9

8 (89%)

< 0.001 **

Osimeritinib

(73)

8

7 (88%)

< 0.001 **

Table 6.2. Survival data of NKTR-102 against chemotherapy in the PC-9-Br model.
Neither BEACON chemotherapy, NKTR-102, or cisplatin-pemetrexed improved median
survival.
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CHAPTER 7
PRELIMINARY DATA OF ETIRINOTECAN PEGOL (NKTR-102)
EFFICACY IN A PRECLINICAL GLIOBLASTOMA MODEL
7.1 Introduction
Primary brain malignancies make up a smaller but significant portion of brain
tumors compared to brain metastases. Within primary brain tumors, almost 80% are
gliomas, with glioblastoma representing the most aggressive, invasive, and fatal subtype.
[1] On diagnosis, many patients have an advanced disease state featuring a large,
heterogeneously distributed tumor on imaging. The symptoms and mortality of
glioblastoma is due to mass effect and compression on tissues, such as the brainstem. [2]
Current treatment options for glioblastoma include either whole-brain or
stereotactic radiation combined with surgical evacuation, with chemotherapy used to
reduce tumor burden. [3] Temozolomide is the most utilized therapy in glioblastoma [4]
and many chemotherapy trials use temozolomide as a backbone as combination therapy.
Other therapy for glioblastoma include Gliadel® (carmustine wafers) [5] and a new
device Optune®, a non-invasive tumor-treating field therapy. [6] Investigational therapy
includes photodynamic therapy (NCT03048240), antibody therapy (NCT03139916),
sonic hedgehog pathway inhibition (NCT03466450), and pegylated chemotherapy. [7]
Though glioblastoma is typically rapid-growing, the U251 model has exhibited
more than a 50-day median survival in multiple models. [8, 9] As we have demonstrated
earlier, a novel PEGylated form of irinotecan has been shown to work on the larger and
slow-growing MDA-MB-231 triple-negative and HER2+ JIMT1 breast cancer brain
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metastases models (Chapter 4), but not the more rapidly growing and smaller 4T1 breast
cancer or PC-9 lung cancer brain metastases models (Chapter 6). It is thought that
NKTR-102 accumulates in tumors and provides sustained chemotherapy effects
throughout its long half-life. [10]
Herein, we report the preliminary survival efficacy of NKTR-102 in the
intracranial U251 glioblastoma model. A dose of 50 mg/kg NKTR-102 allowed 7 of 8
treated mice to survive until the end of our trial at 100 days, while vehicle-treated mice
had a median survival of 73 days. Tumor burden was controlled and minimized within
one week of NKTR-102 therapy initiation and remained below treatment initiation levels
throughout the trial. This supports the use of NKTR-102 in the treatment of slow-growing
glioblastomas.
7.2 Methods and Materials
Animals
The animal protocol used is the same as in Chapter 4.2.
Cells
The original U251 cell line was provided by Dr. Gordon Meares. A lentivirus
containing Firefly luciferase (Fluc) with the hygromycin selection marker was purchased
from Biosettia (GlowCell-16h). 10 μL of viral vector and 10 μL of polybrene (Santa
Cruz, sc-134220) was added to each well in a 6-well plate of U251 cells at 70%
confluence. Plates were spun at 1000 RPM for 60 minutes and placed in a 37C incubator
overnight. The following morning, cells were washed with phosphate-buffer saline (PBS)
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and then introduced to hygromycin at a concentration of 10 μL/mL in media to ensure
successful transduction. After a week, selected cells checked for luciferase expression.
Intracranial injection
Mice were anesthetized under 2% isoflurane and placed in an intracranial
stereotactic injection device (Stoelting). 500,000 U251 cells were suspended in PBS
(100,000 per 1 μL) and injected over 5 minutes. 1 μL was injected every 45 seconds for 4
μL, after a minute pause to let cells distribute, the last 1 μL was injected and the syringe
was pulled out after another minute.
Drugs and dosing
NKTR-102 at 50 mg/kg equivalents of irinotecan (11 mg of NKTR-102 per
mouse) was dissolved in PBS for a total of 200 μL/mouse. PBS was used as the vehicle.
Doses were administered weekly via tail vein to an anesthetized mouse, starting on Day
49.
Bioluminescence imaging
The bioluminescence imaging protocol used is the same from Chapter 5.2. The
timing of injection is based on the pharmacokinetic profiling of Chapter 3.
In vitro toxicology
The toxicology protocol used is the same from Chapter 4.2.
7.3 Results
U251 glioblastoma cells are sensitive to SN-38 in the nanomolar range
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When exposed to 1 femtomolar to 1 millimolar concentrations, the IC50 value of
U251 cells to SN-38, the active metabolite of NKTR-102, was 0.536 nM (Fig. 7.1). This
is lower than in the MDA-MB-231-Br model (10.5 nM), 4T1-Br model (24.9 nM), JIMT1 model (222.8 nM) (Table 4.2), or PC-9-Br model (6.0 uM) (Fig. 6.1).
NKTR-102 controls tumor burden in the preclinical U251 glioblastoma model
Having seen that NKTR-102 improves survival in the preclinical breast-brain
metastatic model due to accumulation in tumors, we then evaluated its efficacy in a
glioblastoma model. U251 cells were intracranially injected and allowed to grow for 49
days (baseline), at which animals were randomized to either vehicle or NKTR-102. BLI
was taken twice weekly to monitor tumor burden and chemotherapy response (Fig. 7.2).
In vehicle animals, tumor burden increased 103-fold over baseline across 7 weeks, while
in weekly-treated NKTR-102 50 mg/kg, tumor burden was controlled from initiation and
reduced 5-fold over the same time span (Fig. 7.3A). Survival reflected BLI, as median
survival in vehicle was 73 days, with all but one mouse administered with NKTR-102
surviving until the end of the 100-day trial (Fig. 7.3B). Of interest, NKTR-102 provided
sustained tumor burden control but did not eliminate BLI signal in any mouse despite 7
weeks of dosing.
7.4 Discussion
As the U251 had the most sensitivity to SN-38 of all cell lines tested (Table 4.2,
Table 6.2, Fig. 7.1), it was hoped that NKTR-102 administration would lead to
significant survival benefit and better outcomes than any previous model. This study
shows that weekly NKTR-102 successfully controls tumor burden and improves survival
in an intracranial glioblastoma model compared to vehicle therapy.
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The efficacy of NKTR-102 is now exhibited in three models, the first two being
triple-negative and HER2+ BCBM. [10][Chapter 4] The reduction of tumor BLI signal
occurred within one week of NKTR-102 dosing in the glioblastoma model, similar to the
MDA-MB-231-Br BCBM model (Fig. 3.2), and stayed below baseline for the duration of
treatment. The survival benefit was significant as NKTR-102 allowed 7 of 8 mice to
survive until the end of therapy administration.
The vascularity within glioblastomas are extremely heterogeneous, with central
cores possessing enhanced permeability while peripheral areas retaining intact
permeability. [11, 12] This intra-lesion discordance may explain NKTR-102’s ability to
significantly reduce, but not completely eliminate tumor presence from intracranial
lesions, even after weeks of dosing.
The basis for NKTR-102 efficacy relies on two factors: size and permeability. As
a 20-kDa molecule, NKTR-102 preferentially accumulates into tumor tissue [10] (Fig.
4.7). Its large size allows the molecule to bypass efflux pumps such as P-glycoprotein;
present in endothelial and astrocytic components of the BBB and BTB. Retention of the
molecule within the circulatory system allows for a long half-life, and subsequent
deposition and residence in tumor parenchyma is a process known as enhanced
permeation and retention (EPR). [13]
The permeability of NKTR-102 through leaky vasculature plays a large role in its
efficacy. [10] Through deposition into tumor tissue and continual release of irinotecan
with subsequent metabolism to SN-38, NKTR-102 provides substantial and sustained
cytotoxic effects to reduce tumor burden. The additional advantage of a long circulating

196

half-life provided by pegylation allows for less frequent dosing, which provides another
advantage over conventional irinotecan dosing. [10]
In conjunction with EPR, it is possible that NKTR-102 finds its efficacy in slowgrowing and larger tumors. In the preclinical BCBM models, the 231-Br and HER2+ are
noted to have larger tumors while 4T1 are more numerous, small, and grow relatively
rapidly. [14] While NKTR-102 improved median survival in the 231-Br and HER2+
lines, it did not do so in the 4T1 line (Chapter 4). Similarly, the PC-9-Br line creates
smaller and rapidly-growing tumors; NKTR-102 administration did not improve median
survival compared to vehicle in this cell line (Chapter 6). Though tumor size and
permeability are not related, it is known that glioblastoma form larger tumors and are
highly permeable compared to metastatic models. [14, 15] In the U251 model, NKTR102 may create a depot and provide sustained tumor burden control, though the cellular
growth may outpace the delivery of drug as evidenced by bioluminescence data.
With NKTR-102 involved in multiple clinical trials ranging from treatment of
metastatic breast cancer, including the ATTAIN trial focusing on BCBM, these
preliminary results show that NKTR-102 causes rapid control of tumor burden from
primary intracranial lesions with significant survival benefits.
7.5 Conclusion
NKTR-102 controls tumor burden and significantly extends survival compared to
vehicle in the preclinical intracranial U251 glioblastoma model. The next step is to test
conventional irinotecan and glioblastoma therapy (temozolomide) against NKTR-102 to
determine if it improves survival compared to currently chemotherapeutics.
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Figure 7.1. U251 is sensitive to SN-38 in the nanomolar range.
The dashed line shows a linearity in dose reduction with log-increases of SN-38, while
the solid line is the non-linear best-fit curve. The U251 glioblastoma cell line is sensitive
to SN-38 at 0.6 nM.
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Figure 7.2. NKTR-102 enhances survival compared to vehicle therapy in the U251
model.
Following intracranial injection of U251 glioblastoma cells and establishment of brain
metastases 49 days later, biweekly imaging on the IVIS Spectrum CT tracked tumor
growth and etirinotecan pegol chemotherapeutic efficacy. Images shown are of the same
animal sequentially. While vehicle bioluminescence increases until animal death,
etirinotecan pegol controls and lowers tumor burden until the end of trial.
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Figure 7.3. Etirinotecan pegol reduces tumor burden and improves survival
compared to vehicle in the U251 glioblastoma model.
(A) Mean BLI signal versus time in mice treated with therapy. Treatment was initiated on
day 49. Each data point represents mean ± SD (n = 2-10 per time point). Tumor burden in
etirinotecan pegol-treated mice was significantly lower than conventional chemotherapy
or vehicle treatment groups (p < 0.05). (B) Etirinotecan pegol significantly increased
median survival in tumor mice compared to vehicle, with 9 mice treated with etirinotecan
surving until the end of the trial (p > 0.05).
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CHAPTER 8
PRELIMINARY DATA OF ABRAXANE AND DOXIL EFFICACY IN
PRECLINICAL BRAIN METASTASES MODELS
8.1 Introduction
Metastases remains one of the leading causes of death from cancer. [1] The most
common organs cancers metastasize to are summed in the mnemonic “BBBLL”: breast,
bone, brain, liver, and lung. [2] Of these sites, metastases to the brain is the most difficult
to treat due to the sanctuary state provided by the blood-brain and blood-tumor barriers,
as well as the difficulty in performing surgical excavations in the small space of a critical
organ. Though advances have been made in surgery and radiation therapy, significant
advances have been made in the realm of chemotherapy to treat brain metastases.
Two current trends exist: to develop new molecules, and to repurpose existing
molecules into novel dosage forms. Four common repurposing techniques involve
liposome encapsulation, PEGylation, nanoparticle creation, and antibody conjugation. [3]
These are often constrained by size to avoid rapid kidney elimination and destruction by
macrophages. [3] Novel dosage forms may also reduce total amounts of drug required to
achieve a therapeutic effect, reduce side effects from dosing, and provide sustained
release of chemotherapy over time. [3] Examples of novel chemotherapeutic agents being
explored to treat brain metastases include NKTR-102 (etirinotecan pegol), T-DM1
(trastuzumab emtansine), Abraxane (nano-albumin-bound paclitaxel), and Doxil
(pegylated liposomal doxorubicin).
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Abraxane, a 130-nanometer nanoparticle albumin-bound conjugate of paclitaxel,
(nab-paclitaxel), is FDA-approved for metastatic breast cancer, non-small cell lung
cancer, and pancreatic cancer. [4, 5] Compared to conventional paclitaxel, nab-paclitaxel
displays a higher amount of systemic drug exposure, faster possible infusion rates, and
higher unbound drug due to not requiring Cremophor EL as a cosolvent, slower drug
elimination, and reduced drug toxicity. [6-8] Its longer half-life may be due to its
formulation with albumin, which allows albumin-mediated transport of paclitaxel through
vasculature and into tumor parenchyma. [8]
Doxil, a pegylated liposomal formulation of doxorubicin, is FDA-approved for
ovarian cancer and multiple myeloma. [9] Pegylation of liposomes allows reduced
removal through the spleen and liver, and additionally reduces the amount of drug
escaping through liposomes and subsequent elimination of free drug. [10] By
encapsulating doxorubicin into pegylated liposomes, the total amount of drug delivered
(AUC) and half-life increases almost 30-fold, while clearance drops almost 100-fold,
when compared to conventional doxorubicin. [10]
Herein, we show that though the triple-negative breast cancer MDA-MB-231-Br
cells are more sensitive to Abraxane than Doxil in-vitro, only Doxil significantly
improves survival in tumor-bearing mice. Doxil does not improve survival in the EGFRmutated PC-9 preclinical LCBM model, which corresponds with other studies showing
only targeted tyrosine kinases improve survival in this setting.
8.2 Methods and Materials
Animals
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The animal protocol used is the same as in Chapter 4.2.
Cells
The MDA-MB-231-Br and PC-9-Br cells used in this Chapter are the same as in
Chapter 4 and Chapter 5, respectively.
Tumor cell injection
The intracardiac injection protocol used is the same as in Chapter 4.2.
Drugs and dosing
Abraxane was provided as a 1-gram powder of 100 mg paclitaxel to 900 mg
human albumin. Doses were based on amount of paclitaxel. Weighed powder was then
suspended in phosphate buffer saline to create a suspension. 50 mg/kg was given weekly
as an intravenous dose, then 25 mg/kg via intraperitoneal injection 3 to 4 days later.
Doxil came solubilized at 2 mg per mL and was further diluted in dextrose 5% prior to
administration at a weekly dose of 6 mg/kg intravenously. [11]
Statistics
Survival data were compared using the log-rank method. Significance is defined
as p < 0.05. All statistics were performed on GraphPad Prism 6.
Bioluminescence imaging
The bioluminescence imaging protocol used is the same from Chapter 4.2.
In vitro toxicology
The toxicology protocol used is the same from Chapter 4.2.
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8.3 Results
231-Br cells are more sensitive to Abraxane than Doxil
To test sensitivity of the triple-negative BCBM line 231, the MTT toxicology
assay was used. Abraxane was suspended initially in PBS and diluted in media. Doxil,
already provided in solution, was directly added to media and then diluted. The IC50 of
231-Br to Abraxane is 20.2 nM (Fig. 8.1A), while the IC50 of 231-Br to Doxil is 2.93
μM (Fig. 8.1B).
Abraxane improves survival in the preclinical triple-negative breast-brain
metastatic model
Abraxane was suspended in PBS and injected via tail vein of mice bearing 231-Br
metastases 14 days after intracardic cancer cell injection. The median survival was 34.5
days, while in historical vehicle it was 36.5 days (Fig. 8.2). One mouse in the Abraxane
group survived until 70 days, whereas no vehicle mice survived until day 50.
Doxil significantly improves survival over vehicle in the 231-Br model
Weekly intravenous injections of Doxil starting 14 days post-cancer cell injection
led to a 670-fold increase in BLI, compared to the nearly 2000-fold increase from
baseline seen in vehicle mice (Fig. 8.3A). The rate of BLI over time is similar to that of
vehicle until week 7 of dosing, where the curve represents one surviving mouse. Doxil
administration improved median survival to of the 231-Br mice to 45 days, 9 more than
vehicle (p < 0.05) (Fig. 8.3B).
Doxil does not significantly control tumor growth in the PC-9-Br model
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As Doxil proved effective in the breast-brain metastatic model, interest turned to
testing its survival efficacy in the PC-9 lung-brain metastatic model. 21 days after
intracardiac injection with PC-9 cells, Doxil was intravenously injected at 6 mg/kg
weekly. Though the BLI rose to only approximately 4500-fold above baseline compared
to 29000-fold in the vehicle group (Fig. 8.4A), survival was unaffected as both vehicle
and Doxil-treated groups had a median survival of 42 days (Fig. 8.4B).
8.4 Discussion
This is the first study to evaluate survival effects of Abraxane (nano-albuminbound paclitaxel) and Doxil (pegylated liposomal doxorubicin) in the setting of brain
metastases from breast cancer and lung cancer. Our finding for Doxil replicates another
BCBM study in which survival was improved by 6 days compared to vehicle, though this
study used the intracranial model of 231-Br. [11] In the clinical setting, Doxil has seen
efficacy when combined with cyclophosphamide and temozolomide in the settings of
brain metastases of solid tumors, including breast cancer.
The in vitro sensitivity of 231-Br to Abraxane is approximately 10-fold lower
than sensitivity to Doxil, but this does not extrapolate to in vivo effects as survival is
improved only in the Doxil-treated model. It is possible that albumin-bound drugs are
unable to escape vasculature as efficiently as liposomes, as protein-binding reduces the
ability of chemotherapy to penetrate through tight junctions. [12] It was determined that
the pegylated liposomes of Doxil allow for extravasation through leaky tumor vasculature
which extended circulation time and enhances drug delivery. [10] In the 231-Br model,
vasculature is highly heterogenous and tumors are more permeable to smaller (< 200 Da)
molecules than larger ones (> 500 Da). [13] This may explain our in vivo finding of a
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chemotherapy nanoparticle being more effective than a albumin-bound chemotherapeutic
agent, though NKTR-102, a 20-kDa pegylated molecule, has improved survival in this
same model and was shown to preferentially accumulate inside tumors. [14]
The lack of survival improvement with Doxil administration in the PC-9 lungbrain metastatic model is expected, as both conventional chemotherapy and NKTR-102, a
pegylated form of irinotecan, similarly did not improve survival (Chapter 6). The tumor
size and permeability characteristics of PC-9-Br are different than that of 231-Br: tumors
are smaller and moderately permeable to 14C-AIB (Chapter 5). This again may explain
why a 20-kDa substance did not show survival advantage compared to targeted small
molecule inhibitors, but does not explain why a 130-nm pegylated liposome failed to do
so.
8.5 Conclusion
Abraxane and Doxil are novel formulations of existing drugs: paclitaxel and
doxorubicin, respectively. While Abraxane is more potent in-vitro, Doxil controls tumor
burden and significantly improves survival in the preclinical triple-negative MDA-MB231 breast cancer brain metastatic model. Doxil does not control tumor burden or
significantly improve survival in the PC-9 lung cancer brain metastasis model. These
agents should be tested in other metastatic models against other upcoming and approved
chemotherapy.
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Figure 8.1. In-vitro cytotoxicity of Abraxane and Doxil on MDA-MB-231-Br cells.
(A) Cells are more sensitive to Abraxane than to (B) Doxil, though this correlation is not
seen in-vivo.
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Figure 8.2. MDA-MB-231-Br survival is not improved on Abraxane therapy.
The median survival for vehicle is not significantly different from Abraxane therapy.

212

Figure 8.3. Doxil bioluminescence and survival effects on MDA-MB-231-Br tumors.
(A) Bioluminescence in Doxil-treated mice followed a similar albeit lower trend than
vehicle, which dropped due to surviving mice. (B) Median survival was significantly
improved in Doxil-treated mice using log-rank statistics.
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Figure 8.4. Effects of Doxil on the PC-9-Br model.
(A) Bioluminescence in Doxil-treated mice was not significantly different from vehicletreated mice (B) Median survival was not significantly improved in Doxil-treated mice
using log-rank statistics.
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CHAPTER 9
CONCLUSION AND FUTURE DIRECTIONS
9.1 Conclusion
In conclusion, this dissertation (a) detailed the optimal imaging times and
quantifiable intervals of the non-toxic tumor surrogate marker D-luciferin in metastatic
and primary brain tumors, (b) characterized the creation, passive permeability, efflux
pump status, and vascularity of a widely-used EGFR-mutant lung cancer cell line, (c)
evaluated the in-vitro cytotoxicity and in-vivo efficacy of three novel chemotherapeutic
agents on brain metastases of lung and breast cancer as well as primary glioblastoma, and
(d) provided a review of the current clinical and preclinical treatment options for breast
cancer and lung cancer brain metastases, and primary glioblastoma.
In order to evaluate the effects of tumor growth and response to chemotherapy,
transfection of cancer cells with firefly luciferase prior to administration allows for a noninvasive, rapid, and quantifiable surrogate of tumor burden in a process known as
bioluminescence. The amount of light produced by cancer cells depends on a multitude of
factors including method of cancer cell and/or D-luciferin injection, and possibly the
amount of luciferase transfected in each cell. We found that lung-brain metastases had a
faster onset to peak bioluminescence and a longer duration of signal, but shorter optimal
(time > 95% peak luminescence time) compared to two models of breast-brain
metastases; these breast-brain models were similar to each other in these parameters,
indicating possible differences due to tissue origin. For intracranially injected
glioblastoma cells, time-to-peak was even faster and optimal imaging time even shorter
than lung-brain metastases, and produced more photons of light in a given time frame
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compared to the three metastatic models. In-vitro bioluminescence correlated nearly
exactly with in-vivo findings, indicating that same timing and conditions allow for
streamlining preclinical compound screening. With these results, we are able to
determine the optimal D-luciferin pharmacokinetics for our longitudinal trials involving
chemotherapy.
After determining luciferin pharmacokinetics in clinically relevant models, we
sought to determine the efficacy of a novel chemotherapeutic agent compared to
conventional chemotherapy utilizing bioluminescence as a surrogate for tumor burden. In
the MDA-MB-231 triple-negative breast cancer brain metastases model, the pegylated
form of irinotecan (etirinotecan pegol) was dosed at 50 mg/kg equivalents of irinotecan
compared to gemcitabine, docetaxel, vinorelbine, and eribulin components of BEACON
therapy. Etirinotecan pegol increased median survival compared to vehicle and BEACON
agents, with four of ten mice surviving until the end of the trial. In the JIMT-1 HER2+
model, etirinotecan modestly improved survival compared to lapatinib and vehicle, and
one mouse survived until the end of the trial. Bioluminescence showed increasing tumor
burden in all conventional chemotherapy treated mice, with a plateau in etirinotecan
pegol groups, signifying control of tumor burden. In contrast, the murine 4T1 model
responded poorly to etirinotecan pegol, with only gemcitabine showing an improvement
in median survival and tumor burden control compared to vehicle.
In the PC-9 lung cancer brain metastatic model, neither etirinotecan pegol nor any
non-targeted conventional chemotherapy improved median survival or featured a
bioluminescence curve that was significantly different from vehicle therapy. In contrast,
two targeted EGFR-inhibitors showed early tumor burden control which was sustained
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until the end of the trial, with only one mouse dying of drug administration in each group.
It is possible that the third targeted agent would improve survival if used at a higher dose.
A preliminary intracranial U251 glioblastoma model revealed etirinotecan pegol having a
similar early tumor burden control and improvement in survival compared to the vehicle
group, with only one mouse dying until the end of trial. These findings pose the
hypothesis that etirinotecan pegol may work best in slower growing and larger brain
tumors.
While the breast-brain metastatic models and glioblastoma cell line have been
extensively characterized, sufficient data does not exist for lung-brain metastases. Taken
from terminally ill animals in the aforementioned study, a passive permeability marker
(14C-AIB), vascularity marker (ICG), and P-glycoprotein marker (OG) were used to
determine characteristics of the PC-9 brain metastatic model. Fold increases compared to
non-tumor regions were analyzed. It was found that P-glycoprotein is expressed in the
PC-9-Br line which may explain the lack of efficacy in conventional chemotherapeutic
agents. Vascularity is increased in regions of tumor, indicating that typical neoplastic
angiogenesis occurs, which may be targeted by such agents as Notch-4 inhibitors and
bevacizumab. Finally, 14C-AIB permeability was increased to levels similar to that of
breast-brain metastases, and lower values of passive permeability were associated with
therapy that increased median survival. Tumor size and fold increases in markers were
not correlated, much like in the breast-brain models. Lastly, smaller tumor sizes were
associated with therapy that increased median survival.
With the efficacy of etirinotecan pegol in three cancer lines established, two other
novel chemotherapeutic agents were evaluated in these models. Pegylated liposomal
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doxorubicin improved median survival over vehicle in the MDA-MB-231 model, but not
the PC-9 model. Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) did not improve
survival in the MDA-MB-231 model.
9.2 Future Studies
Future studies, based on the results within this dissertation, include:
1. We have found that pegylated irinotecan (etirinotecan pegol) crosses the BTB
and preferentially accumulates in tumors of breast-brain metastases, acting as
a depot and providing sustained SN-38 levels. When compared to
conventional chemotherapy and vehicle, etirinotecan pegol significantly
prolonged survival and controlled tumor burden. A Phase 3 clinical study with
etirinotecan pegol is recruiting patients to correlate these findings in breast
cancer patients with brain metastases (NCT02915744). Unfortunately,
etirinotecan pegol did not extend survival in the preclinical EGFR-mutated
lung-brain metastatic line compared to conventional lung cancer therapy, or
newly introduced targeted EGFR inhibitors. We also found that etirinotecan
pegol has similar effects in a preclinical intracranial glioblastoma model
compared to vehicle therapy. Future studies with etirinotecan pegol should
evaluate its efficacy in the preclinical EML4/ALK fusion (NCI-H2228,
NCI-H3122) and KRAS mutated (A549) lung cancer models, as well as its
efficacy compared to conventional glioblastoma chemotherapy.
2. We observed that the EGFR-mutated PC-9-Br lung-breast metastatic model is
similarly permeable to the passive diffusion marker 14C-AIB as some
preclinical breast-brain metastatic models, despite being significantly smaller.
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Smaller tumor volumes and lower 14C-AIB permeability is associated with
therapy that prolongs median survival. The presence of efflux pumps such as
P-glycoprotein is prominent in the PC-9-Br line and inhibits chemotherapy
from entering tumor regions. Future studies should evaluate 14C-AIB
permeability and efflux pump effects on chemotherapy in the preclinical
EML4/ALK fusion (NCI-H2228, NCI-H3122) and KRAS mutated (A549)
lung cancer models, and evaluate if drug therapy changes tumor
properties.
3. We observed that while albumin-bound paclitaxel (Abraxane) did not improve
median survival in the preclinical 231-Br model, pegylated liposomal
doxorubicin (Doxil) extended median survival by nearly 20%. Conversely,
Doxil had no effect on median survival in the PC-9-Br model. Future studies
should evaluate Doxil in the HER2+ breast-brain metastatic model,
EML4/ALK fusion (NCI-H2228, NCI-H3122) and KRAS mutated (A549)
lung cancer models, and glioblastoma.
Current therapeutic options for treating brain metastases include surgery, whole-brain or
stereotactic radiosurgery, and chemotherapy. Incremental advances have improved
radiation therapy, but significant advances have been made in chemotherapy. The
creation of targeted chemotherapy against oncogenic mutations, especially those that
penetrate the blood-brain and blood-tumor barriers, have clinically demonstrated
improvements in median survival in both in-vivo and patient settings. In combination
with novel chemotherapeutic dosage forms, the outlook of brain metastases treatment is
promising.
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